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1  Summary 
SIVsmmPBj-derived  lentiviral  vectors  are  capable  of  efficient  primary  human  monocyte 
transduction, a capacity which is linked to the viral accessory protein Vpx. To enable novel 
gene  therapy  approaches  targeting  monocytes,  in  this  thesis  it  was  aimed  to  generate 
enhanced  lentiviral  vectors  that meet the required  standards for  clinical  applications  with 
respect to gene transfer efficiency and safety. The vectors were tested for their suitability in a 
relevant therapeutic gene transfer approach. 
 
At  first,  it  was  investigated  whether  vectors  derived  from  another  Vpx-carrying  lentivirus 
reveal  the  same  capacity  for  monocyte  transduction  as  SIVsmmPBj-derived  vectors.  A 
transduction experiment using HIV-2-derived vectors in comparison to PBj-derived vectors 
revealed a comparable transduction capacity, thus disproving the assumed uniqueness of 
the PBj vectors. The further generation and analysis of expression constructs for the vpx 
genes of HIV-2 and SIVmac demonstrated a similar functionality in monocyte transduction as 
the Vpx of PBj. As VpxPBj, both Vpx proteins facilitated monocyte transduction of a vpx-
deficient PBj-derived vector system.  
 
For the generation of enhanced SIVsmmPBj and HIV-2 vector systems, only the transfer 
vectors  were  optimized,  since  the  packaging  vectors  available  already  meet  current 
standards. At first, several modifications were introduced into an available preliminary PBj-
derived  transfer  vector  by  conventional  cloning.  The  modifications  included  insertions  of 
cPPT/CTS and WPRE as well as the deletions of the remaining pol sequence, the second 
exons of tat end rev, and the U3-region within the 3‟LTR to generate a SIN vector. Thus, 
beside  safety  enhancement,  the  vector  titers  were  also  increased  from  9.1x10
5  TU/ml 
achieved after concentration with the initial transfer vector up to 1.1x10
7 TU/ml with the final 
transfer  vector.  The  PBj  vector  retained  its  capability  of  monocyte  transduction  when 
supplemented with Vpx. 
 
This conventional method of vector enhancement is time-consuming and may result in only 
sub-optimal vectors, since it depends on the presence of restriction sites which may not allow 
deletion of all needless sequences. Moreover, mutations may accumulate during the high 
number of cloning and amplification steps. Therefore, a new and easier method for lentiviral 
transfer  vector generation was conceived. Three  essential  segments of the viral genome 
(5„-LTR, RRE, ΔU3-3‟ LTR) are amplified on the template of the lentiviral wild-type genome 
and  fused  by  Fusion-PCR.  Further  necessary  elements  namely  the  cPPT/CTS-element, 
MCS, and PPT are included into the resulting vector by extension of the nucleotide primers     Summary 
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used for the PCRs. The amplified and fused vector-scaffold can easily be integrated into a 
plasmid backbone, followed by insertion of the expression cassette of choice. By applying 
this approach, two novel lentiviral transfer vectors, based on the non-human SIVsmmPBj and 
the  human  HIV-2,  were  derived.  Vector  titers  achieved  for  PBj  and  HIV-2  vectors 
supplemented with Vpx reached up to 4.0x10
8 TU/ml and 5.4x10
8 TU/ml, respectively. The 
capacity for monocyte transduction was maintained. Thus, safe and efficient, state of the art 
HIV-2- and PBj-derived vector systems are now available for future gene therapy strategies. 
 
Finally, the new vectors were used to set up an approach for gene correction of gp91
phox-
deficient monocytes for the treatment of X-linked chronic granulomatous disease (xCGD). 
The  administration  of  autologous,  gene-corrected  monocytes  to  counteract  systemic  and 
acute infections could lead to a decreased infection load, dissolve granulomas and therefore 
improve  the survival  rate  of  hematopoietic  stem  cell transplantation (HSCT)  which  is  the 
current treatment of choice for this disease. First, methods for analysis of gp91
phox function 
were  established.  Next,  they  were  employed  to  demonstrate  the  capacity  of  monocytes, 
obtained  from  healthy  humans  or  mice,  for  phagocytosis,  oxidative  burst,  and 
Staphylococcus aureus killing. The in vivo half-life of murine monocytes in the bloodstream 
and their distribution to specific tissues was determined. Lastly, HIV-1 vectors were used to 
transfer the gp91
phox gene into monocytes from gp91
phox-deficient mice. This resulted in the 
successful restoration of the oxidative burst ability in the cells.  
 
In summary, the general suitability of the new vectors for treatment of CGD by monocyte 
transduction  was  demonstrated.  The  results  of  the  mouse  experiments  provide  the 
foundation  for  future  challenge  experiments  to  evaluate  the  capability  of  gene-corrected 
monocytes to kill off microbes in vivo. 
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2  Introduction 
2.1 Lentiviral vectors – Origin, Structure and Applications 
Lentiviral gene transfer vectors can be derived from different lentiviruses, a genus of the 
family Retroviridae. In order to appreciate the design and function of a lentiviral vector, it is 
important to understand their origin, the wild-type lentivirus.  
2.1.1 Lentiviruses 
The  most  prominent  members  of  the  lentivirus  family  are  the  human  immunodeficiency 
virus-1  (HIV-1)  and  HIV-2,  followed  by  the  simian  immunodeficiency  viruses  of  rhesus 
macaques (SIVmac) and sooty mangabeys (SIVsmm).  
Structure and genome 
All lentiviruses share the same structure of a lipid-enveloped virus particle of approx. 100 nm 
in diameter. A host-derived membrane embeds the envelope complex. It interacts with the 
matrix (MA) proteins which encompass the cone-shaped viral core, consisting of the capsid 
(CA) proteins. Within the core, two positive-strand RNA copies of about 7-10 kb, covered by 
nucleocapsid (NC) proteins, encode the viral genome (Figure 1).  
 
Figure 1: Structure of a lentivirus. (Modified from Karlsson Hedestam et al., 2008) 
 
The different lentiviral genomes are flanked by two long terminal repeats (LTRs), harboring 
the viral enhancer and promoter elements (U3 region) as well as the polyadenylation signal 
(R region). They encode the structural proteins Gag and Env, the pol-encoded enzymes, the     Introduction 
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regulatory  proteins  Tat  and  Rev,  and  depending  on  the  virus,  several  of  the  accessory 
proteins: Vif, Vpr, Nef, Vpu, or Vpx. Apart from the viral genes, the genomic RNA contains a 
number of cis-acting elements necessary for reverse transcription (primer binding site (PBS), 
central polypurine tract (cPPT), polypurine tract (PPT)), integration (attachment sites), mRNA 
export (Rev-responsive element (RRE)), and packaging ( -site) (Figure 2). 
 
Figure  2:  Schematic  representation  of  the  lentiviral  genomes  of  HIV-1-  and  the 
HIV-2/SIVsmm/SIVmac-group.  
The  products  of  the  gag  gene  are  precursor  proteins  which  are  necessary  for  particle 
formation  and  sufficient  for  the  development  of  noninfectious,  viruslike  particles.  They 
perform  several  major  functions  during  viral  assembly  like  (I)  forming  the  structural 
framework of the virion, (II) packaging of the viral genome and (III) acquiring the lipid bilayer 
with associated Env glycoproteins during particle release, a process called budding. After 
budding, the Gag precursor polyprotein is cleaved by the viral protease into matrix, capsid, 
nucleocapsid, and p6 proteins to form a mature virus particle (Figure 1). The Env protein, 
encoded  by  the  env  gene,  consists  of  a  transmembrane  glycoprotein  and  an  external 
envelope glycoprotein. The external envelope glycoprotein dictates the tropism of the virus.  
From lentiviral binding to DNA integration 
By binding to the CD4-receptor and subsequently to a co-receptor such as CCR5 or CXCR4, 
the viral membrane fuses with the host membrane resulting in the release of the viral core 
into  the  cytoplasm.  After  the  virion  core  has  entered  the  cytoplasm  of  the  infected  cell, 
reverse transcription of the viral single-stranded RNA to the proviral double-stranded DNA is 
initiated. This reaction is catalyzed by the reverse transcriptase (RT) in conjugation with its 
associated ribonuclease H (RNase H). Whereas the reverse transcriptase copies either the 
RNA template (minus strand synthesis) or the DNA templates (for second- or plus-strand 
synthesis), the RNase H degrades the RNA in generated RNA-DNA hybrids. Many cis-acting 
elements of the viral genome are important for the reverse transcription. The primer binding 
site (PBS), which participates in the placement and stabilization of the transfer tRNA-primer 
necessary for initiation of reverse transcription, is located downstream of the 5‟LTR. The     Introduction 
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central  polypurine  tract  (cPPT)  and  the  polypurine  tract  (PPT)  are  resistant  to  RNase 
degradation and can therefore be used by the reverse transcriptase to initiate plus-strand 
synthesis. The plus-strand synthesis terminates either at the end of the template or at the 
central termination sequence (CTS). Thereby, a triple helix structure named the DNA flap is 
formed at the position of the cPPT upstream of the CTS. The DNA flap is necessary for 
efficient replication and nuclear import (De Rijck and Debyser, 2006). 
The generated viral DNA is transported into the nucleus (Figure 3). After the completion of 
reverse  transcription,  the  viral  complex  is  referred  to  as  the  viral  preintegration  complex 
(PIC).  Several  cellular  (e.g.  high-mobility  group  protein  A1  and  barrier-to-autointegration
 
factor (BAF)) and viral proteins (RT, IN, MA,  Vpr, and NC) as well as the DNA  flap are 
described  to  be  part  of  the  preintegration  complex,  but  the  import  mechanism  into  the 
nucleus remains to be clarified (Freed and Martin, 2007). Once inside the nucleus, the viral 
DNA  is  integrated  randomly  into  the  host  genome,  a  process  which  is  catalyzed  by  the 
integrase. The sequences at the end of the viral DNA, the attachment sites, are cleaved 
endonucleolytically by the integrase leaving 3‟-recessed ends. Subsequently, the integrase 
catalyses a staggered cleavage in the cellular DNA where the 5‟ termini are joined with the 
3‟ ends of the viral DNA.  
 
Figure 3: Lentiviral DNA integration. After the viral particle binding, the viral core is released into the 
cytoplasm, the viral genome reverse transcribed, transported into the nucleus and integrated in the 
host genome. BAF: barrier-to-autointegration factor; IN, integrase; NPC, nuclear pore complex; PIC, 
pre-integration  complex;  RTC,  reverse  transcription  complex.  (Modified  from  Suzuki  and  Craigie, 
2007)     Introduction 
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Regulatory and accessory proteins 
The  provirus  serves  as  template for the  synthesis  of  viral  RNA.  The  nuclear  protein  Tat 
transactivates the LTR-directed transcription. It binds to the TAR (trans activation response) -
stem loop, a secondary single stem-loop (HIV-1) or double stem-loop (HIV-2) RNA-structure 
within the U3 region of the viral LTRs (Emerman et al., 1987). After binding to the TAR loop, 
Tat  recruits  the  cellular  cyclin  T-CDK9  complex  –  the  so-called  Tat-associated  kinase 
complex. By this Tat mediates  the  hyperphosphorylation of  the C-terminal domain of the 
RNA  polymerase  II  resulting  in  a  processive  synthesis  of  viral  messenger  RNA  (mRNA) 
(Garriga and Grana, 2004). In the absence of Tat binding to the TAR loop, the processivity of 
the RNA polymerase II is impaired.  
The viral pre-mRNAs are processed by the cellular transcription machinery (capping, 3‟-end 
cleavage, polyadenylation, and splicing). Lentiviruses produce several alternatively spliced 
mRNAs but the cellular export machinery is only capable of transporting fully spliced mRNAs 
coding for Rev, Tat, or Nef, into the cytoplasm. The partially spliced mRNAs (encoding Vif, 
Vpr, Vpx, Vpu, and Env) as well as the unspliced primary transcript rely on a Rev-mediated 
export (Felber et al., 1989). Rev (regulator of expression of viral proteins) is a 16-19 kDa, 
predominantly nucleolar, phosphoprotein. It regulates the mRNA-export by binding to the cis-
acting Rev-responsive element (RRE) present on all unspliced and partially spliced mRNAs. 
Therefore, the RRE must be present in the sense orientation within the transcripts. 
The accessory protein Vpx is only encoded by viruses of the HIV-2/SIVsmm/SIVmac lineage 
(HIV-2, SIVmac, SIVsmm, SIVmnd-2, SIVrcm, SIVdrl). This 17 kDa protein is packaged to 
high levels in the virion through the interaction with the C-terminal p6 domain of the Gag 
polyprotein (Henderson et al., 1988; Pancio and Ratner, 1998; Wu et al., 1994). It is required 
for an efficient virus replication in macrophages and in dendritic cells (Fletcher et al., 1996; 
Hirsch et al., 1998; Srivastava et al., 2008) and essential for the lentiviral vector transduction 
of primary human monocytes (Wolfrum et al., 2007). Its function is part of efficient reverse 
transcription in monocyte-derived cells (Srivastava et al., 2008) and to the nuclear import of 
the viral preintegration complex (Belshan and Ratner, 2003; Fletcher et al., 1996). 
The  remaining  accessory  proteins,  Vif,  Vpu,  Vpr,  and  Nef,  are  not  essential for  lentiviral 
vector transduction, hence they will not be described in more detail. The functions are well 
reviewed by E. Freed, and M. Martin (Freed and Martin, 2007). 
2.1.2 Lentiviral vectors  
Retroviral vectors integrate their viral genome into the genome of the host. Thus, a stable, 
long-term expression of a transgene can be achieved. The γ-retroviral based vectors like 
MLV  cannot  transduce  non-dividing  cells.  On  the  contrary,  lentiviral  vectors  efficiently     Introduction 
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transduce non-dividing cells and are therefore of special interest for research and clinical 
applications.  
Structure 
The first lentiviral vector was constructed by Luigi Naldini and others in 1996 (Naldini et al., 
1996b). Since then, lentiviral vector development has been often modified in order to improve 
the efficiency and safety of the system. The initial design of lentiviral vectors provides for the 
separation  of  the  necessary  viral  elements,  rendering  the  produced  vectors  replication-
incompetent. The vector RNA to be packaged into the vector particles is separated from the 
structural genes (gag, pol) which are important for the particle formation itself, and from the 
envelope-encoding sequence. This results in a transfer-, a packaging-, and an envelope-
construct, respectively. For vector production the different constructs are usually used for 
293T-cell transfection, where 48 h post transfection the vectors can be harvested from the 
supernatant. Subsequently, the titer can be analyzed and the vectors used for target cell 
transduction (Figure 4). 
 
Figure  4:  Transient  vector  production.  The  transfer-  packaging-  and  envelope-construct  are 
transiently transfected into 293T cells. Two days post transfection, vector particles are harvested and 
titrated on HT1080 cells (I). Subsequently, they can be used for target cell transduction (e.g. monocyte 
transduction) (II).  
Envelope construct 
In general, the native lentiviral envelope is exchanged for the vesicular stomatitis virus G 
(VSV-G) protein (Naldini et al., 1996b). Pseudotyping with VSV-G allows transduction of a 
wide range of target cells and tissues and redirects, in contrast to the receptor mediated  
entry with wild-type envelope, vector entry through to the endocytic pathway (Aiken, 1997).     Introduction 
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Using the very stable VSV-G as envelope allows the concentration of the viral vectors by 
ultracentifugation. Although VSV-G occasionally mediates an immune response in patients 
which leads to a clearance of the vectors, VSV-G pseudotyping is most widely used as it 
yields very high transduction efficiencies.   
Packaging construct 
The packaging construct encodes from the gag and pol genes all structural and enzymatic 
proteins that are required for vector particle production and efficient transduction of target 
cells, with the exception of the envelope protein. Additionally to the Gag/Pol expression, the 
first generated packaging constructs coded for both regulatory proteins, Tat and Rev, and for 
all  accessory  proteins  (Naldini  et  al.,  1996a;  Naldini  et  al.,  1996b).  The  viral  full-length 
mRNA, which encodes for the trans-elements, is usually packaged into vector particles and 
transferred to the target cell. To prevent this, the LTRs, PBS- and  -sites were removed. The 
expression is  therefore  normally driven by a  heterologous constitutive promoter  (CMV or 
RSV) and ended by polyadenylation signals from the SV40 and insulin gene. These so-called 
first-generation packaging constructs were improved to second-generation constructs by the 
deletion  of  all  accessory  proteins  (Figure  4)  (Zufferey  et  al.,  1997)  and,  further,  to third-
generation vectors where the tat gene was deleted and the gag/pol and rev genes were split 
onto separate plasmids (Dull et al., 1998). Further improvements to increase the biosafety of 
the  packaging  constructs  have  been  achieved,  i.e.  a  codon-optimized  Rev-independent 
Gag/Pol expression (Kotsopoulou et al., 2000) or the separation of the gag/pol genes on two 
different plasmids (Kappes et al., 2003; Wu et al., 2000).  
Transfer vector 
The  lentiviral  transfer  vector  encodes  for  the  transgene  mRNA.  Independent  of  the 
generation  status,  the  RNA  contains  all  elements  necessary  for  its  packaging,  reverse 
transcription, nuclear import, and integration. Besides, it harbors an expression cassette for 
transgene expression under control of an internal promoter.  
The basic transfer vector consists of a 5‟ UTR, spanning the 5‟ LTR, the primer binding site, 
the splice donor (SD), the packaging signal, the rev-responsive element, the splice acceptor 
(SA), the transgene expression cassette, and the 3‟UTR containing the PPT and the 3‟LTR 
(Naldini et al., 1996a; Naldini et al., 1996b). Different changes within the transfer vector led to 
an increase in vector titer, transduction efficiency, and transgene expression. In addition, it 
improved the safety of the vectors. Through the addition of a cPPT and CTS a 2-10fold 
increase  in  transduction  efficiency  was  achieved  (Zennou  et  al.,  2000).  During  reverse 
transcription the viral RNA, with the exception of the PPT and cPPT region, is degraded by 
the RNase H. The resulting two locations prime the plus strand synthesis for the proviral     Introduction 
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DNA. The synthesis from the PPT is terminated at the CTS which generates a DNA flap 
(triple helix structure) necessary for efficient replication and important for nuclear import (De 
Rijck and Debyser, 2006).  
The woodchuck hepatitis virus posttranscriptional regulatory element 
The transgene expression was improved by the incorporation of the woodchuck hepatitis 
virus  posttranscriptional  regulatory  element  (WPRE)  downstream  of  the  transgene.  The 
WPRE stabilizes the mRNA through secondary structures resulting in a five-fold increased 
gene  expression  (Hlavaty  et  al.,  2005;  Zufferey  et  al.,  1999).  As  it  codes  for  enhancer-
promoter  elements  and  for  the  first  60  amino  acids  of  the  woodchuck  hepatitis  virus  X 
protein,  concerns  about  a  possible  oncogenic  activity  were  expressed  (Kingsman  et  al., 
2005).  To  exclude  those  safety  concerns,  a  modified  WPRE  which  lacks  the  potential 
oncogenic  sequences  but  maintains  its  ability  to  enhance  transgene  expression  was 
developed (Schambach et al., 2006a).  
Vectors derived from the simian immunodeficiency SIVsmmPBj 
The PBj strain of simian immunodeficiency virus from sooty mangabeys (Cercocebus atys) 
(SIVsmm) (Fultz et al., 1989), has been shown to replicate in vitro in non-stimulated primate 
PBMCs (Fultz, 1991). As this feature is unique for SIVsmmPBj, compared even to closely 
related viruses like HIV-2, SIVmac251, it was used to generate SIVsmmPBj-derived two-
plasmid  system  lentivectors.  These  replication-incompetent  vectors  enabled  an  efficient 
transduction of primary human monocytes (Mühlebach et al., 2005). The ability to transduce 
monocytes was found to be connected to the viral accessory protein Vpx (Wolfrum et al., 
2007).  The  PBj-derived  two-plasmid  lentivector  was  further  enhanced  to  a  basic  three-
plasmid system. It includes the envelope construct pMD.G2 (9.2), the packaging-construct 
pPBj-pack (9.4), and the transfer vector pPBj-trans (Wolfrum, 2005). This system was used 
as the origin for further vector enhancements in this thesis.  
2.1.3 Risk associated to lentiviral vector transduction 
The method for generating retroviral and lentiviral vectors is greatly influenced by possible 
risks linked to vector gene therapy, such as insertional mutagenesis, vector mobilization, 
generation of replication competent lentivirus (RCL), and germ-line transmission of vector 
sequences.  In  contrast to  retroviral  vectors,  lentiviral  vectors  show  a  different  integration 
preference into active transcription units as opposed to regulatory gene regions (Lewinski et 
al.,  2006;  Schroder  et  al.,  2002;  Wu  et  al.,  2003).  Although  there  is  evidence  that  this 
different  integration  preference  of  lentiviral  vectors  minimizes  the  risk  of  cellular  proto-
oncogene upregulation in comparison to MLV vectors (Cattoglio et al., 2007; Montini et al.,     Introduction 
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2006), the risk of lentiviral mediated insertional mutagenesis is present and has to be further 
investigated. Safety concerns had a great impact on the design of lentiviral vectors. Several 
different modifications of the transfer vectors are used to increase their safety profile. They 
are described in the following paragraphs. 
Self-inactivating lentiviral vectors 
The generation of self-inactivating (SIN) lentiviral vectors has improved the vector systems 
substantially (Miyoshi et al., 1998; Zufferey et al., 1998). Here, the promoter and enhancer 
sequences  within  the  U3  region  of  the  3‟-LTR  were  deleted.  In  the  process  of  reverse 
transcription,  this  promoter/enhancer  deficient  U3  region  of  the  3‟-LTR  replaces  the  U3 
region of the 5‟-LTR in the proviral DNA and thus prevents an RNA transcription. Therefore, 
only the transgene is expressed by the internal promotor. This shut-off of full-length vector 
mRNA averts vector mobilization upon superinfection with wild-type virus. Furthermore, the 
deletion of enhancer and promoter sequences reduces the risk of insertional mutagenesis, 
homologous recombination, and vector mobilization. 
Insulators 
The safety  of  lentiviral  vector  systems  can  be improved  with  insulators. These  boundary 
elements can prevent enhancer-promoter interactions if placed between those elements and 
protect  transgene  cassettes  from  silencing  and  positional  effects.  For  this,  chromatin 
insulators can be integrated into the U3 region of the transfer vector (Recillas-Targa et al., 
2004). The most widely used insulator is the chicken b-globin insulator (cHS4).  
Ubiquitously acting chromatin opening elements 
The  ubiquitously  acting  chromatin  opening  elements  (UCOEs),  like  the  UCOE  from  the 
human  HNRPA2B1-CBX3  locus  (A2UCOE),  consist  of  methylation-free  CpG  islands  and 
dual divergently transcribed housekeeping promoters but lack enhancer sequences. They 
are shown to be resistant to transcriptional silencing and to produce a consistent, ubiquitous, 
and  stable  transgene  expression  due  to  the  obviation  of  chromosomal  position  effects 
(Antoniou et al., 2003; Ramezani et al., 2003).  These features could be transferred to  a 
lentiviral vector context. This resulted in a vector with a stable gene expression which is 
hardly effected by insertion-site position effects and is implied to have a far lower insertional 
mutagenesis activation potential (Zhang et al., 2007) 
2.1.4 Gene Therapy 
The general principle of ex vivo gene therapy to correct genetic disorders looks very simple. 
A relevant cell type is isolated from the patient, gene modified ex vivo using viral vectors, and     Introduction 
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reintroduced into the patient (Figure 5). Important targets for gene therapy are hematopoietic 
stem cells (HSCs) as a functional correction of these results in a correction of all blood and 
immune cells in the body. However, basically all long-lived cells can be gene corrected.  
 
Figure  5:  Correcting  genetic  diseases  by  ex  vivo  gene  therapy.  Gene  defective  cells  are 
harvested and transduced with lentiviral vectors encoding the potentially therapeutic transgene. The 
gene-corrected cells are then reintroduced into the patient.  
  
Retroviral vectors in gene therapy 
In the most prominent gene therapy trials using retroviral vectors, they were employed to 
treat  hematopoietic  disorders  such  as  adenosine  deaminase-deficient  severe  combined 
immunodeficiency  (ADA-SCID)  (Aiuti  et  al.,  2009),  X-linked  severe  combined 
immunodeficiency (SCID-X1) (Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2002), 
and  X-linked  chronic  granulomatous  disease  (xCGD)  (see  Chpt.  2.3)  (Ott  et  al.,  2006). 
Although  all  of  these  retroviral  gene  therapy  trials  were  great  successes,  certain  risks 
associated  with  gene  therapy  became  visible.  One  major  concern,  i.e.  insertional 
mutagenesis, persists. As viral vectors integrate with little preference into the host genome, 
host genes can be directly affected or indirectly activated. In the case of the SCID-X1 trial, 
insertional mutagenesis led to cancer in several patients (Check, 2005; Hacein-Bey-Abina et 
al., 2003) and for xCGD-patients a clonal dominance was observed (Grez, 2008). Another 
problem  was  the  observed  gene-silencing  in  the  xCGD  patients  (Schultze-Strasser, 
unpublished data).     Introduction 
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Lentiviral vectors in gene therapy 
The main advantages of lentivirus-derived vectors over retroviral vectors are the ability to 
transduce different non-dividing cells, a more robust gene expression, and the size-flexibility 
in the design of the expression cassette (Schambach and Baum, 2008). Although to date 
retroviral  vectors  were  used  in  more  than  20%  of  the  approved,  ongoing,  or  completed 
clinical gene therapy trials (317 out of 1472), only the small number of 18 trials employed 
lentiviral vectors (as of Sept. 2008) (www.wiley.co.uk/genetherapy/clinical/). Many of those 
are currently in an early phase I/II. Only a few clinical trials are reported on so far:  
The first clinical trial with lentiviral vectors was performed on individuals suffering from the 
acquired immunodeficiency syndrome (AIDS) caused by HIV-1 (Dropulic and June, 2006; 
Levine et al., 2006). In this case CD4
+-T-cells were transduced ex vivo using HIV-1-derived 
vectors to express an HIV Env antisense RNA. After i.v. injection the viral load remained 
unaffected,  but  the  T-cell  count  remained  stable  or  even  increased.  After  36  months  no 
evidence for insertional mutagenesis could be seen.  
Two clinical trials have been started using HIV-1-derived vectors for patients suffering from 
β-thalassemia and X-linked adrenoleukodystrophy (ALD) in 2006 and 2007, respectively. To 
date only conference reports are available. For ALD, two children have been treated with 
gene-corrected HSCs and are doing well (Cartier et al., 2007).  
Lentiviral vectors generated from the equine infectious anemia virus (EIAV) were used for 
treatment  of  Parkinson‟s  disease.  The  EIAV  vector  encodes  for  three  basic  dopamine 
biosynthetic enzymes, and is currently tested in a phase I/II clinical trial for evaluation of 
biosafety and efficiency in patients (Jarraya et al., 2008). 
2.2 Monocytes 
Monocytes play an important role in immune defense, inflammation, and tissue remodeling. 
These functions are fulfilled by means of phagocytosis, antigen processing and presentation, 
and  cytokine  production.  Monocytes  stem  from  a  common  hematopoietic  progenitor,  the 
macrophage and dendritic cell (DC) precursor (MDP). Apart from monocytes, MDPs are the 
common precursors of macrophages and the two main DC-subsets, i.e. splenic DCs (cDCs) 
and plasmacytoid DCs (pDCs) (Figure 6) (Fogg et al., 2006; Naik et al., 2006; Varol et al., 
2007).  
Monocyte subsets 
In  humans,  two  major  subsets  of  circulating  monocytes  can  be  distinguished  by  their 
expression of CD14 (a component of the lipopolysaccharide receptor complex) and CD16     Introduction 
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(an FcγRIII immunoglobulin receptor). The major monocyte population, representing 80% - 
90%  of  the  circulating  monocytes,  are  CD14
highCD16
-  monocytes  (referred  to  as  CD14
+ 
monocytes).  The  minor  CD14
lowCD16
+  monocyte  population  (referred  to  as  CD16
+ 
monocytes) only contributes to 10% - 20% of the circulating monocytes.  
Murine  monocytes  can  be  identified  by  the  surface  marker  CD115  (a  receptor  for 
macrophage  colony  stimulating  factor),  CD11b,  the  FSC-SSC  FASC-profile,  and  the 
expression of Gr1 (Geissmann et al., 2003). Gr1 is an epitope which is expressed on Ly6G 
and Ly6C antigens (Fleming et al., 1993). It is therefore also present on granulocytes, pDCs, 
and on 40% of the NK cells. In comparing human and murine monocyte populations, the 
following similarities are found: The CX3CR1
lowCCR2
+Ly6C
+ population (referred to as Gr1
+-
monocytes)  is  most  similar  to  the  CD14
+  monocytes  and  the  CX3CR1
+CCR2
-Ly6C
low 
population (referred to as CX3CR1
+-monocytes) best resembles the CD16
+ monocytes. Both 
subsets of murine monocytes are present to equal quantities (Geissmann et al., 2003). The 
CX3CR1
+-monocytes are a product of the Gr1
+-monocytes (Sunderkötter et al., 2004; Varol 
et al., 2007). 
Monocyte function 
The Gr1
+- and CD14
+-monocytes (the so-called inflammatory monocytes) are recruited to 
inflamed tissue and lymph nodes and produce high levels of TNF-α and IL-1. Upon microbial 
infection  they  egress  from  the  bone  marrow  to  the  bloodstream  and  differentiate  into 
TNF-α/iNOS-producing  DCs  (Tip-DCs).  The  main  function  of  these  monocyte-derived 
inflammatory DCs is to kill bacteria rather than to regulate T cell functions (Auffray et al., 
2009).  In  contrast  to  Gr1
+-  and  CD14
+-monocytes  the  CX3CR1
+-and  CD16
+-monocytes, 
termed resident monocytes, patrol the blood vessels. In the case of damage and infection, 
they rapidly invade the tissue followed by initiation of an innate immune response, i.e. the 
recruitment of inflammatory cells, and by their differentiation into macrophages (Auffray et al., 
2007). While the antigen presentation is a classical feature described for monocytes, it has 
been found to be less efficient in monocytes than in DC subsets (Banchereau and Steinman, 
1998).       Introduction 
     
14 
 
 
Figure 6: Origin and hematopoietic differentiation of myeloid antigen-presenting cells. (MDP, 
dendritic cell precursor; DC, dendritic cell; pDC, plasmacytoid DC; cDC, splenic DCs) 
2.3 Chronic granulomatous disease  
Chronic granulomatous disease (CGD) is a rare disease with approximately one case per 
200-500  thousand  individuals.  Patients  with  CGD  suffer  from  severe,  life-threatening 
infections  and  chronic  inflammation  due  to  an  inability  of  phagocytes  (neutrophils, 
eosinophils, monocytes and macrophages) to generate reactive oxygen species (ROS), such 
as superoxide, hydrogen peroxide and hydroxyl radicals,  to  mediate phagocytic oxidative 
killing.  O2
−,  the  precursor  of  ROS,  is  produced  by  the  NADPH  oxidase,  a  multi-protein 
enzyme complex. The enzyme is inactive in resting phagocytes, but becomes activated by 
the interaction of the phagocytic cells with pathogens and by their subsequent uptake. A 
genetic alteration in one of the NADPH subunits, either gp91
phox, p67
phox, p47
phox, or p22
phox 
(phox: phagocytic oxidase), results in a non-functional NADPH-oxidase, causing the disease. 
The most common form (50-70%) is linked to a deficiency of the gp91
phox subunit, resulting 
from a mutation in the CYBB gene encoding gp91
phox (Johnston, 2001). The CYBB gene is 
located on the x-chromosome; hence, the gp91
phox defect leads to the so-called X-linked 
chronic granulomatous disease (xCGD).  
NADPH oxidase and ROS 
The  NADPH  oxidase  consists  of  six  hetero-subunits.  The  catalytic  core,  a  heterodimeric 
flavocytochrome b558, is formed by the membrane proteins gp91
phox and p22
phox. Only after     Introduction 
     
15 
 
the appropriate stimuli, the enzymatic activity is activated by the translocation of the other 
NADPH subunits p67
phox, p47
phox, and p40
phox, and the small GTPase Rac, from the cytosol to 
the membrane. The activated NADPH-complex can perform an electron transfer from the co-
enzyme NADPH to oxygen, resulting directly in superoxide. It is also described to activate 
microbicidal azurophil granule proteases, such as cathepsin G and elastase (Rada et al., 
2004; Reeves et al., 2002), as well as microbicidal neutrophil extracellular traps (Fuchs et al., 
2007)  (Figure  7).  The  reactive  oxygen  species  have  also  been  shown  to  be  involved  in 
functions  other  than  oxidative  killing.  These  include  metabolism,  cell  death,  apoptosis, 
regulation of inflammation, induction of host defense genes, and oxidative signaling (Bylund 
et al., 2005; Kimura et al., 2005). 
 
Figure  7:  Phagosome  formation  and  oxidative  killing  of  microbes  (bacteria  and  fungi)  by 
phagocytic cells. (Modified from Seger, 2008) 
 
The CGD individuals suffer from a range of infections, mainly pneumonia, abscesses of the 
skin, tissues, and organs, suppurative arthritis, osteomyelitis, and bacteremia/fungemia. The 
most  common  organisms  causing  diseases  are  the  fungi  from  Aspergillus  species  and 
Candida  albicans,  and  the  bacteria  Staphylococcus  aureus  and  Burkholderia  cepacia 
complex bacteria (Mouy et al., 1989; Winkelstein et al., 2000). In addition to the infections, 
CGD patients frequently have exuberant and persistent tissue granuloma formation - clinical 
manifestations of chronic inflammation. As a result of these recurring and severe infections, 
CGD individuals have an average life expectancy of 18 years +/- 2.6 years (Wolach et al., 
2008).     Introduction 
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Treatment of CGD 
The general medication for CGD is a lifelong prophylaxis against infections. The antibiotic 
trimethoprim-sulfamethoxazole  is  administered  to  decrease  the  frequency  of  bacterial 
infections, itraconazole to prevent fungal infections, and IFN-γ is used to reduce severity of 
infections. In acute phases, the treatment depends on the type and severity of the infection 
and includes antibiotic treatment, antifungal therapy, or surgical interventions. In selected 
CGD  patients  with  life-threatening  bacterial  and  fungal  infections  a  white  cell  transfusion 
(granulocyte  transfusion)  has  been  performed  (von  Planta  et  al.,  1997).  Although  the 
allogenic cell transfusion is generally well tolerated, adverse events often arise and the risk 
of  alloimmunization  to  HLA  antigens  may  complicate  later  allogeneic  stem  cell 
transplantation (Stroncek et al., 1996). Interestingly, a small amount of wild-type neutrophils 
is able to synergize with CGD neutrophils in extracellular Aspergillus hyphae killing (Rex et 
al., 1990). 
In order to cure CGD, hematopoietic stem cell transplantation (HSCT) is possible if a human 
leukocyte antigen identical donor is available. A study of 27 patients who received a marrow 
graft after conditioning from HLA-identical sibling donors showed an overall cure in 81% of 
the patients. Severe side effects and graft-versus-host disease were exclusively observed in 
patients with ongoing infections at the time of transplantation (Seger et al., 2002). Hence, at 
best infections should be under control before starting to condition for HSCT (Seger, 2008). 
In the absence of a potential stem cell donor, HSCT is considered to be very risky due to 
graft failure and a delayed immune reconstitution, but has been performed twice (Kikuta et 
al., 2006).  
In such cases, stem cell gene therapy might become more and more an option for xCGD. As 
a small amount of corrected neutrophils (~ 5-10%) appears to be highly beneficial (Dinauer et 
al., 2001; Mills et al., 1980) and the expression of only small amounts of gp91
phox is needed 
for sufficient superoxide production (Bjorgvinsdottir et al., 1997), gene therapy seems well 
feasible. The problem is that corrected cells lack a selective growth advantage (Stein et al., 
2006). Recent gene therapy trials have been performed on one patient in Zurich (2002) and 
two patients in Frankfurt (2004) using gene-modified CD34
+-cells (Ott et al., 2006). In the two 
patients in Frankfurt a high gene marking in peripheral blood leukocytes between 10% and 
30% was achieved 3-4 months after transplantation, leading to the elimination of pre-existing 
bacterial and fungal infections. Later, in both patients the activation of the growth-promoting 
genes  MDS1/EVI1,  PRDM16  and  SETBP1  caused  by  insertional  activation  led  to  an 
increase of the gene-corrected cells up to 50-60% of all peripheral blood granulocytes with 
an  existing  clonal  dominance  (Grez,  2008).  Although  the  presence  of  the  transgene 
remained high in both patients, the expression of gp91
phox decreased to almost undetectable     Introduction 
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levels caused by methylated gene-silencing (Schultze-Strasser, unpublished data). One of 
the patients died from a severe sepsis 2.5 years after gene therapy (Alexander et al., 2007). 
2.4 Objective 
In  contrast  to  other  lentiviral  vectors,  SIVsmmPBj-derived  vectors  have  been  proven  to 
efficiently transduce primary human monocytes. This capacity was linked to the vpx-gene of 
PBj, one of this lentivirus‟ accessory genes. As monocytes constitute a potential target for 
gene therapy, enhanced PBj vectors suitable for clinical applications had to be developed, 
and their capacity for functional transfer of therapeutic genes demonstrated.  
 
In the first part of this thesis, the aim was to clarify whether vectors derived from other vpx-
carrying lentiviruses also reveal the capacity for monocyte transduction. Therefore, lentiviral 
vectors  derived  from  other  viruses  of  the  HIV-2/SIVsmm/SIVmac  lineage  were  to  be 
investigated. The monocyte transduction capacity of HIV-2 and SIVmac vectors was to be 
tested in comparison to PBj and HIV-1 vectors, and the contribution of the respective vpx-
genes analyzed. 
 
The main focus of the thesis was on the enhancement of monocyte-transducing lentiviral 
vectors  meeting  the  required  standards  for  clinical  applications  concerning  gene  transfer 
efficiency and safety. On the basis of the preliminary vector systems available, the goal was 
to  generate  high  titer  vectors  revealing  a  high  safety  profile.  Since  available  packaging 
constructs already hold a satisfactory stage of development, the emphasis was laid on the 
optimization of transfer vectors. Therefore, all elements required for efficient gene transfer 
had to be inserted and as many needless sequences as possible deleted from the transfer 
constructs. The vectors should best be designed as self-inactivating (SIN) vectors in order to 
avoid activation of adjacent cellular genes after integration into the target cell´s genome. 
 
Finally,  the  new  vectors‟  suitability  for  future  gene  therapy  approaches  was  to  be 
demonstrated. The inherited human xCGD was chosen as disease model since a transfer of 
the correct version of the mutant gene gp91
phox into monocytes may offer a clinical benefit for 
patients. In this thesis, the goal was to lay a foundation for analyzing gp91
phox gene therapy 
of monocytes. Since the use of rare patient´s monocytes is not advisable at this early stage 
of development, it was decided to study the efficiency of gp91
phox-gene transfer in a murine 
model, using monocytes of healthy human donors only for the development of methods to 
demonstrate gp91
phox-dependent functions like oxidative burst and killing of pathogens. In     Introduction 
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murine  models  including  gp91
phox-knockout  mice,  the  functional  ex  vivo  transfer  of  the 
gp91
phox-gene  into  murine  monocytes,  as  well  as  the  in  vivo  half-life  of  transplanted 
monocytes in the bloodstream and their biodistribution were to be investigated to predict the 
suitability of this novel gene therapy approach. 
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3  Material and Methods 
3.1 Material 
3.1.1 Chemicals and consumables  
Unless noted otherwise, all chemicals used were obtained in p.a. quality from the companies 
Merck, Sigma-Aldrich, or Roth. The consumables for cell culture and molecular biology were 
obtained from the companies BD™, Eppendorf, Gipco, Greiner, Nunc, or Sarstedt. 
3.1.2 Enzymes and antibiotics 
     enzymes 
 
     source 
      restriction endonucleases     New England Biolabs 
T4-DNA-ligase 
 
New England Biolabs 
Taq-High-Fidelity-DNA-Polymerase     Invitrogen 
Klenow-polymerase 
 
New England Biolabs 
Antarctic Phosphatase     New England Biolabs  
 
     antibiotics 
 
     source 
      ampicillin     Roche 
penicillin 
 
Biochrom AG 
streptomycin     Biochrom AG 
 
3.1.3 Kits 
     kits 
 
     source 
      QIAprep Spin Miniprep Kit     Qiagen 
EndoFree Plasmid Maxi Kit 
 
Qiagen 
DNeasy Blood and Tissue Kit     Qiagen 
QIAquick Gel Extraction Kit 
 
Qiagen 
QIAquick PCR Purification Kit 
 
Qiagen 
Monocyte Isolation Kit II, human 
 
Mitenyi Biotech 
QuikChange Site-Directed Mutagenesis Kit     Stratagene 
BURSTTEST (PHAGOBURST) 
 
ORPEGEN Pharma 
Cytofix/Cytoperm Fixation/Permeabilization 
Solution Kit     
BD Biosciences 
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3.1.4 Plasmids 
  name 
 
   characterization 
 
   source 
                expression plasmids       
pVpxPBj   
Expression plasmid of unmodified Vpx of 
SIVsmmPBj   
Nina Wolfrum,    
Paul-Ehrlich-Institut 
pVpxHIV-2     Expression plasmid of unmodified Vpx of HIV-2    this thesis 
pVpxMAC    Expression plasmid of unmodified Vpx of SIVmac    this thesis 
pVpxHIV-2-
nFLAG     Expression plasmid of unmodified Vpx of 
SIVsmmPBj carrying a n-terminal FLAG-tag    this thesis 
pHA-VpxPBjsyn   
Expression plasmid of codonoptimized Vpx of 
SIVsmmPBj carrying a n-terminal HA-tag   
André Berger,    
Paul-Ehrlich-Institut 
pVpxPBjsyn 
(9.1)     Expression plasmid of codonoptimized Vpx of 
SIVsmmPBj    this thesis 
pVpxHIV-2syn   
Expression plasmid of codonoptimized Vpx of 
HIV-2   
Andre Berger,  
Paul-Ehrlich-Institut 
pcDNA3.1(+)    
Commercially available backbone for expression 
plasmids, contains a MCS downstream a CMV 
promoter, ampicillin resistance 
  Invitrogen 
pMD.G2 (9.2)    VSV-G expression plasmid   
D. Trono, Tronolab, 
Switzerland 
                two-plasmid vector systems       
pPBj-ΔEeGFP   
Genome of SIVsmmPBj1.9 containing a 1 kb 
deletion in the env gene. Expresses eGFP under 
the control of a CMV promoter.   
(Mühlebach et al., 
2005) 
pPBj-
4xKOeGFP    
Genome of SIVsmmPBj1.9 containing a 1 kb 
deletion in the env gene and point mutations in 
the start-ATGs of vif, vpx, vpr, and nef. Expresses 
eGFP under the control of a CMV promoter.  
  Julia Kaiser,     
Paul-Ehrlich-Institut 
pHIV-1-NL4-3    
Genome of HIV-1 (NL4-3) containing a 1.2 kb 
deletion in the env gene. Expresses eGFP under 
the control of a CMV promoter.  
  (Mühlebach et al., 
2005) 
pHIV-2-RodA    
Genome of HIV-2 (Rod A) containing deletion in 
the env gene. The eGFP is inframe within the nef 
gene and therefore expressed under control of 
the viral LTR. 
  (Reuter et al., 2005) 
                packaging constructs       
pCMVΔR8.9 
(9.3)    HIV-1 packaging plasmid   
U. Blömer, 
University Hospital 
Kiel, (Zufferey et al., 
1997) 
pSIV3+     SIVmac packaging plasmid    
F.-L. Cosset, 
University of Lyon, 
(Negre et al., 2000) 
pPBj-pack    
(9.4)    SIVsmmPBj packaging plasmid   
Nina Wolfrum 
(Wolfrum 2005 
pHIV-2d4    
(9.5)     HIV-2 packaging plasmid    Carsten Münk,  
Paul-Ehrlich-Institut  
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      SIVsmmPBj-derived transfer vectors       
pPBj-trans   
SIVsmmPBj-derived transfer vector encoding 
eGFP under control of the CMV promoter, 
contains second exons of tat and rev, deficient for 
CTS-element 
  (Wolfrum, 2005) 
pPBj-trans-SIN     Based on pPBj-trans, the second exons of tat and 
rev are deleted, SIN-configuration    this thesis 
pPBj-trans-cSIN   
Based on pPBj-trans-SIN, 1 kb pol-deletion and 
reintroduced cPPT/CTS-element    this thesis 
pPBj-SEW-SIN     Based on pPBj-trans-SIN encoding eGFP under 
control of the SFFV promoter, contains WPRE    (Högner, 2007), 
diploma thesis 
pPBj-SEW-cSIN   
Based on pPBj-trans-cSIN and pPBj-SEW-SIN, 
encoding eGFP under control of the SFFV 
promoter, contains WPRE, SIN-configuration    this thesis 
pPBj-SR-SEW-
cSIN            
(9.6) 
   Based on pPBj-SEW-cSIN, SV40/RSV-element 
replaces U3 in 5'LTR    this thesis 
pPBj-MCS   
(9.7)   
SIVsmmPBj-derived transfer vector with MCS 
derived by Fusion-PCR    this thesis 
pPBj-SEW     Based on pPBj-MCS. encoding eGFP under 
control of the SFFV promoter, contains WPRE    this thesis 
pPBj-g'-SEW   
Based on pPBj-SEW, integrated stop-codon 10 
triplets downstream the gag start-ATG    this thesis 
pPBj-SR-SEW     Based on pPBj-SEW, SV40/RSV-element 
replaces U3 in 5'LTR    this thesis 
pPBj-SR-g'-
SEW            
(9.8)   
Based on pPBj-g'-SEW and pPBj-SR-SEW, 
integrated stop-codon 10 triplets downstream the 
gag start-ATG, SV40/RSV-element replaces U3 
in 5'LTR 
  this thesis 
                HIV-2-derived transfer vectors       
pHIV-2-MCS 
(9.9)   
HIV-2-derived transfer vector with MCS derived 
by Fusion-PCR    this thesis 
pHIV-2-SEW     Based on pHIV-2-MCS encoding eGFP under 
control of the SFFV promoter, contains WPRE    this thesis 
pHIV-2-g'-SEW   
Based on pHIV-2-SEW, integrated stop-codon 11 
triplets downstream the gag start-ATG    this thesis 
pHIV-2-SR-
SEW     Based on pHIV-2-SEW, SV40/RSV-element 
replaces U3 in 5'LTR    this thesis 
pHIV-2-SR-g'-
SEW (9.10)   
Based on pHIV-2-g'-SEW and pHIV-2-SR-SEW, 
integrated stop-codon 11 triplets downstream the 
gag start-ATG, SV40/RSV-element replaces U3 
in 5'LTR 
  this thesis 
pHIV-2-SgW 
(9.11)     Based on pHIV-2-MCS, encoding gp91
phox under 
control of the SFFV promoter, contains WPRE    this thesis 
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      HIV-1-derived transfer vectors       
pHR-CMV-GFP   
Genome of HIV-1 containing a deletion in the env 
gene, encoding eGFP under control of the CMV 
promoter   
U. Blömer, 
University Hospital 
Kiel, (Miyoshi et al., 
1998) 
pHIV-1-SgpSw 
(9.12)     
HIV-1 transfer-vector encoding gp91
phox under 
control of the CMV promoter,  contains WPRE, 
SIN-configuration 
  Manuel Grez,  
Georg-Speyer-Haus 
pHIV-1-SEW 
(9.13)   
HIV-1 transfer-vector encoding eGFP under 
control of the SFFV promoter, contains WPRE, 
SIN-configuration   
Manuel Grez,  
Georg-Speyer-Haus 
                SIVmac-derived transfer vectors       
pGAE-SFFV-
WPRE   
SIVmac transfer-vector encoding eGFP under 
control of the SFFV promoter, contains WPRE, 
SIN-configuration   
Dorothee von Laer, 
Georg-Speyer-Haus 
                MLV-derived transfer vectors       
pSER11S91-
SW   
SIVmac transfer-vector encoding eGFP under 
control of the SFFV promoter, contains WPRE, 
SIN-configuration, SV40/RSV-element replaces 
U3 in 5'LTR 
 
A. Schambach, 
Hannover Medical 
School (Schambach 
et al., 2006b) 
3.1.5 Oligonucleotides 
All oligonucleotides were synthesized from the company Eurofins MWG Operon. 
   name 
 
    5'→ 3' sequence 
 
     
restriction     
site 
          BPK 1 
 
tgagaattctaggtagtaagcgatgtcagatcccag 
 
EcoRI 
BPK 2    atcctcgagctattatgctagtcctggagggggagg    XhoI 
BPK 3 
 
tgagaattctagagtgcaacaaaatgacagac 
 
EcoRI 
BPK 4    atcctcgagctattagaccagacctggagggggag    XhoI 
BPK 5 
 
ggtggaattcgagccatgagcgaccccagagagagaatc 
 
EcoRI 
BPK 6    tcactcgagtcattaggccagtccaggagggggag    XhoI 
BPK 7 
 
tcaagcttcgaattctgcagtcga 
 
EcoRI 
BPK 8    gtaggtaggctatctgaactctgctttacttgtacagctcgt      
BPK 9 
 
acgagctgtacaagtaaagcagagttcagatagcctacctac 
 
 
BPK 10    tgactgaatacagagcgaaatgttttatgtcttctatcactg      
BPK 11 
 
cagtgatagaagacataaaacatttcgctctgtattcagtca 
 
 
BPK 12    ggtggcggccgctctagaactagggcgactaggagagat    NotI 
BPK 13 
 
gcaggttggcgcccgaacag 
 
KasI 
BPK 14    aactgccattagtactatagtccaaatctgtccaattcattt      
BPK 15 
 
aaatgaattggacagatttggactatagtactaatggcagtt 
 
 
BPK 16 
  
aaggcaattggagtaatctctactaatttgtaatctcccaactccaatcgttccacagct
ggtctctgcc    
MfeI 
BPK 17 
 
tgaggcgcctgaactagtgaaggcctgaaataacctctgaaag 
 
KasI, SpeI 
BPK 18    tgccagcctctccgcagagtgagtttattgtatcgagctaggca      
BPK 19 
 
tgcctagctcgatacaataaactcactctgcggagaggctggca 
 
 
BPK 20    tcttccctgacaagacggagttt          Material and Methods 
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   name 
 
    5'→ 3' sequence 
 
     
restriction     
site 
          BPK 21 
 
acggtatcgataagcttctg 
 
HindIII 
BPK 22 
  
ttgttctgtggtgatcatattgactaatctttctgctggagtcatatcccctattcctccccttc
ttttaaaattctcatcatggagctaaaactgaaagaa    
  
BPK 23 
 
gtcaatatgatcaccacagaacaagaaatacaattccaacaatcaaaaaattcaaa
atttaaaaattttcgggtctgattggagttgggagattacaa 
 
 
BPK 24 
  
taataaatcccttccagtccccccttttcttttataaaatgatcaaccggtggatcctgca
gaattctcatttggccatggtacagtagt    
  
BPK 25 
 
gggactggaagggatttattacagtgatagaagacataaaatgacatttcgctctgtat
tcagt 
 
 
BPK 26    ggtggcggccgctctagaac      NotI 
BPK 27 
 
ttgatatcgaattcctgcag 
 
EcoRI 
BPK 28    tcagaattctcatcgacggtatcgatcaggcg    EcoRI 
BPK 29 
 
gcgagaaactccgtcttgtgagggaagaaagcag 
 
 
BPK 30    ctgctttcttccctcacaagacggagtttctcgc      
BPK 31 
 
tgactcgaggtccgtggcctgaaataacctct 
 
 XhoI 
BPK 32    tgccagcctctccgcagagtgagtttattgtatcgagctaggca      
BPK 33 
 
tgcctagctcgatacaataaactcactctgcggagaggctggca 
 
 
BPK 34    gctctcactctccttcaagt    KasI 
BPK 35 
 
tgaaagcttgtcgactgagaggatgtattacagtgagagaa 
 
HindIII, SalI 
BPK 36 
  
gttctgtggtgatcatattgattaatctttctgatggagtcatatcccctattcccccccttctt
ttaaaattcatgctcatcataccattggatctaaaactgtaagaa    
  
BPK 37 
 
caatatgatcaccacagaacaagagatacaattcctccaagccaaaaattcaaaat
taaaaaattttcgggtctatttcagagtgagtgtgttcgtgctagggttc 
 
 
BPK 38 
  
aaacatcccttccagtcccccccttgtttttattaaatgttcactcgaggtaccggtcaatt
gctagcccctcccagtcaggtgctaagga    
  
BPK 39 
 
ggggactggaagggatgttttacagtgaaagaagacataaaatcttcggtcgctctg
cggagaggctgg 
 
 
BPK 40    ccgcggcggccgctcaaccg    SacII, NotI 
BPK 41 
 
tgacaattgtgaagattttatttagtctccag 
 
MfeI 
BPK 42    tcacaattgcgacggtatcgatcaggcgg    MfeI 
BPK 43 
 
gaaactccgtcttgagagggtaaaaagcagatgaattagaa 
 
 
BPK 44    ttctaattcatctgctttttaccctctcaagacggagtttc      
BPK 45 
 
ttgctcacatgttctttcct 
 
PciI 
BPK 46    ttcagaggttatttcaggccctctcagtcgacaagcttat      
BPK 47 
 
ataagcttgtcgactgagagggcctgaaataacctctgaa 
 
 
BPK 48    cctagctcgatacaataaactcgctctgcggagaggctgg      
BPK 49 
 
ccagcctctccgcagagcgagtttattgtatcgagctagg 
 
 
BPK 50    ctgttcaggcgccaacctgc    KasI 
BPK 51 
 
tgacaattgtgagggaatgaaagaccccacct 
 
MfeI 
BPK 52    tcaaccggttcaaattcgacaacaccacggaa    AgeI 
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3.1.6 Bacterial strains and culture media 
Name 
 
genotype 
 
source 
         
E. coli TOP 10 F‟   
F´{lacI
q Tn10 (Tet
R)} mcrA, D(mrr-hsdRMS-
mcrBC) F80 lacZDM15 DlacX74 deoR recA1 
araD139 D(ara-leu)7697 galU galK rpsL 
(Str
R) endA1 nupG 
 
Invitrogen 
E. coli GM2163    
dam13::Tn9(Cam
R) dcm-6 hsdR2 leuB6 
hisG4 thi-1 ara-14 lacY1 glnV44 galK2 
galT22 xylA5 mtl-1 rpsL136(Str
R) tsx78 mcrA 
mcrB1 fhuA31 rfbD1 R(zgb210::Tn10) TetS 
endA1    
New England Biolabs 
E. coli Stable2   
F
- mcrA D(mrr-hsdRMS-mcrBC) recA1 
endA1 lon gyrA96 thi-1 supE44 relA1l
-D (lac-
proAB) 
 
Invitrogen 
S. aureus 
  
ATCC25923 
  
Julia Brachert,         
Paul-Ehrlich-Institut 
 
 
Luria-Bertani (LB) medium 
    Bacto-Trypton   1.0% (w/v) 
yeast extract   0.5% (w/v) 
NaCl   1.0% (w/v) 
pH 7.0 
   
 
 
S.O.C. medium (Invitrogen) 
    Tryptone   2.0% (w/v) 
yeast extract   0.5% (w/v) 
NaCl   10 mM 
KCl   2.5 mM 
MgCl2  10 mM 
MgSO4  10 mM 
glucose   20 mM 
3.1.7 Cell lines and culture media 
   name 
 
   Genotype 
 
   source 
         
HEK-293T   
human embryonic kidney cell line genetically 
engineered to express the large T antigen 
 
ICLC HTL04001 
HT1080     human fibrosarcoma cell line     ATCC CCL-121 
PLB-985    human acute myeloid leukemia cell line 
 
Manuel Grez,              
Georg-Speyer-Haus 
xCGD-PLB-985 
  
human acute myeloid leukemia cell line with a 
disrupted CYBB gene by homologous 
recombination (Zhen et al., 1993)    
Manuel Grez,              
Georg-Speyer-Haus 
 
Culture medium for HEK-293T and HT1080 cells  
Dulbecco`s modified Eagle medium (DMEM) obtained from Biochrom AG supplemented with 
10% fetal calf serum (FCS; Biochrom AG), 2 mM L-glutamine (Biochrom AG), 100 units/ml 
streptomycine, and 50 µg/ml penicillin.     Material and Methods 
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Culture medium for PLB-985 and xCGD-PLB-985 cells 
RPMI  1640  medium  obtained  from  Biochrom  AG  supplemented  with  10%  FCS,  2  mM 
L-glutamine, 100 units/ml streptomycine, and 50 µg/ml penicillin. 
 
Culture medium for murine and human monocytes 
Dulbecco`s modified Eagle medium (DMEM) obtained from Biochrom AG supplemented with 
10% AB serum (Sigma-Aldrich), 2 mM L-glutamine (Biochrom AG), 1x non-essential amino 
acids (NEAA) (Gibco), 100 units/ml streptomycine, and 50 µg/ml penicillin. 
3.1.8 Mouse strains 
strain name 
 
Discription 
 
source, 
provided by 
         
C57BL/6 
 
C57BL/6 is the most widely used inbred 
mouse strain 
 
The Jackson 
Laboratory 
B6.SJL-Ptprc
a Pepc
b/BoyJ          
(CD45.1 mice)    
Congenic strain which carries the antigen 
CD45.1 expressed on all hematopoietic 
cells except mature erythrocytes and 
platelets. Background strain: C57BL/6 
  
The Jackson 
Laboratory, 
Manuel Grez 
B6.129S6-Cybb
tm1Din/J                  
(xCGD mice)   
Mice with a null allele of the Cybb
tm1Din 
gene involved in X-linked CGD, which 
encodes the 91 kD subunit of the oxidase 
cytochrome b. (Pollock et al., 1995)   
Background strain: C57BL/6  
 
The Jackson 
Laboratory, 
Manuel Grez 
BALB/cAJic-RAG2
null IL-2Rg
null                                        
(Rag-2/gc
-/- mice) 
  
Mice lacking T cells, B cells, and NK cells                                                   
Background strain: BALB/c  
  
Markus Manz,  
Dorothee von 
Laer 
C57BL/6-Tg(CAG-GFP)1Osb/J                                 
(GFP mice) 
 
Mice expressing eGFP that makes all of 
the tissues, with the exception of 
erythrocytes and hair, appear green 
under excitation light.(Okabe et al., 1997)    
Background strain: C57BL/6  
 
Dorothee von 
Laer 
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3.2 Methods of molecular biology 
3.2.1 Cultivation of bacteria 
Liquid culture 
Bacteria were grown in LB medium supplemented with 0.1 mg/ml ampicillin (LBAmp) either at 
37°C over night or at 25°C for 60 - 72 h and 200 rpm in a bacteria shaker (Innova
®
 4200, 
New Brunswick Scientific). 
 
Culture plate 
The cultivation on LBAmp plates (1% (w/v) Bacto-Trypton, 0.5% (w/v) yeast extract, 1% NaCl, 
50  μg/ml  ampicillin,  1.5%  (w/v)  agar  agar)  or  standard-1-agar  plates  (1.5%  (w/v)  Bacto-
Peptone, 0.3% (w/v) yeast extract, 0.6% NaCl, 0.1% (w/v) D (+)-Glucose, 1.2% (w/v) agar 
agar)  were  performed  by  applying  bacteria  onto  the  plates  using  inoculation  spreader 
(Sarstedt) and subsequent incubation at 37°C or 25°C in a bacteria incubator (Innova
®
 4200, 
New Brunswick Scientific) until bacteria colonies were visible. The overgrown plates were 
stored for up to one month at 4°C. 
3.2.2 Cloning processes 
Restriction  
All  DNA  restrictions  were  performed  using  commercially  available  type  II  restriction 
endonucleases  from  New  England  Biolabs  (NEB)  according  to  the  manufacturer‟s 
instructions. For a preparative restriction 3 µg and for an analytical restriction 500 ng DNA 
were used.  
Standard restriction: 
500 ng or 3 μg  DNA for analytical or preparative purpose 
1 µl or 1.5 µl     restriction enzyme for analytical or preparative purpose      
2 μl       10x buffer (corresponding NEB buffer 1-4) 
2 μl       10x BSA 
ad 20 μl     Aqua bidest 
The  reaction  was  incubated  for  1  h  at  37°C  in  a  thermoblock  (Thermomixer  comfort, 
Eppendorf). In case of a double digest the optimal buffer for the double digest was chosen to 
the manufacturer‟s instructions. 
DNA Polymerase I, Large (Klenow)  
The Klenow polymerase is a proteolytic product of E. coli DNA polymerase I which retains 
polymerization and 3'→ 5' exonuclease activity, but has lost 5'→ 3' exonuclease activity.     Material and Methods 
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Therefore, the Klenow polymerase was used to fill-in 5´ overhangs or for the removal of 3´ 
overhangs to form blunt ends. 
Standard Klenow-reaction: 
30-50 μl   restricted DNA, purified by gel extraction or PCR purification 
1 μl     Klenow 
10 μl     NEBuffer 2 
3,3 μl    dNTPs (1 mM) 
ad 100 μl   Aqua bidest 
 
The reaction was incubated for  15 min  at  25°C in a  thermoblock (Thermomixer  comfort, 
Eppendorf).  
Antarctic Phosphatase 
The Antarctic Phosphatase catalyzes the removal of 5´ phosphate groups from DNA and 
RNA.  Since  phosphatase-treated  fragments  lack  the  5´  phosphoryl  termini  required  by 
ligases, they cannot self-ligate. This property was used to decrease the vector background in 
cloning strategies.  
Standard Antarctic Phosphatase reaction:  
50 μl     restricted DNA 
6 μl    Antarctic-Phosphatase-Buffer 2 (10x) 
1 μl     Antarctic-Phosphatase 
ad 60 μl   Aqua bidest 
The reaction was incubated for 15-60 min at 37°C in a thermoblock (Thermomixer comfort, 
Eppendorf). 
Ligation 
For  ligation,  the  T4-DNA-ligase,  which  catalyses  the  formation  of  phosphodiester  bonds 
between the fragments under consumption of ATP, was used. The Ligation was applied for 
fragments exhibiting complementary overhangs (sticky-end ligation) or blunt ends (blunt-end 
ligation).  
Standard ligation: 
3:1      Insert:Vector ratio     
0.1-1.0 μg     Total DNA       
1.0 or 0.1 units   Ligase for blunt-end or for sticky-end     
ad 20 μl     Aqua bidest 
The reaction mix was incubated at 16°C over night in a thermomixer (Thermomixer comfort, 
Eppendorf).     Material and Methods 
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3.2.3 Generation and transformation of competent bacteria 
Transformation of E. coli (TopF10, GM2163, Stable2) is the method of choice to amplify 
plasmid DNA through cellular replication. For this purpose, bacteria have to be prepared for 
the uptake of foreign DNA.  
For the generation of chemically competent bacteria 2.5 ml of an overnight culture were used 
to inoculate 100 ml LB medium, which were subsequently incubated at 37°C and 180 rpm in 
a bacteria shaker (innova™ 4200, New Brunswick scientific). Cells were grown to an OD550 of 
about 0.5 - 0.55 reaching the logarithmic growth phase. Then the culture was incubated on 
ice for 5 min, divided into two portions and pelleted at 4,000 rpm for 10 min at 4°C (Multifuge 
3SR,  Heraeus).  Next,  the  pellets  were  each  resuspended  in  20  ml  TFB1  buffer  (sterile 
filtrated  solution  of  30  mM  KOAc,  100  mM  RbCl2,  10  mM  CaCl2,  50  mM  MnCl2,  15% 
glycerine, pH adjusted to 5.8 with HAc), incubated on ice for 5 min and once again pelleted 
as above. Subsequently the bacteria were resuspended each in 2 ml TFB2 buffer (sterile 
filtrated solution of 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% glycerine, pH adjusted 
to 6.5 using KOH-solution) and incubated on ice for 15 min. Afterwards the suspension was 
portioned á 100 μl into 1.5 ml reaction tubes and frozen at -80°C.  
To  transform  the  chemically  competent  E.  coli  bacteria,  they  were  thawed  on  ice  and 
approximately 50 ng DNA or 10 μl of a ligation reaction (3.2.2) were added to one aliquot. 
After further incubation on ice for 30 min, a heat shock at 42°C for 45 sec was performed in a 
thermoblock (Eppendorf). Then 500 μl of pre-warmed (37°C) S.O.C. medium were added to 
the  sample  before  it  was  incubated  at  600  rpm  for  60  min  at  37°C  in  a  thermoblock 
(Eppendorf). Then the bacteria suspension was applied to LBAmp plates (2.2.1) and incubated 
at 37°C over night or at 25°C for 72 h.  
3.2.4 Plasmid preparation 
Plasmid  preparation  from  transformed  bacteria  was  performed  using  the  QIAprep
®  Spin 
Miniprep kit or the EndoFree
® Plasmid Maxi kit according to the manufacturer‟s instructions. 
These kits use an anion-exchange tip where plasmid DNA selectively binds under low-salt 
and pH conditions. RNA, proteins, metabolites, and other low-molecular-weight impurities are 
removed by a medium-salt wash, and pure plasmid DNA is eluted in high-salt buffer. The 
DNA  is  concentrated  and  desalted  by  isopropanol  precipitation  and  collected  by 
centrifugation. 
For purification of low amounts of DNA (Miniprep), 3 ml LBAmp medium were inoculated with 
one bacteria clone in a 13 ml tube (Sarstedt) and incubated over night at 37°C or for 48 h at 
25°C.  The  bacteria  broth  was  transferred  to  a  15  ml  conical  tube  (Greiner  bio-one)  and 
pelleted  at  2,400  rpm  for  10  min  at  RT  in  a  centrifuge  (Multifuge  3SR,  Heraeus).  The     Material and Methods 
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resulting pellet was used for the preparation of plasmid DNA according to the manufacturer‟s 
instructions of the QIAprep
® Spin Miniprep kit.  
For extraction of larger amounts of DNA (Maxiprep) 250 ml LBAmp medium were inoculated 
and cultivated over night at 37°C or for 48 h at 25°C in 500 ml glass bottles (Schott Duran). 
The bacteria broth was transferred to a 250 ml tube (Nalgene) and centrifuged at 6,000 rpm 
for 10 min at RT (Beckman J2-21). The resulting pellets were used for the preparation of 
plasmid DNA according to the manufacturer‟s instructions of the EndoFree
® Plasmid Maxi kit 
(Quiagen). 
Finally,  the  concentration  of  the  isolated  plasmid  DNA  was  determined  photometrically 
(GeneQuant pro, Amersham Biosciences) at absorption A260. 
3.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis allows the separation of DNA molecules by their size. For this 
purpose 1% agarose gels were used, by default. For their preparation, the corresponding 
amount  agarose  (Biozym  Scientific  GmbH)  was  dissolved  in  1x  TAE  buffer  (40  mM 
Tris‐Acetat, 1 mM EDTA) by heating the emulsion in a microwave oven. Before the gel was 
casted into a tray, 0.1 µg/µl ethidium bromide was added. The ethidium bromide intercalates 
into DNA strands and can be visualized under UV light. After the polymerization of the gel it 
was covered in 1x TAE buffer and loaded with the samples. The DNA samples were mixed 
with 6x loading buffer (0.25% brome phenol blue, 0.25% xylenxyanol, 30% glycerin in aqua 
bidest). As marker, 1.0 μg of a 1 kb DNA ladder (NEB) was used. The DNA fragments were 
separated  by  applying  80 V  or  120  V  for  approx.  45  min  in  an  Xcell  SureLock™ 
electrophoresis cell (Invitrogen). The DNA fragment were visualized on a transilluminator 
(Intas  Science  Imaging  Instruments  GmbH)  and  documented  or  extracted  from  the  gel 
(3.2.6). 
3.2.6 Gel extraction of DNA fragments 
After electrophoretic separation, the DNA fragment of interest was cut out of the gel and 
transferred into a 1.5 ml micro tube (Sarstedt). The following purification of the DNA from the 
agarose  gels  was  performed  using  the  Gel  Extraction  Kit  (Quiagen)  according  to  the 
manufacturer‟s instructions. This kit is based on binding of DNA to silica gel membranes in 
the presence of a high concentration of chaotropic salt. After impurities are washed away the 
pure DNA was eluted using 50 µl of aqua bidest.     Material and Methods 
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3.2.7 Nucleic acid sequencing 
Nucleic acid sequencing was performed at the company Eurofins MWG Operon. For this 
purpose, DNA samples containing approximately 1 μg plasmid DNA were lyophilized in a 
Speedvac sc 100 (Savant) and sent via regular mail together with appropriate primers of 
10 pmol/μl to the company. 
3.2.8 Polymerase chain reaction (PCR) 
PCR  allows  the  amplification  of  specific  DNA  sequences  from  different  origins,  such  as 
plasmid, genomic or complementary DNA. The amplified fragment can be used for further 
molecular  biological  methods.  In  this  thesis,  the  PCR  was  performed  with  the  DNA-
dependent  High-Fidelity  Taq  Polymerase  (Invitogen).  With  the  appropriate  buffers, 
oligonucleotides  (primers),  deoxynucleotides  and  cycling  conditions, the  DNA  polymerase 
amplifies  a  DNA  fragment  (template)  bordered  by  the  forward  and  reverse  primer  in  an 
exponential manner. A typical PCR cycle contains a denaturizing step at 94°C, leading to the 
dissociation of the double stranded template. The following hybridization step allows primer 
annealing  to  the  complementary  sequences  on  the  single  stranded  template.  The  exact 
hybridization temperature TH is depends on the G/C-A/T content of the primers. It can be 
calculated roughly corresponding to the Wallace rule (Suggs et al., 1981): TH = 4x(G+C) + 
2x(A+T) - 5. After hybridization, DNA elongation is performed at the temperature optimum of 
the used DNA-polymerase. By repeating this cycle sequence, the template is amplified in an 
exponential manner. 
Standard PCR-reaction 
 
2 µl  Plasmid DNA template (5 ng/µl) 
    1 μl  dNTP (10 mM) 
      1 μl   Forward primer (5 pm/μl) 
    1 μl   Reverse primer (5 pm/μl) 
    5 μl  Buffer (10x) mit MgCl2 
    0.5 μl  High-Fidelity Taq Polymerase (2.5 U/μl) 
      ad 50 μl Aqua bidest 
 
Standard-PCR-protocol:   
 
denaturation       2 min    94°C  
denaturation      30 sec   94°C 
primer hybridization    1 min    58°C      30x   
elongation      60-90 sec  72°C 
elongation      7 min    72°C 
        ∞    4°C 
 
The length of the primer elongation step depends on the length of the amplification product 
and was adjusted if necessary. In some cases a temperature gradient was used to determine     Material and Methods 
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the optimal primer hybridization temperature. All PCR reactions were performed using DNA 
Engine  (PTC-200)  Peltier  Thermal  Cycler  (Bio-Rad)  and  were  subsequently  analyzed  by 
agarose gel electrophoresis (3.2.5) for analytic or preparative purposes. In the case of a 
Fusion-PCR (3.2.9) the isolated PCR amplification product was used as PCR-template itself. 
Depending on the detected strength analyzed by agarose gel electrophoresis, 2-10 µl (of a 
50 µl elution volume) were used.  
3.2.9 Fusion-PCR 
The  Fusion-PCR  is  a  variation  of the  normal PCR  method (3.2.8).  It permits  to join  two 
pieces of DNA that share bases of homology at their linear ends. In general, the method 
consists of two separate PCR amplification steps. In a first step, the DNA fragments to be 
joined  are  generated  by  PCR.  For  this,  primers  were  designed  that  share  20  bases  of 
homology with both PCR-fragments. The first 20 bp hybridize with the template of the first 
PCR-reaction, while the second 20 bp are homologous to the template of the second PCR 
reaction. Hence, two complementary primer sequences of 40 bp were constructed resulting 
in the reverse primer for the first PCR-reaction and the forward primer for the second PCR-
reaction. 
The two generated PCR-fragments were verified on an agarose gel and subsequently used 
as templates in a Fusion-PCR reaction. In this reaction, both templates hybridized at their 
complementary parts during the PCR reaction and can therefore be fused together using the 
terminal primers from the 1
st round PCRs (Figure 8). The general PCR reaction is conducted 
as described in section 3.2.8.  
 
Figure 8: Schematic representation of a Fusion-PCR.      Material and Methods 
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3.2.10 QuikChange™ site-directed mutagenesis kit 
The QuikChange™ site-directed mutagenesis kit (Stratagene) was used to introduce point 
mutations into lentiviral transfer vectors. Within this method a specific mutation is introduced 
into the vectors using modified oligonucleotide primers containing the desired mutation. The 
oligonucleotide primers, each complementary to opposite strands of the vector, are extended 
during PCR by PfuTurbo DNA polymerase. This DNA polymerase replicates both plasmid 
strands with high fidelity and without displacing the mutant oligonucleotide primers producing 
a mutated plasmid containing staggered nicks. Subsequently, the parental DNA template is 
digested by DpnI endonuclease which is specific for methylated and hemimethylated DNA. 
The nicked vector DNA containing the desired mutations is then transformed into competent 
bacteria.  
The QuikChange™  site-directed mutagenesis kit  (Stratagene)  was used  according to the 
manufacturer‟s instructions. 
3.2.11 Staphylococcus aureus killing assay 
The human and murine monocytes used for the killing assay were isolated as described 
(3.3.4, 3.3.5). For the preparation of S. aureus (ATCC25923) a cryotube containing S. aureus 
with a concentration of 3-5x10
8 bacteria/ml was thawed at RT until a small clump of ice was 
left and transferred into a 50 ml conical tube containing LB-medium at 37°C. The bacteria 
were incubated for 10 min at 200 rpm in a bacteria shaker (Innova
®
 4200, New Brunswick 
Scientific), centrifuged (5 min, 2,400 rpm in a Multifuge 3SR, Heraeus) and resuspended in 
10 ml DMEM (supplemented with human 10% AB-Serum (Sigma-Aldrich), 1x NEAA (Gipco), 
and 2 mM L-glutamine (Biochrom AG)). The bacteria suspension was diluted once more 1:5 
with DMEM in case murine monocytes were used.  
The desired amount of monocytes (in 75 µl), the bacteria (10 µl or 20 µl) and 5 µl PMA 
(16.2 µM)  were  mixed  in  wells  of  a  96well  plate  (Nunc).  For  each  desired  monocyte-to-
bacteria ratio and time-point, one separate well was set up. Samples were taken after 0 min, 
60 min, 120 min, and 180 min incubation at 37°C. 10 µl of the sample were diluted 1:1000 
with aqua bidest and 25 µl spread on an agar plate. The number of colonies was counted 
15-24 h later.      Material and Methods 
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3.3 Cell culture and virological methods 
3.3.1 Cultivation of cell lines 
Cell  lines  were  cultivated  in  the  appropriate  medium  (3.1.7)  in  an  incubator  (BBD  6220, 
Heraeus) at 37°C, 6.0% CO2 and saturated water atmosphere and were passaged twice a 
week. For this purpose, adherent cells were washed once with PBS and detached with PBS-
EDTA (PBS (Biochrom AG), 100 mM EDTA) before an appropriate fraction of the resulting 
suspension was seeded into a new culture flask with fresh medium. 
3.3.2 Freezing and thawing of cultured cells 
Freezing 
Adherent cells were washed once with PBS, detached by trypsinising (PBS (Biochrom AG), 
100 mM EDTA, 0.25% Trypsin-Melnick) and resuspended in the appropriate medium before 
they were, like suspension cells, centrifuged (1000 rpm for 10 min at 4°C in a Multifuge 3SR, 
Heraeus) to pellet the cells. These were then resuspended in 4°C cold freezing medium 
(DMEM or RPMI with 20% FCS, 10% DMSO, 2 mM L-glutamine), aliquoted á 1.5x10
6 cells 
into precooled cryotubes and frozen in a 5100 Cryo 1°C Freezing Container (Nalgene) at -
80°C. After 24 h the cells were transferred into liquid nitrogen. 
Thawing 
Cryotubes were thawed at RT until a small clump of ice was left. Then the cell suspension 
was immediately transferred into a 50 ml falcon tube with 40 ml prewarmed medium. To 
exclude the cytotoxic DMSO, cells were subsequently centrifuged (1000 rpm for 10 min at 
RT,  Multifuge  3SR,  Heraeus),  resuspended  in  fresh  medium  (containing  20%  FCS)  and 
seeded into appropriate cell culture flasks. 24 h later the medium was exchanged to fresh 
medium (3.1.7). 
3.3.3 Isolation  of  human  peripheral  blood  mononuclear  cells 
(PBMC) 
Human  PBMCs  were  isolated  from  freshly  drawn  blood,  treated  with  an  anti-coagulant 
heparin or citrate, by density centrifugation using Histopaque
®-1077 (Sigma-Aldrich). For this 
purpose, 15 ml cold Histopaque (4°C) were overlaid with 25 ml of a 1:1 mixture of human 
blood and PBS (Biochrom AG) in a 50 ml conical tube (Greiner bio-one), By centrifugation 
400×g for 30 min at 20°C in a swinging-bucket (without break; Multifuge 3SR, Heraeus) the 
red  blood  cells  and  granulocytes  were  pelleted.  Above  the  Histopaque  solution  the     Material and Methods 
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lymphocytes, monocytes and macrophages were concentrated within the whitish interface 
(“lymphocyte-ring”). The interfaces of maximal four conical tubes were pooled into a new 50 
ml conical tube already containing approx. 5 ml PBS using a 5 ml pipette (Greiner bio-one). 
The tubes were filled up to 50 ml with PBS. The cells were centrifuged at 300×g for 10 min at 
20°C  (Multifuge  3SR,  Heraeus)  and  the  supernatant  carefully  removed.  Next,  remaining 
erythrocytes were lysed through incubation in 10 ml 0.86% ammonium chloride solution at 
37°C for 5-10 min, depending on the amount of red blood cells. Then, the cells were washed 
twice with PBS as described above. Finally, they were resuspended in 30 ml MACS-buffer, 
counted in a Neubauer counting chamber and used for monocyte isolation. 
3.3.4 Isolation of primary human monocytes 
Primary  human  monocytes  were  isolated  from  fresh  human  PBMCs  with  the  Monocyte 
Isolation  Kit  II  (Mitenyi  Biotech)  following  the  manufacturer‟s  instructions.  With  this  kit, 
untouched monocytes were isolated by depleting B cells, T cells, natural killer (NK) cells, 
dendritic cells and basophils. For this purpose, the unwanted cells are indirectly magnetically 
labeled  using a cocktail of biotin-conjugated antibodies against CD3,  CD7,  CD16, CD19, 
CD56,  CD123  and  Glycosphorin  A  as  well  as  biotin  MicroBeads.  By  retaining  the 
magnetically labeled cells on a MACS
® column in a magnetic field, the unlabeled monocytes 
are isolated to a high purity as they pass through the MACS
® column. 
Depending on subsequent experiments, the freshly isolated monocytes were either cultivated 
in RPMI-monocyte medium (3.1.7) or kept on ice in cold PBS (4°C) for a short period of time.  
3.3.5 Isolation of murine monocytes from BM 
A number of necessary mice were sacrificed and the tibias and femurs flushed with PBS 
(Biochrom AG) (4°C) using a 0.8 mm syringe (HSW). The bone-marrow cells from different 
numbers of mice were pooled in a 50 ml conical tube, centrifuged (300×g, 10 min, 4°C) and 
resuspended in 10 ml PBS. The cells were overlaid on 5 ml sucrose solution (Histopaque 
1083, density 1.083 g/ml, Sigma-Aldrich), and centrifuged for 30 min at 400×g at RT in a 
15 ml  conical  tube.  The  mononuclear  cell  interface  was  collected  with  a  1  ml  pipette 
(Eppendorf) in a 50 ml conical tube and washed by filling the tube up to 50 ml with PBS and 
centrifugation (300×g, 10 min, 4°C). Remaining erythrocytes were lysed through incubation in 
5 ml 0.86% ammonium chloride solution at 37°C for 5-10 min. The cells were washed once 
more with PBS and resuspended in 10 ml MACS-buffer, counted in a Neubauer counting 
chamber and used for monocyte isolation. Therefore, the cells were centrifuged  (300×g, 
10 min, 4°C), resuspended in 100 µl MACS-buffer and incubated with a mixture of FITC-
conjugated  antibodies  (10  µl  per  1x10
7  cells)  against  T  cells  (CD90.2),  B  cells  (CD45R     Material and Methods 
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(B220)), NK cells (CD49b (DX5)), and erythrocytes (Ter119) (Mitenyi Biotech) for 10 min at 
4°C. The antibodies were chosen on the bases of the murine monocyte isolation of F. Swirski 
and co-workers (Swirski et al., 2006). The cells were washed by filling the tube up to 50 ml 
with  MACS-buffer  and  centrifugation  (300×g,  10  min,  4°C).  The  resuspended  cells  were 
incubated once more with αFITC-antibody MicroBeads (Mitenyi Biotech) (10 µl per 1x10
7 
cells) for 10 min at 4°C, washed and resuspended in 500 µl MACS-buffer. The cells were 
then run through an LD-negative selection column (Mitenyi Biotech). The negative (putative 
monocyte) fraction was collected, and cells were counted. 
 
The following antibodies were used for murine monocyte isolation: 
name    dilution    source 
          FITC conjugated rat α-mouse CD90.2 mAb 
 
-                       
 
Miltenyi Biotec 
FITC conjugated rat α-mouse CD45R (B220) mAb     -                           Miltenyi Biotec 
FITC conjugated rat α-mouse CD49b (DX5) mAb 
 
-                       
 
Miltenyi Biotec 
FITC conjugated rat α-mouse Ter-119 mAb     -                           Miltenyi Biotec 
MicroBeads conjugated αFITC mAb 
 
-                       
 
Miltenyi Biotec 
3.3.6 Production and concentration of vector particles 
Vector particles were generated by transient transfection of HEK-293T cells. Depending on 
the  lentiviral  vector  system  two,  three  or  four  plasmids  were  used  for  transfection.  The 
plasmid DNA was introduced into the cells by calcium phosphate transfection. The procedure 
is based on slow mixing of HEPES-buffered saline (HBS) containing sodium phosphate with 
a CaCl2 solution containing the DNA. A DNA-calcium phosphate co-precipitate forms, which 
adheres to the cell surface and is taken up by the cell, presumably by endocytosis. 
Three days before transfection, 4.6x10
6 HEK-293T cells were seeded into a T175 flask. One 
hour  before  transfection  the  medium  was  replaced  by  9  ml  pre-warmed  (37°C)  medium 
supplemented with chloroquine (DMEM supplemented with 10% FCS, 2 mM L-glutamine, 
100 units/ml streptomycine, 50 µg/ml penicillin, and 25 µM chloroquine).  
Depending on the vector system different amounts of plasmid DNA were used to set up the 
transfection reagents for four T-175 flasks: 
Two-plasmid vector systems: 262.8 µg vector DNA, 131.4 µg pMDG.2 
Three-plasmid vector systems: 100 µg transfer vector, 100 µg packaging construct and 33 µg 
pMD.G2.  Additionally,  33  µg  of  unmodified  Vpx-expression  plasmid  or  16.5  µg  of 
codonoptimized Vpx-expression plasmids were used. 
To the plasmid DNA 600 μl 2.5 M CaCl2 solution was added and the tube filled up with H2O 
(Sigma-Aldrich W-3500) to 6 ml. While vortexing 6 ml 2x HBS Buffer (281 mM NaCl; 100 mM 
HEPES;  1.5  mM  Na2HPO4,  pH  7.12)  was  added  dropwise.  Afterwards  the  solution  was     Material and Methods 
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vortexed for an additional minute. Then, the 3 ml precipitate was added to the cells of one 
T175 flask. After 8 h and 24 h the medium was replaced by 25 ml and 10 ml fresh DMEM 
medium, respectively. Forty-Eight hours after transfection, the cell supernatant, containing 
the  pseudotyped  lentiviral  vector  particles,  was  harvested  and  replaced  by  10  ml  fresh 
DMEM.  The  supernatants  of  four  T175  flasks,  transfected  with  the  same  expression-
plasmids,  were  combined,  centrifuged  (3,500  rpm,  5  min),  and  filtered  (0.45  μm  filter, 
Sortorius  Stedim  Biotech  GmbH).  The  filtered  supernatant  was  concentrated  by 
centrifugation  at  25,000  rpm,  at  4°C  for  2  h  in  an  ultracentrifuge  (Optima™  L-70k 
Ultrazentrifuge, Beckman) through a 20% (w/v) sucrose cushion in pollyallomer centrifuge 
tubes (Beckman). The pellet was resuspended in 200 μl FCS-free RPMI-medium (Biochrom 
AG). Vector particle aliquots were stored at -80°C. 
The  vectors  were  also  harvested  and  prepared  the  same  way  at  72  h  and  96  h  post 
transfection. The third vector preparation was used to generate vector lysates (3.4.1). 
3.3.7 Transfection of cells in six well plates 
Transfection  of  cells  in  six  well  plates  was  performed  by  calcium  phosphate  or 
Lipofectamine™ LTX (Invitrogen) transfection. Twenty-four hours before transfection, 8x10
5 
293T cells were seeded into a single well of a six well plate.  
This low scale calcium phosphate transfection was used to analyze the best plasmid ratios of 
transfer vector to packaging construct in the generation of vector particles. One hour before 
transfection,  the  medium  was  replaced  by  800  µl  fresh  medium  supplemented  with 
chloroquine. Not more than 5 µg plasmid DNA was mixed with 7 µl CaCl2 filled up with H2O 
(Sigma-Aldrich  W-3500)  to  62.5  µl.  While  vortexing  62.5  μl  2x  HBS  buffer  was  added 
dropwise. Afterwards the solution was vortexed for an additional minute. Then, the 125 µl 
precipitate was added to the cells. After 8 h and 24 h the medium was replaced by 2 ml and 
1 ml fresh DMEM medium, respectively. 
The Lipofectamine™ LTX (Invitrogen) transfection was used together with PLUS™ reagent 
(Invitrogen) for all other 6well transfections. The Lipofectamine™ LTX transfection reagent 
[µl]  to,  PLUS™  reagent  [µl]  to  DNA  [µg]  ratio  used  was  4:1:2.  The  transfection  was 
performed according to the manufacturer‟s instructions. 
3.3.8 Titration of vector particles 
For the titration of eGFP-transferring vector particles about 3x10
4 HT1080 cells were seeded 
into a single well of a 24well plate (Nunc). On the next day, the vector particle stocks were 
serially diluted in 1:10 steps with medium and a total of 315 μl of the dilutions added per well. 
In advance the old medium was removed from the cells. After incubation for 4 - 6 h, the     Material and Methods 
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transduction reaction mix was exchanged for 1 ml of fresh medium (3.1.7). After 5 days, the 
titers were calculated by determining the percentage of eGFP-fluorescent cells by FACS-
analysis (LSR II System, BD). The counted cells per well were multiplied by the dilution factor 
and the factor  3.17  (used  315  μl x  3.17  =  1 ml) to obtain transducing units  per milliliter 
(TU/ml).  For  vector  titer  calculation,  dilutions,  in  which  about  5-20%  of  the  cells  were 
transduced, were chosen. 
The titration of gp91
phox-transferring vector particles was performed by transduction of 2x10
5 
xCGD-PLB-985 cells. Therefore, vector particle stocks were serially diluted in 1:10 steps and 
a total of 250 µl of the dilutions added to 250 µl suspension cells per well. After 5 days, the 
titers were calculated by determining the percentage of 7-AAD negative, gp91
phox-expressing 
cells  using  7-AAD  (BD  Biosciences)  and  FITC  conjugated  mouse  α-human 
flavocytochrome b558 mAb (MoBiTec), respectively, by FACS-analysis (LSR II System, BD). 
3.3.9 Transduction of primary monocytes 
For the transduction of murine and human monocytes, the cells were taken into cell culture 
directly after isolation. If not indicated otherwise, 2x10
5 or 5x10
5 monocytes per well of a 
48well plate were transduced one day post isolation. Therefore, the monocytes were washed 
once with PBS and the desired amount of vector particles, diluted in 200 µl DMEM medium 
(supplemented with human 10% AB-Serum (Sigma-Aldrich), 1x NEAA (Gipco), and 2 mM 
L-glutamine (Biochrom AG) added onto the cells. After incubation for 6-8 h, the transduction 
reaction mix was exchanged by 500 µl of fresh medium. After 5 days the monocytes were 
analyzed depending on the transgene. 
3.3.10 Fluorescence activated cell sorting (FACS) 
FACS analysis allows assaying cell populations for eGFP-expression or surface expression 
of  proteins.  The  method  makes  use  of  scattered  light  and  fluorescence  of  eGFP  or 
fluorophore labeled antibodies. The cells are excited with a laser beam and the fluorescence 
is detected. FACS analysis was performed on the LSR II system (BD Bioscience). For this 
purpose,  adherent  cells  were  detached  by  incubation  with  PBS-EDTA  solution  (PBS 
(Biochrom  AG),  100  mM  EDTA).  Approximately  2x10
5  -  5x10
5  cells  were  pelleted  by 
centrifugation at 3,500 rpm, 4°C, 5 min (Multifuge 3SR, Heraeus). Then they were washed 
with 5 ml PBS and centrifuged (3,500 rpm, 4°C, 5 min). The cells were resuspended in PBS 
and incubated with 1 µl FcR Blocking reagent (Miltenyi Biotech) for 10 min at 4°C in the dark. 
Afterwards, the cells were incubated with 1-3 µl of the appropriate antibody/antibodies for 15 
min at 4°C in the dark. After antibody incubation, the cells were washed with 5 ml FACS 
washing buffer (PBS, 1% FCS, 0.1% (w/v) NaN3) and finally fixed in 100-600 μl FACS-Fix     Material and Methods 
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(PBS, 1% paraformaldehyde). For the detection of eGFP-positive cells, they were directly 
fixed  after  the  first  washing  step.  To  determine  the  rate  of  unspecific  staining  by  the 
antibodies, cells were incubated with isotype controls conjugated with the same fluorofore as 
the applied antibody. The samples were either used directly for FACS analysis or stored up 
to three days at 4°C in the dark.  
FACS-data were analyzed either with the FACSDiva™ software (BD Bioscience) program or 
FlowJo (version 7) (Tree Star, Inc.).  
 
The following antibodies were used for FACS analysis: 
name    dilution    source 
          PE conjugated rat α-mouse CD90.2 mAb    1:10                    Miltenyi Biotec 
PE conjugated rat α-mouse CD45R (B220) mAb     1:10                            Miltenyi Biotec 
PE conjugated rat α-mouse CD49b (DX5) mAb    1:5                           Miltenyi Biotec 
PE conjugated mouse α-mouse NK1.1 mAb     -                        Miltenyi Biotec 
PE conjugates rat α-mouse Ly6G    1:10                         BD Biosciences 
PE conjugated mouse α-mouse CD45.1 mAb     -                    eBiosciences 
PE Mouse IgG2a Isotype Control    -                          Miltenyi Biotec 
PE rat IgG2b Isotype Control     -                           Miltenyi Biotec 
PE rat IgM Isotype Control    -                          Miltenyi Biotec 
PE-Cy7 conjugated rat α-mouse CD11b mAb     -                    BD Biosciences 
PE-Cy7 Rat IgG2b, k Isotype control    -                    BD Biosciences 
APC conjugated rat α-mouse CD11b     1:20                           Miltenyi Biotec 
APC rat IgG2b Isotype Control    -                          Miltenyi Biotec 
Vio-Blue conjugated rat α-mouse Gr1 mAb     -                    Miltenyi Biotec 
Pacific Blue
® Rat IgG2b Isotype Control    -                   eBiosciences 
PerCP-Cy5.5 conjugated mouse α-mouse CD45.2 mAb     -                    eBiosciences 
PerCP-Cy5.5 Mouse IgG2a, K Isotype Control    -                   eBiosciences 
FITC conjugated mouse α-human flavocytochrome b558     -                    MoBiTec 
FITC mouse IgG1 Isotype control    -    Miltenyi Biotec 
APC conjugated mouse α-human CD14     -                    Miltenyi Biotec 
APC mouse IgG2a Isotype control 
 
-    Miltenyi Biotec 
3.3.11 Determination of in vivo biodistribution of murine monocytes 
Murine  bone-marrow  monocytes  were  isolated  from  GFP  mice  (C57BL/6-Tg(CAG-
GFP)1Osb/J) as described (3.3.5). After the isolation, 4x10
7 monocytes were resuspended in 
400  µl  PBS  (Biochrom  AG)  and  drawn  up  with  a  1  ml  syringe  (HSW).  200  µl  of  the 
suspension (equated 2x10
7 monocytes) were transplanted into the tail vein of one of two 
recipient Rag-2/γc
-/- mice (BALB/cAJic-RAG2
null IL-2Rg
null), a mouse strain that lacks T cells, 
B  cells,  and  NK  cells.  For  control,  two  other  Rag-2/γc
-/-  mice  received  200  µl  PBS.  The 
transplantation procedure was performed by Janine Kimpel (Georg-Speyer-Haus, Frankfurt). 
Five hours prior to the injection the mice received a sublethal dose of five gray radiated     Material and Methods 
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(Biobeam2000, Eckert & Ziegler BEBIG GmbH). One and four days after the injection one 
transplanted Rag-2/γc
-/- mouse and one of the control mice were sacrificed. From both mice 
tissue of the liver, spleen, bone marrow, kidney, blood-samples, lymph nodes and fluid of the 
abdominal cavity was collected. The cells of the different organs were singularized using a 
40 µm cell strainer (BD Falcon), the erythrocytes lysed by 0.86% ammonium chloride and the 
tissues analyzed for eGFP-positive cells by FACS spectrometry. As different tissue cell types 
have a different autofluorescence a positive control was prepared for each tissue sample by 
mixing 1x10
6 eGFP-monocytes with the negative cell population. Therefore, monocytes of 
another GFP mouse were isolated. 
3.3.12 Intracellular  flavocytochrome  b558  staining  of  murine 
monocytes 
For the intracellular flavocytochrome b558 staining of murine monocytes, 2x10
5 or 5x10
5 cells 
were  transferred  into  FACS-tubes  (Sarstedt),  and  incubated  with  3  ml  Pharmlysis  (BD 
Biosciences) for 10 min in the dark. The cells were subsequently centrifuged (5 min at 1400 
rpm  (Multifuge  3SR,  Heraeus),  and  washed  with  PBS  (resuspended  in  PBS  and 
centrifugation for  5  min  at  1400  rpm).  If,  next  to  the  intracellular  stain,  also  cell  surface 
molecules were detected, the cells were incubated with 1 µl mouse FcR Blocking reagent 
(Miltenyi Biotech) and the corresponding mAb for 15 min at 4°C in the dark. Following the 
incubation,  the  cells  were  washed  once  with  PBS,  vortexed  and  mixed  with  500  µl 
Cytofix/Cytoperm solution (BD Biosciences) for 15 min in the dark. Subsequently, the cells 
were washed with, 1 ml Perm/Wash and incubated with 3 ml Perm/Wash for 10 min in the 
dark. Then, the cells were centrifuged (5 min at 1400 rpm) and incubated with 1 µl mouse 
FcR  Blocking  reagent  (Miltenyi  Biotech)  and  the  FITC  conjugated  mouse  α-human 
flavocytochrome b558 mAB (MoBiTec) for 30 min in the dark. After the incubation, the cells 
were  centrifuged  (5 min at  1400 rpm) once more,  resuspended in 3  ml Perm/Wash and 
incubated  for  5  min  in  the  dark.  Then,  the  cells  were  centrifuged  (5  min  at  1400  rpm), 
vortexed, resuspended in 200 µl Cytofix/Cytoperm solution (BD Biosciences), and analyzed 
by FACS (3.3.10) 
3.3.13 Analysis of murine monocyte half-life in bloodstream 
Murine bone-marrow monocytes were isolated from C57BL/6 mice as described (3.3.5). After 
the isolation, 1.9x10
8 monocytes were resuspended in 422 µl PBS (Biochrom AG) and drawn 
up with a 1 ml syringe (HSW). 200 µl of the suspension (equated 9x10
7 CD45.2 monocytes) 
were  injected  into  the tail  vein  of  each  of  the  two  recipient  CD45.1  mice  (B6.SJL-Ptprc
a     Material and Methods 
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Pepc
b/BoyJ), a congenic mouse strain which carries the differential B cell antigen CD45.1. 
The  transplantation  procedure  was  performed  by  Christian  Brendel  (Georg-Speyer-Haus, 
Frankfurt). As control one CD45.1 mouse was left untransplanted. The weight of the mice 
was 26.3 g, 28.0 g, and 27.5 g, respectively. 4 h, 24 h, 47 h, 73 h, 94 h, and 117 h after 
transplantation, blood samples were taken from the tail vein of each animal. Therefore, a 
small cut was made into the tail of the mouse to derive a small droplet of blood, which was 
collected in capillary tube (Microvette
® CB 300, Sarstedt). If necessary, the caused wound in 
the  tail  of  the  mouse  was  closed  by  a  caustic  agent  (ARGENTRIX
®  Einmal-Höllenstein-
Ätzstift, Ryma Pharm).  
The  blood  samples  were  transferred  into  FACS-tubes (Sarstedt)  and  treated  with  Pharm 
Lyse™ (BD Biosciences) to remove erythrocytes and most of the neutrophils. The samples 
were subsequently stained with antibodies (Gr-1-Vio-Blue, CD11b-PE-Cy7, CD45.1-PE, and 
CD45.2-PerCP-Cy5.5) and analyzed by flow cytometry on a FACSCanto™ II system (BD 
Biosciences) (3.3.10).  
The  half-life  was  calculated  by  a  nonlinear  regression  (curve  fit)  using  a  one  phase 
exponential decay with the program GraphPad Prism 4. For this, the plateau constrain was 
set constant equal to zero.  
3.3.14 Phagocytosis assay 
Phagocytosis is the ingestion of solid particles by endocytosis. The phagocytosis capacity of 
cells  can  be  quantified  by  different  ways.  In  contrast  to  using  FITC-labled  yeast  cells 
(Rohloff et  al.,  1994),  DQ-BSA  (Invitrogen)  was  used.  DQ-BSA  is  a  derivative  of  bovine 
serum albumin (BSA) that is labeled to such a high degree with BODIPY TR-X, that the dye 
is  strongly  selfquenched.  After  uptake  by  phagocytotic  cells,  the  proteolysis  of  the  BSA 
results in dequenching of the dye. The fluorescence can be monitored easily by FACS. This 
way, the endocytosis capacity of phagocytes can be monitored.  
To  measure  the  DQ-BSA  uptake  of  monocytes,  1x10
6  freshly  isolated  monocytes  were 
incubated for 2 h with 5 µg (1 mg/ml) DQ-BSA (Invitrogen) at 37°C. For a negative control, 
the same amount of monocytes were pre-incubated for 30 min at 4°C and subsequently 
incubated for 2 h with 5 µg (1 mg/ml) DQ-BSA at 4°C. Following the DQ-BSA incubation, the 
cells are washed once with PBS, detached and transferred into FACS-tubes (Sarstedt). The 
cells were washed with 5 ml FACS washing buffer (PBS, 1% FCS, 0.1% (w/v) NaN3), and 
finally fixed in 400 μl FACS-Fix (PBS, 1% paraformaldehyde). The cells were analyzed by 
FACS on the LSR II system (BD Biosciences) for the uptake of DQ-BSA.     Material and Methods 
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3.3.15 Phagoburst assay 
The  quantification  of  the  oxidative  burst  activity  of  monocytes  was  measured  with  the 
BURSTTEST  kit  (ORPEGEN  Pharma).  It  determines  the  percentage  of  phagocytic  cells 
which produce reactive oxidants and their enzymatic activity. 
Therefore, 5x10
5 isolated human monocytes from heparinized whole blood (3.3.4) or 5x10
5 
murine monocytes from bone marrow (3.3.5) were resuspended in 100 µl DMEM-medium 
supplemented with 10% AB serum (Sigma-Aldrich), 2 mM L-glutamine (Biochrom AG), and 
1x NEAA (Gibco) in a FACS-tube (Sarstedt). The cells were activated with 20 µl PMA (1:200 
stock solution) for 10 min at 37°C in a water bath (GFL). A sample without stimulus (20 µl 
washing-solution) served as negative background control. Upon stimulation, monocytes (as 
granulocytes)  produce  reactive  oxygen  metabolites  which  destroy  bacteria  inside  the 
phagosome. The reactive oxidants during the oxidative burst were monitored by the addition 
and  oxidation  of  DHR  123.  Therefore,  20  µl  of  a  substrate  solution  was  added  to  the 
samples,  vortexed and incubated for  10 min at 37°C in a  water  bath.  At the end of the 
incubation,  100  µl  FACS-FIX  (PBS,  1%  w/v  paraformaldehyde)  was  added  and  the 
evaluation of oxidative burst activity performed by flow cytometry (3.3.10). 
3.4 Methods of protein biochemistry 
3.4.1 Preparation of cell- and vector lysates and Bradford assay 
Preparation of cell lysates 
To  analyze  the  expression  of  intracellular  proteins,  the  cells  (transfected  in  a  6well  by 
Lipofectamine™ LTX transfection (3.3.7)) were washed ones with 5 ml PBS (Biochrom AG), 
detached  and  transferred  into  a  1.5  ml  reaction  tube.  The  cells  were  pelleted  by 
centrifugation (12,000 rpm, 4°C, 1 min) and resuspended in 200 µl ice-cold RIPA lysis buffer 
(25  mM  Tris  pH  8.0,  137  mM  NaCl,  1%  Glycerin,  0.1%  SDS,  0.5%  Na‐deoxycholate, 
1% NonidentP40  and  40  μl/ml  protease  inhibitor  cocktail  (Roche)).  After  incubation  for 
5-30 min  at  4°C,  the  lysates  were  centrifuged  at  13,000  rpm,  4°C  for  10 min  (Heraeus 
Fresco) to  get rid of the cell debris.  The supernatant was transferred into  a new 1.5  ml 
reaction tube and either directly used for Bradford assay or frozen at -20°C. To determine the 
protein concentration in cell lysates by Bradford the Quick StartTM Bradford Dye reagent 
from Bio-Rad was used. Therefore, 5 µl of the cell lysate was added to 1 ml Breadford in a 
cuvette.  After  5  min,  the  absorption  was  detected  at  595  nm  using  a spectrophotometer 
(GeneQuant II, RNA/DNACalculator, Pharmacia Biotech).     Material and Methods 
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Preparation of vector lysates 
For the preparation of vector lysates, concentrated vector particles (3.3.6) were resuspended 
in  1  ml  RPMI  (Biochrom  AG)  and  layerd  over  a  10  ml  20%  w/v  sucrose  cushion  in  a 
polyallomer ultracentrifuge tube (Beckman). After centrifugation at 35,000 rpm (4°C) for 1.5 h 
(Optima™ L-70k Ultrazentrifuge, Beckman) the pellet was resuspended in 100 µl RIPA lysis 
buffer (25 mM Tris pH 8.0, 137 mM NaCl, 1% Glycerin, 0.1% SDS, 0.5% Na‐deoxycholate, 
1% NonidentP40 and 40 μl/ml protease inhibitor cocktail complete (25x)). The amount of 
20 µl vector lysate was generally used for Western blot analysis. 
3.4.2 SDS-polyacrylamide-gelelectrophoresis 
The  SDS-polyacrylamide-gelelectrophoresis  (SDS-PAGE)  allows  the  separation  of  protein 
mixtures  according  to  the  molecular  weight  of  the  proteins.  The  basic  principle  includes 
binding  of  multiple  molecules  of  the  anionic  detergent  sodium  dodecyl  sulfate  (SDS)  via 
hydrophobic interactions causing the denaturation of the protein. That way, irrespective of 
their native charges, the denatured proteins acquire an excess of negative charge on their 
surface  and  can  thus  be  applied  to  electrophoresis.  For  this purpose, the  samples  were 
loaded on polyacrylamid gels, which act like molecular sieves. 
To  denature  the  proteins  and  allow  binding  of  SDS,  the  samples  were  mixed  with  the 
appropriate amount of 4x Roti
® load (Carl Roth GmbH) and heated for 5 min at 95°C. Then, 
they were loaded on NuPage 4-12% Bis-Tris gels (Invitrogen) within an Xcell SureLock™ 
electrophoresis cell (Invitrogen) and filled with NuPage running buffer (Invitrogen). As protein 
standard 5 μl of the SeeBlue
® Plus2 pre-stained marker (Invitrogen) was used. SDS-PAGE 
was performed at 200 V until the dye front had left the resolving gel. 
3.4.3 Western blot analysis 
The Western blot technique is a method which enables the transfer of proteins onto protein-
binding surfaces such as nitrocellulose membranes (Towbin et al., 1979). This transfer, also 
termed  blot,  enables  the  specific  visualization  of  proteins  of  interest  by  immunostaining. 
Usually, proteins which have been separated by SDS-PAGE are applied to Western blot 
analysis.  The  transfer  of  the  proteins  from  the  SDS  polyacrylamid  gels  onto  PVDF 
membranes  (Millipore  Corporation)  was  performed  electrophoretically  within  a  Xcell 
SureLock™ electrophoresis cell (Invitrogen) according to the manufacturer‟s instructions. In 
advance, four 3 mm Whatman filter papers (Schleicher & Schuell) were shortly incubated in 
NuPage  transfer  buffer  (Invitrogen).  The  PVDF  membranes  were  activated  for  1  min  in 
methanol. After blotting at 200 mA for approx. 90 min, unspecific binding sites were blocked 
with blocking solution (PBS, 5% milk powder (AppliChem), 0.5% Tween 20) for 1 h at RT.     Material and Methods 
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For specific protein staining, antibodies diluted in blocking solution have been used. Staining 
was performed either for 1 h at RT or over night at 4°C. Then, the membranes were rinsed 
once with 0.5% PBST (PBS, 0.5% Tween 20) and washed three times for 10 min at RT with 
0.1%  PBST  (PBS,  0.1%  Tween 20)    before  they  were  incubated  for  1  h  at  RT  with  the 
appropriate  horseradish  peroxidase  (HRP)  conjugated  secondary  antibodies  diluted  in 
blocking solution. After washing as described above, detection of the proteins was performed 
using  ECL-  or  ECLPlus-reagent  (GE  Healthcare)  according  to  the  manufacturer‟s 
instructions. The reagents contain a HRP substrate that emits light during conversion into the 
product by the HRP conjugated secondary antibodies. Hence, the signal can be visualized 
using chemiluminescence films (Amersham Biosciences). The latter ones were exposed to 
the substrate-incubated membrane/s for 5 sec to 30 min depending on the signal intensities. 
 
The following antibodies were used for Western blotting: 
primary antibody    dilution     source 
          rabbit αTubulin mAb    1:200 
 
Cell Signaling 
Technology, Inc. 
mouse αVSV mAb     1:1000     Sigma-Aldrich 
mouse αVpxHIV-2 mAb    1:50 
 
NIH AIDS Research 
and Reference 
Reagent Program, 
Rockville, USA 
   
   
 
secondary antibody    dilution     source 
          HRP conjugated sheep α-mouse Immunoglobulins    1:7,500    GE Healthcare 
HRP conjugated donkey α-rabbit Immunoglobulins     1:7,500     GE Healthcare  
 
For the detection of VSV-G or tubulin ECL-reagent (GE Healthcare), and for the detection of 
Vpx ECLPlus-reagent (GE Healthcare) was used.      Results 
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4  Results 
This thesis shows  that vectors derived from the  HIV-2/SIVsmm/SIVmac  lentivirus lineage 
enable primary human monocyte transduction. Therefore the generation of novel PBj- and 
HIV-2-transfer  vectors  for  the  generation  of  3
rd  generation  lentiviral  vector-systems  is 
described.  One  possible  clinical  application  for  PBj/HIV-2-vector  driven  monocyte 
transduction  -  the  correction  of  gp91
phox-deficient  monocytes  from  xCGD-patient  for 
autologous  cell  transfusion  -  was  conceived  and  human  and  murine  monocytes  were 
investigated for their potential to be used in such a setting. 
4.1 HIV-2-derived  lentivectors  are  able  to  transduce 
primary human monocytes 
In  previous  work  it  could  be  shown  that  vectors  derived  from  SIVsmmPBj  are  able  to 
transduce primary human monocytes efficiently, where HIV-1 vectors fail (Mühlebach et al., 
2005). Our lab could demonstrate that the viral protein Vpx is solely necessary to facilitate 
this transduction of monocytes (Wolfrum et al., 2007). As HIV-1-derived lentivectors do not 
code for the accessory vpx gene, these vectors are incapable of efficient human monocytes 
transduction.  Besides  SIVsmmPBj  also  other  prominent  lentiviruses,  namely  HIV-2  and 
SIVmac, contain a vpx gene. Therefore, an HIV-2-derived two-plasmid-system was obtained 
for comparison to PBj vectors in its ability to transduce primary human monocytes.  
4.1.1 Comparison  of  HIV-1-,  SIVsmmPBj-  and  HIV-2-derived 
lentiviral vector transduction of primary human monocytes 
In order to investigate, whether HIV-2-derived lentiviral vectors are able to transduce primary 
human  monocytes,  the  vectors  from  an  HIV-2  two-plasmid  system  (HIV-2-RodA)  were 
generated. The monocyte transduction capacity of HIV-2 vectors was compared to that of 
HIV-1-  (HIV-1-NL4-3)  and  PBj-derived  (PBj- EeGFP)  two-plasmid  systems.  The  vectors 
were  generated  by  transient  transfection  of  293T  cells  with  one  of  the  vector  constructs 
HIV-2-RodA, HIV-1-NL4-3 or PBj- EeGFP (Figure 9A) and the VSV-G expression plasmid 
pMD.G2.  The  vector  particle  containing  supernatant  was  harvested  two  days  post 
transfection, concentrated over a 20% sucrose cushion and used for titration  on HT1080 
cells (3.3.8). The titers reached were 1.0x10
9 TU/ml, 4.4x10
8 TU/ml, and 6.2x10
7 TU/ml for 
HIV-2-RodA, PBj- EeGFP, and HIV-1-NL4-3, respectively.      Results 
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Figure 9: Transduction efficiency of various lentiviral vectors on primary human monocytes.  
Primary human monocytes of three different donors were transduced with PBj-∆EeGFP-, HIV-2-RodA- 
or HIV-1-NL4-3-vectors at day one, two or three after isolation using the indicated moi. (A) Schematic 
representation of the indicated vectors. (B) eGFP-expression of transduced monocytes (moi 1) of one 
representative donor shown by fluorescent microscopy (20 x magnifications). (C) Transduction rates of 
αCD14
+-APC-stained monocytes determined by FACS-analysis. The star (∗) indicates that data of only 
one donor is shown as the monocytes of the two other donors died.     Results 
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Monocytes of three different donors were isolated from whole blood samples via MACS and 
taken into cell-culture (3.3.4). One, two or three days after isolation the monocytes were 
transduced using the different vector-systems at the moi of one or ten. Seven days post 
transduction  they  were  analyzed  for  transgene  expression  by  FACS  and  fluorescent 
microscopy (Figure 9). For FACS-analysis, the cells were stained with αCD14-APC. This way 
only the specific transduction efficiency of HIV-2-RodA, PBj-∆EeGFP, and HIV-1-NL4-3 for 
CD14
+-monocytes  transduction  was  determined.  The  transduction  efficiencies  for  HIV-2-
derived vectors of approx 60% - 70% at an moi of one and ten were in the range of those for 
PBj-derived vectors. Only HIV-2-RodA showed a 30% reduced transduction of monocytes at 
an moi of ten at day one after isolation in comparison to PBj-∆EeGFP transduced cells. The 
transduction  with  HIV-1-NL4-3  was  not  feasible  at  either  moi  as  expected.  For  the 
transduction at moi of ten, only one donor was FACS-analyzed as the monocytes of both 
other donors died.   
The monocyte transduction experiments confirmed the assumption that vectors derived from 
HIV-2 are able to transduce monocytes. 
4.1.2 Monocyte  transduction  with  Vpx-supplemented  SIVsmmPBj-
4xKOeGFP vectors 
Generation of Vpx-expression plasmids 
As VpxPBj is the determining factor facilitating the monocyte transduction of PBj-derived 
vectors (Wolfrum et al., 2007) and HIV-2-derived vectors are able to transduce monocytes 
(Figure 9), it can be assumed that VpxPBj homologues like VpxHIV-2 and VpxMAC also 
facilitate monocyte transduction. To confirm this assumption, expression plasmids for Vpx of 
HIV-2-RodA and SIVmac were generated. The vpx genes of HIV-2 and SIVmac were PCR-
amplified out of the templates HIV-2-RodA and SIV-3+ (Negre et al., 2000; Reuter et al., 
2005)  using  the  primer  pairs  BPK1  /  BPK2  and  BPK3  /  BPK4,  respectively.  The  PCR 
amplificates were inserted into the pcDNA3.1(+) backbone via the restriction sites EcoRI and 
XhoI. The  expression  plasmids  were  used for  transfection  of  293T  cells. Two  days  after 
transfection cell lysates were prepared and examined for Vpx-expression by Western blot 
using a αVpxHIV-2 monoclonal antibody. The Vpx-expression of VpxPBj and VpxHIV-2 was 
very weak and VpxMAC expression was not detectable (Figure 10). In order to achieve an 
enhanced protein expression, codonoptimized Vpx-expression plasmids for PBj (VpxPBjsyn) 
and HIV-2 (VpxHIV-2syn) were used. The VpxHIV-2syn expression plasmid was available in 
the lab whereas the VpxPBjsyn expression plasmid had to be constructed by removing the 
HA-tag  of  an  available  HA-tagged  VpxPBjsyn  plasmid.  For  this  purpose  the  VpxPBjsyn 
fragment was PCR-amplified out of the template HA-VpxPBjsyn using the primer pair BPK5 /     Results 
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BPK6.  The PCR product was inserted into a pcDNA3.1(+) backbone via the EcoRI and XhoI 
restriction sites. The codonoptimized Vpx-expression plasmids were used to transfect 293T-
cells. Two days after transfection the Vpx expression was analyzed by Western blot. The 
expression  of  the  codonoptimized  proteins  VpxPBjsyn  and  VpxHIV-2syn  was  strongly 
enhanced compared to that of VpxPBj and VpxHIV-2. 
 
Figure  10:  Analysis  of  Vpx-expression.  Western  blot  analysis  of  Vpx-expression  in  293T  cells 
transfected  with  the  Vpx-expression  plasmids  indicated  using  αtubulin-  and  αVpx-antibodies.  For 
VpxPBj, VpxHIV-2 and VpxMAC exposition times of 1 min for αTubulin and 5 min for αVpx were used, 
and for VpxPBjsyn and VpxHIV-2syn 5 min for αTubulin and 10 sec for αVpx, respectively.  
Vpx mediated monocyte transduction 
The different Vpx-expression plasmids were tested in their ability to facilitate the transduction 
of a PBj-∆EeGFP-derived two-plasmid-system, deficient for all four accessory genes (vpr, vif, 
nef,  and  vpx)  and  therefore  termed,  SIVsmmPBj-4xKOeGFP  (PBj-4xKOeGFP).  For  this 
purpose 293T cells were transfected with pPBj-4xKOeGFP and VSV-G expression plasmids 
necessary for vector production. The transfection was supplemented with no (control) or one 
of  the  respective  Vpx-expression  plasmids.  Two  days  later  the  vector  containing  cell 
supernatants  were  harvested  and  concentrated  over  a  20%  sucrose  cushion  by 
ultracentrifugation. The collected vectors were titrated on HT1080 and used for transduction 
of  freshly  isolated  monocytes  at  an  moi  of  one  or  five  (Figure  11).  The  transduction 
efficiencies  were  determined  five  days  post  transduction  by  FACS-analysis.  Prior  to  the 
analysis the cells  were  stained with  αCD14-APC antibodies,  hence only the transduction 
efficiencies of the CD14
+-cell population was taken into account. 
As expected, the PBj-4xKOeGFP (-) vector, generated in absence of Vpx, was not able to 
transduce monocytes efficiently. In contrast, all but one vector generated in the presence of 
Vpx allowed a dose-dependent transduction. Thereby, the codon-optimized Vpx were most 
efficient.  Only  the  unmodified  Vpx  of  HIV-2  failed  to  facilitate  monocyte  transduction     
(Figure 11).      Results 
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Figure 11: Vpx dependent transduction of primary human monocytes. The transduction efficiency 
of  PBj-4xKOeGFP-derived  vectors  supplemented  with  the  indicated  Vpx  in  CD14
+-monocytes  was 
analyzed by FACS.  
Vpx incorporation in vector particles 
The  corresponding  vector-lysates  of  the  latter  4xKOeGFP-vectors  used  for  monocyte 
transduction were tested for Vpx incorporation by Western-blot analysis (Figure 12). Except 
for the well detectable codonoptimized VpxPBjsyn and VpxHIV-2syn, the unmodified VpxPBj, 
VpxHIV-2 and VpxMAC were not detected using αVpxHIV-2 monoclonal antibody. Vector 
particles generated in the presence of the stable, but non-functional n-terminally Flag-tagged 
VpxHIV-2 were used as positive control. The used particle amount was visualized by αVSV 
antibodies. For VpxHIV-2nFLAG, VpxPBj, VpxHIV-2 and VpxMAC exposition times of 2 min 
for αVSV and 5 min for αVpx were used and for VpxPBjsyn and VpxHIV-2syn exposition 
times of 15 sec for αVSV and 2 min for αVpx. 
 
Figure 12: Incorporation of different Vpx proteins into PBj-4xKOeGFP vector particles. Western 
blot analysis of vector lysates of PBj-4xKOeGFP vectors supplemented with the Vpx indicated. The 
VSV-G- and Vpx-protein expression is visualized.  
 
Obviously,  the  amount  of  Vpx  packaged  into  vector  particles  is  not  correlated  with  the 
efficiency of monocyte transduction.     Results 
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4.2 Construction of novel HIV-2- and PBj-derived lentiviral 
vector systems 
In  the  first  section  it  was  shown  that  next  to  SIVsmmPBj-derived  vectors,  HIV-2-derived 
lentiviral vectors are also able to transduce primary human monocytes. In both cases the 
transduction is facilitated through Vpx. Both systems were used to establish a human and 
non-human derived three-plasmid vector system. To construct safe lentiviral vector systems, 
it is necessary to separate the viral genetic information onto different plasmids and minimize 
their viral DNA content. The separation of the structural gag/pol genes from the sequences 
used  for  the  transfer-DNA-construct  and  the  envelope-construct  minimizes  the  risk  of 
unwanted recombination events.   
As previous results demonstrated that it is possible to construct basic HIV-2- and PBj-derived 
three-plasmid systems (Negre et al., 2000; Wolfrum, 2005), one aim of this thesis was to 
develop transfer vectors for both systems which allow the production of high titer and safe 
lentiviral vectors for the transduction of primary human monocytes.  
Fully functional packaging constructs were available for both vectors systems (Negre et al., 
2000; Wolfrum, 2005). Hence, it was necessary to construct new transfer vectors. 
4.2.1  Construction  of  a  PBj-derived  transfer  vector  –  the 
conventional way 
The conventional way to generate a lentiviral transfer vector is to remove all needless parts 
from  the  wild-type  sequence  (i.e.  gag/pol  and  accessory  genes),  leaving  the  cis-acting 
sequences  intact,  and  to  introduce  necessary  modifications  (i.e  transgene  expression 
cassette) in successive cloning steps. This conventional cloning strategy has been used to 
gradually enhance the PBj-derived transfer vector pPBj-trans (Wolfrum, 2005) (Figure 13A). 
For most of the cloning steps the Fusion-PCR technique was used (3.2.9), as described on 
page 31. Correct cloning was confirmed by sequencing of the relevant parts (3.2.7).     Results 
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Figure 13: Generation of PBj-derived transfer vector constructs. Schematic representation of the 
different  transfer  vector  plasmids  derived  from  SIVsmmPBj.  The  vector  elements  exchanged  in  a 
subsequent cloning step are highlighted in red. The restriction sites and the method used for each 
step, such as the insertion of fragments after digestion (cloning) or generation of fragments by Fusion-
PCR, are shown.  , packaging signal; 
b, generated blunt-ends; LTR, long terminal repeat; SD, splice 
donor;  cPPT,  central  polypurine  tract;  CTS,  central  termination  sequence;  RRE,  Rev-responsive 
element;  SA,  splice  acceptor;  CMV,  human  cytomegalovirus  early  promoter;  SFFV,  spleen  focus 
forming  virus  early  promoter;  WPRE,  woodchuck  hepatitis  virus  post-transcriptional  regulatory 
element. 
Construction of a self-inactivating (SIN) vector  
In a first step, a SIN vector was generated by deleting the U3 promoter sequences in the 
3`LTR. This resulted in the construct pPBj-trans-SIN (Figure 13B). For the deletion of the 
promoter  sequences, a  Fusion-PCR  was performed to generate a SIN-3‟-LTR sequence, 
including the attachment sites and the R- and U5-region. The PPT was included upstream of 
the  SIN-3‟-LTR.  The  Fusion-PCR  was  performed  by  fusing  three  different  PCR  products 
derived with the primer pairs BPK 7 / BPK 8, BPK 9 / BPK 10 and BPK 11 / BPK 12 on the 
PBj-trans template. The restriction sites EcoRI and NotI were included through the primers 
BPK  7  and  BPK  12,  respectively.  Using  these  restriction  sites  allowed  the  Fusion-PCR 
fragment to be interchanged with the respective PBj-trans sequence. For this, the EcoRI-NotI 
fragment was excised from the PBj-trans backbone, and the Fusion-PCR fragment integrated     Results 
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in a directed ligation. The insertion of the Fusion-PCR fragment also led to the deletion of the 
useless second exons of tat and rev.  
Integration  of  the  cPPT/CTS  element  and  SFFV-eGFP-WPRE  expression 
cassette 
In  order  to  assure  an  accurate  reverse  transcription  of  the  transfer  vector,  the  central 
termination sequence (CTS) was reintroduced downstream of the central polypurine tract 
(cPPT). In the same step, it was possible to remove  the remaining part of the  pol gene 
(1107 bp) to further minimize the presence of viral sequences. These changes resulted in the 
construct pPBj-trans-cSIN (Figure 13C). To generate the latter, another Fusion-PCR was 
performed with the fragments derived from PCRs using the primer pairs BPK 13 / BPK 14 
and BPK 15 / BPK 16 on the templates pPBj-trans and pPBj-ΔEeGFP, respectively. The 
Fusion-PCR-fragment containing the corrected cPPT/CTS sequence was integrated into PBj-
trans-SIN via the restriction sites KasI and MfeI.  
In parallel, the CMV-eGFP expression cassette of pPBj-trans-SIN was replaced by a SFFV-
eGFP-WPRE  expression  cassette  resulting  in  pPBj-SEW-SIN  (Figure  13D).  The  SFFV-
eGFP-WPRE expression cassette insert was obtained by excision out of a HIV-1-derived 
transfer vector (pHIV-1-SEW) through the restriction sites EcoRI and XhoI. In contrast, the 
CMV-eGFP was excised from the pPBj-trans-SIN backbone via the restriction sites NsiI and 
PstI. In order to join the backbone and insert fragments, they were processed with Klenow-
Enzyme  to  yield  blunt-ends  (3.2.2).  Consequently,  the  SFFV-eGFP-WPRE  expression 
cassette was integrated into the pPBj-trans-SIN backbone by blunt-end ligation to yield the 
construct pPBj-SEW-SIN (Högner, 2007). 
The combination of both modifications - the deletion of the remaining pol-gene sequence 
leaving a corrected cPPT/CTS sequence in pPBj-trans-cSIN and the insertion of an SFFV-
eGFP-WPRE expression cassette in pPBj-SEW-SIN - resulted in the construct pPBj-SEW-
cSIN (Figure 13E). For the construct combination pPBj-trans-cSIN and pPBj-SEW-SIN were 
cut with MfeI und DraIII and joined in a directional ligation.  
Construction of a Tat-independent transfer vector 
The  U3-region  within  the  5´LTR  was  substituted  by  a  chimeric  SV40-enhancer/RSV-
promoter-(SV40/RSV)-element to obtain a strong, Tat-independent vector RNA expression in 
the packaging cells (Schambach et al., 2006b). For this purpose a cloning strategy via an 
intermediate construct was performed.  
First, a Fusion-PCR was conducted. For this, the PCR-products using the primer pairs BPK 
17  /  BPK  18  and  BPK  19  /  BPK  20  on  the  SV40/RSV-element  containing  plasmid 
SER11S91-SW  and  the  transfer  vector  pPBj-trans  SIN  as  templates,  respectively,  were     Results 
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used. During this, the primer sequence BPK 17 introduced a KasI and a SpeI restriction site 
at  the  5‟-end  of  the  Fusion-PCR  construct.  The  primer  sequence  BPK  20  hybridized 
downstream of a KasI restriction site at the 3‟ end of the Fusion-PCR construct. This way, the 
generated SV40/RSV-R-U5 sequence was inserted downstream of the 5‟LTR of PBj-trans-
cSIN via the KasI restriction sites (intermediate construct not shown).  
Second, from the intermediate construct the integrated SpeI site was used together with an 
upstream MfeI restriction site to excise the Insert-DNA-fragment containing the SV40/RSV-
element,  the  -site  and  the  corrected  cPPT/CTS-element.  This  fragment  was  used  to 
replace  the  corresponding  sequence  of  pPBj-SEW-cSIN.  For  this,  the  corresponding 
sequence was excised from the pPBj-SEW-cSIN-backbone via the XhoI and MfeI restriction 
sites.  For  successful  cloning,  the  insert  and  backbone  fragments  were  processed  with 
Klenow-Enzyme after the first restriction of SpeI or XhoI, respectively, in order to yield blunt-
ends. Only then, the MfeI restriction was performed. In a last step, the insert and backbone 
were ligated to yield the transfer vector pPBj-SR-SEW-cSIN (Figure 13F).  
Evaluation of the generated PBj-derived transfer vectors 
To compare the functionality of the different generated transfer vectors, VSV-G pseudotyped 
vector particles were generated by transient transfection of 293T cells with the packaging 
construct  pPBj-pack,  the  envelope-construct  pMD.G,  the  VpxPBj  expression  plasmid  and 
one of the respective transfer vectors (3.3.7). The gained vectors were titrated on HT1080 
cells (3.3.8) (Figure 14). The introduced modifications within the transfer vector lead to a 
gradual  increase  in  vector  titers.  Compared  to  the  starting  construct  PBj-trans,  the  final 
vector system PBj-SR-SEW-cSIN resulted in a nearly 100-fold increase in vector titers before 
concentration and an additional 10-fold increase after concentration. The enhanced vector 
construct yielded vector titers above 10
7 TU/ml after concentration (Figure 14A). 
 
Next, vector particles derived from the most sophisticated transfer vector, PBj-SR-SEW-cSIN 
were compared to vector particles derived from the starting construct PBj-trans and to HIV-1-
derived  vectors  in  their  ability  to  transduce  primary  human  monocytes.  Both  PBj-derived 
vectors were produced in the presence and absence of the VpxPBj-expression plasmid and 
used  for  monocyte  transduction  at  an  moi  of  one.  The  vector  particles  produced  in  the 
absence of VpxPBj transduced monocytes only at background level as did HIV-1-derived 
vectors.  However,  vector  particles  produced  in  the  presence  of  VpxPBj  resulted  in  an 
efficient transduction of monocytes. About 20% of the primary human monocytes could be 
transduced one day after isolation (Figure 14B).     Results 
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Figure 14: Evaluation of vector particles generated with PBj-derived transfer vectors. (A) Titers 
reached  on  HT1080  cells  for  generated  vector  particles  using  the  indicated  transfer  vector  before 
(native)  and  after  concentration.  (B)  Transduction  efficiency  of  primary  human  monocyte  for  the 
indicated lentivectors in presence and absence of VpxPBj using an moi of one. 
In summary, a safe SIVsmmPBj-derived vector system, reaching titers of up to 1x10
7 TU/ml 
for an efficient monocyte transduction was successfully constructed.  
4.2.2 Constructing lentiviral transfer vectors – the new way 
The construction of lentiviral derived transfer vectors by gradual enhancing cloning steps is 
very time consuming. A general transfer vector encompasses normally more than 7000 bp 
with repetitive sequences, i.e. LTR. Hence, the procedure is prone to mutations occurring 
throughout  the  cloning  steps.  The  more  cloning  steps  have  to  be  performed,  the  more 
unwanted viral DNA sequences between the necessary vector elements are likely to remain 
due to unfitting restriction sites. These sequences enhance the homology to the wild-type-
virus sequences and needlessly increase the size of the transfer vector. In order to construct 
a lentiviral transfer vector in a fast way by simultaneously minimizing the non-functional DNA 
sequences, a novel way to design transfer vectors from a lentiviral origin was conceived. The 
concept was to generate a transfer vector directly by Fusion-PCR. In order to demonstrate 
that this concept was in principle possible, it was used in the construction of an HIV-2- and 
PBj-derived transfer vector (Figure 15). The primers used for the different PCR reactions 
generating PBj-MCS and HIV-2-MCS are depicted in Table 1. The exact primer sequences 
are given in section 3.1.5.     Results 
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Figure 15: Schematic representation of the new cloning strategy to generate lentiviral transfer 
vectors.  On  the  basis  of  HIV-2-  and  PBj-  lentiviral  wild-type  sequences  lentiviral  transfer  vector 
scaffolds  were  generated  and  further  processed  to  HIV-2-SEW  and  PBj-SEW  transfer  vectors, 
respectively. The primer binding positions are represented by the horizontal, black arrows. The angled, 
grey  extensions  of  the  primers  contain  the  indicated  elements.  Complementary  sequences  are 
indicated by the bold, white vertical arrows. PCR products are depicted A-F.  , packaging signal; LTR, 
long terminal repeat; cPPT, central polypurine tract; CTS, central termination sequence; RRE, Rev-
responsive element; SFFV, spleen focus forming virus early promoter; WPRE, woodchuck hepatitis 
virus post-transcriptional regulatory element; pA, bovine growth hormone polyadenylation signal. 
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Table 1: Primers used for the generation of PBj-MCS and HIV-2-MCS.  
Generation of PBj-MCS    
PCR notation            
(see Figure 15)      Forward-
Primer     Reverse-
Primer     Templates 
                 
1
st round PCRs 
   A     BPK 21     BPK 22     PBj-ΔEeGFP 
   B     BPK 23     BPK 24     PBj-ΔEeGFP 
   C     BPK 25     BPK 26     PBj-ΔEeGFP 
                 
1
st round Fusion-PCRs   
D     BPK 21     BPK 24     A, B 
 
E     BPK 23     BPK 26     B, C 
                  2
nd round Fusion-PCR     F     BPK 21     BPK 26     D, E 
                 
Generation of HIV-2-MCS   
PCR notation      
(see Figure 15)    
Forward-
Primer   
Reverse-
Primer    Template 
                 
1
st round PCRs 
   A     BPK 35     BPK 36     HIV-1-RodA 
   B     BPK 37     BPK 38     HIV-1-RodA 
   C     BPK 39     BPK 40     HIV-1-RodA 
                 
1
st round Fusion-PCRs   
D     BPK 35     BPK 38     A, B 
 
E     BPK 37     BPK 40     B, C 
                  2
nd round Fusion-PCR     F     BPK 35     BPK 40     D, E 
 
1
st round PCRs 
In a first step, the wild-type sequence of a lentivirus was used as template for three different 
PCR reactions. The PCR product sequences together form the scaffold for the PBj- and 
HIV-2  transfer  vectors.  The  first  PCR  reaction  (A)  stretches  out  over  the  5‟LTR,  the 
 sequence and 200 bp of the gag gene. The forward primer carried a HindIII restriction site. 
For the second PCR (B) the primers were placed to flank the RRE. The third PCR reaction 
(C) was set to amplify the R-U5-region of the 5‟-LTR. In this PCR reaction the reverse primer 
carried a NotI restriction site. All other sequences necessary for a lentiviral transfer vector 
which  could  not  be  PCR  amplified  were  included  in  the  primer  extensions  (indicated  as 
angled arrow extensions in Figure 15). These sequences included the cis-acting elements 
cPPT, CTS, and PPT as well as a MCS and the attachment sites of the 3‟LTR. Hence, the 
length of the designed primers was up to 100 bp long. 
1
st and 2
nd round Fusion-PCRs 
The products of the first three PCRs (A-C) were used as templates for subsequent Fusion-
PCRs. The PCR products of A and B as well as B and C were joined by the Fusion-PCRs 
D and E, respectively. The products of the 1
st round Fusion-PCRs (D and E) in turn served as 
template for a 2
nd round Fusion-PCR resulting in the transfer vector scaffold.      Results 
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Insertion into backbone 
The  transfer  vector  scaffolds  derived  by  the  Fusion-PCRs  were  cloned  into  a  plasmid-
backbone taken from the pPBj-pack vector. The backbone originated from a pBluescript-
plasmid and included an antibiotic resistance gene (ampicillin) and an f1 helper phage origin 
of replication. For this, the HIV-2- or PBj-derived transfer vector scaffolds and the pPBj-pack 
vector were cut with the restriction enzymes HindIII and NotI and fused together in a directed 
ligation to give HIV-2-MCS or PBj-MCS, respectively. These constructs could be used as a 
foundation for different transfer vectors as they contain an MCS (Figure 16), e.g. to insert an 
expression cassette of choice. The MCS was integrated into the PBj- or HIV-2 construct with 
help  of  the  primers  BPK  24  or  BPK  38,  respectively.  The  MCSs  within  the  respective 
PBj-MCS or HIV-2-MCS constructs contain four restriction sites designed to be present only 
once within the vector (single-cutter). In addition, the MCS in HIV-2-MCS also contains a 
KpnI restriction site which has three additional recognition sites throughout the vector. All 
restriction sites produce sticky ends. 
 
Figure 16: Multiple cloning site of PBj-MCS and HIV-2-MCS.  
 
Integration of a eGFP expression cassette into HIV-2-MCS and PBj-MCS 
To prove the functionality of the newly derived vectors, an eGFP gene under the control of an 
SFFV-promoter followed by a WPRE (SFFV-eGFP-WPRE) was inserted into HIV-2-MCS and 
PBj-MCS. For  the generation of HIV-2-SEW, the SFFV-eGFP-WPRE-expression cassette 
was  amplified  out  of  the  SIVmac-derived  transfer  vector  pGAE-SFFV-WPRE  using  the 
primers BPK 41 and BPK 42. Both primers contain an MfeI restriction site for subcloning of 
the PCR product into the HIV-2-MCS vector. The PBj-SEW vector was cloned almost in the 
same manner. Here, the primers BPK 27 and BPK 28, both containing an EcoRI restriction 
site, were used to amplify the sequence identical SFFV-eGFP-WPRE-expression cassette 
out of the HIV-1-derived transfer vector template pHIV-1-SEW. Subsequently, the expression 
cassette was inserted into PBj-MCS via the EcoRI restriction sites (Figure 15).      Results 
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Titers achieved using the HIV-2-SEW and PBj-SEW transfer vectors 
The newly derived transfer vectors HIV-2-SEW or PBj-SEW were used together with the 
packaging  vectors  pPBj-pack  or  pHIV-2d4,  respectively,  and  with  the  VSV-G  expression 
plasmid pMD.G2 in a transient transfection of 293T cells. The transfection to generate vector 
particles was performed in 6well plates (3.3.7). The harvested vector particles were titrated 
on  HT1080  cells  (3.3.8)  (data  not  shown).  Vector  particles  generated  with  both,  the 
HIV-2-SEW  and  the  PBj-SEW  transfer  vectors  were  able  to  transduce  HT1080  cells. 
Therefore both transfer vectors were used for high concentrated vector particle production 
(3.3.6). This way, vector titers about 100fold higher than those for particles generated with 
the PBj-trans transfer vector were reached. Nevertheless, they were still about 5 - 10fold less 
than  the  titer  of  HIV-1-SEW-derived  vector  particles  (Figure  17).  In  order  to  achieve 
especially high vector titers, large amounts of vector supernatant were concentrated and the 
gained vectors pooled in small aliquots. This way, vector titers of 5.4x10
8 TU/ml for HIV-2-
SEW and 4.0x10
8 TU/ml for PBj-SEW compared to titers of 2.0x10
9 TU/ml for HIV-1-SEW 
were feasible. 
 
Figure  17:  Evaluation  of  vector  particles  generated  with  the  novel  HIV-2-  and  PBj-derived 
transfer vectors. Titers reached on HT1080 cells for generated vector particles using the indicated 
transfer  vector  after  concentration.  (A)  The  mean  titers  of  at  least  three  separate  transduction 
experiments. (B) The highest titers reached for PBj-SEW, HIV-2-SEW and HIV-1 SEW vectors. 
4.2.3 Enhancing the transfer vectors generated by Fusion-PCR 
Introduction of a stop-codon into HIV-2-SEW and PBj-SEW gag sequence 
As the novel transfer vectors HIV-2-SEW and PBj-SEW still contained the first 200 bp of the 
gag  sequence,  there  was  still  a  potential  for  an  initiation  of  its  translation.  Although  the 
truncated  gag  gene  would  probably  not  lead  to  a  functional  protein,  a  stop-codon  was     Results 
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introduced downstream the gag start-ATG to abrogate any initiated translation resulting in 
the constructs HIV-2-g’-SEW and PBj-g’-SEW (Figure 18).  
In  order  to  introduce  a stop-codon  into  the  gag  gene  of  HIV-2-SEW the  “aaa”-codon  11 
triplets  downstream  of  the  start-ATG  was  changed  to  “taa”,  resulting  in  the  sequence 
„atgggcgcgagaaactccgtcttgagagggtaa‟. For PBj-SEW the “tca”-codon 10 triplets downstream 
of the start-ATG was changed into a “tga” sequence (atgggcgcgagaaactccgtcttgtgagggaag) 
to introduce a stop-codon. Both experiments were performed with the QuikChange™ site-
directed mutagenesis kit (Stratagene) (3.2.10) using the primer-pairs BPK 43 / BPK 44 for 
the generation of HIV-2-g‟-SEW and BPK 29 / BPK 30 for the generation of PBj-g‟-SEW. 
Construction of Tat-independent transfer vectors 
In  a  analogous  experiment,  the  U3-region  of the  5‟LTR  was  replaced  by  an  SV40/RSV-
element to gain a Tat-independent vector RNA expression in packaging cells. For this, the 
SV40/RSV  sequence  was  PCR-amplified  out  of  the  MLV-derived  transfer  vector 
SER11S91-SW.  It  was  then  fused  upstream  the  R-U5-region  of  the  respective  5‟LTR 
sequence  by  Fusion-PCR.  The  subsequent  SV40/RSV-R-U5  sequence  was  cloned  into 
HIV-2-SEW  or  PBj-SEW  resulting  in  the  constructs  HIV-2-SR-SEW  and  PBj-SR-SEW, 
respectively (Figure 18).  
The exact cloning steps are described in the following: 
HIV-2-SR-SEW:  For  the  generation  of  the  HIV-2-SR-SEW  construct  three  different  PCR 
sequences  were  combined  by  Fusion-PCR  to  give  the  SV40/RSV-R-U5  sequence.  The 
different 1
st round PCRs were performed using the primer pairs BPK 45/ BPK 46, BPK 47 / 
BPK  48  and  BPK  49  /  BPK  50  on  the  templates  HIV-2-SEW,  SER11S91-SW,  and 
HIV-2-SEW,  respectively.  The  subsequent  Fusion-PCR  linked  the  latter  PCR  products 
together. It was performed with the primers BPK 45 and BPK 50. These also introduced the 
restriction sites PciI and KasI, respectively. The latter were used to integrate the Fusion-PCR 
construct into the HIV-2-SEW construct, thereby replacing the common 5‟LTR sequence with 
the SV40/RSV-R-U5 sequence.  
PBj-SR-SEW:  To  construct  PBj-SR-SEW  the  1
st  round  PCRs  were  performed  using  the 
primer pairs BPK 31 / BPK 32 and BPK 33 / BPK 34 on the templates SER11S91-SW and 
PBj-SEW, respectively. The primers BPK 31 and BPK 34 used for the subsequent Fusion-
PCR  introduced  the  restriction  sites  XhoI  and  KasI.  The  latter  were  used  to  insert  the 
resulting  SV40/RSV-R-U5  sequence  into  the  HIV-2-SEW construct,  thereby  replacing  the 
native 5‟LTR sequence.     Results 
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Combining  the  introduced  stop-codon  and  the  SV40/RSV-element  on  one 
transfer vector 
In order to construct an HIV-2- or PBj-derived transfer vector that will contain a stop-codon 
downstream of the gag gene start-ATG as well as an SV40/RSV element within the 5‟LTR, 
both  of  the  latter  constructed  vectors,  which  each  harbor  one  of  these  elements,  were 
combined. 
For this purpose, HIV-2-SR-SEW was restricted with PciI and KasI to excise the SV40/RSV-
R-U5  sequence. It  was  then  integrated  into  HIV-2-g‟-SEW  via the  same  restriction  sites, 
replacing the native 5‟LTR to give HIV-2-g’-SR-SEW.  
In  the  same  manner  PBj-SR-SEW  was  restricted  with  KasI  and  XhoI  to  excise  the 
SV40/RSV-R-U5 sequence. It was integrated into PBj-g‟-SEW replacing the native 5‟LTR 
resulting in PBj-g’-SR-SEW (Figure 18). 
 
 
 
Figure 18: Schematic representation of the final PBj- and HIV-2-derived transfer vectors. The 
introduced stop-codon and SV40/RSV-element are highlighted in red. 
Evaluation of the generated HIV-2- and PBj-derived transfer vector particles 
After completing the optimization steps, enhanced HIV-2- and PBj-lentiviral transfer vectors 
were used to generate vector particles. The vector particles were produced in the presence 
and/or absence of the codonoptimized Vpx-expression plasmids VpxHIV-2syn or VpxPBjsyn, 
respectively.  The  harvested  vector  particles  were  concentrated  by  ultracentrifugation  and 
titrated  by  HT1080  cell  transduction  (3.3.8).  The  difference  in  vector  titers  between  the 
constructs is marginal. The PBj-derived vectors resulted in titers around 5x10
7 TU/ml, where 
the HIV-2-derived vectors resulted in titers of 1x10
8 TU/ml (Figure 19).     Results 
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Figure 19: Titers of enhanced HIV-2- and PBj-derived vector particles on HT1080 cells. Titers of 
(A)  HIV-2-  or  (B)  PBj-based  vectors  after  concentration  in  the  presence  or  absence  of  Vpx  as 
indicated. 
The  consistent  titers for  the  vector  particles  generated  with  the  different  transfer  vectors 
show, that the latter modifications to increase the safety profile of the vector systems, had no 
negative impact on vector titers.  
Monocyte transduction using HIV-2- and PBj-derived vector particles 
The  constructed  HIV-2  and  PBj  vectors  were  used  for  transduction  of  primary  human 
monocytes.  For  this,  blood  monocytes  from  two  donors  were  isolated  by  Ficoll-gradient 
centrifugation followed by a negative MACS selection (3.3.4). The isolated monocytes were 
cultivated in VLE-RPMI-medium for 24 h and transduced with the novel PBj- and HIV-2-
derived lentiviral vectors at an moi of one or ten. The transduction efficiencies were analyzed 
five days post transduction. 
For  the  HIV-2-derived  vectors  generated  in  presence  of  VpxHIV-2syn,  the  transduction 
increased in general from an moi of one to an moi of ten (Figure 20A). The HIV-2-derived 
vectors  with  no  incorporated  VpxHIV-2syn  were  used  as  control  and  transduced  the 
monocytes with low efficiencies.  For the transduction experiments  with the HIV-2-derived 
lentivectors  the  mean  transduction  was  calculated  from  three  to  twelve  transduction 
experiments on different donor-monocytes. 
All vectors derived from SIVsmmPBj were able to transduce the monocytes efficiently when 
supplemented  with  VpxPBjsyn  (Figure  20B).  The  transduction  efficiency  increased  by 
changing the moi from one to ten for PBj-SEW (VpxPBjsyn), PBj-g‟-SEW (VpxPBjsyn), and 
PBj-SR-g‟-SEW  (VpxPBjsyn),  but  decreased  for  PBj-SEW  (-),  PBj-SR-SEW-cSIN 
(VpxPBjsyn), and PBj-SR-g‟-SEW (-). The mean transduction efficiency from one to eleven 
experiments on different donor-monocytes was considered.      Results 
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As the Vpx-incorporation into the vector particles is crucial for the ability to transduce primary 
human  monocytes,  all  vectors  were  tested  for  their  Vpx-incorporation.  Therefore,  vector 
lysates of concentrated vector particles were analyzed by Western blotting (Figure 20C). For 
the detection of Vpx the αVpxHIV-2 monoclonal antibody (αVpx) was used. The antibody is 
described to be cross-reactive to VpxPBj. As expected, Vpx was detectable for all lentiviral 
vectors generated by cotransfection of the Vpx-expression plasmid.   
 
Figure 20: Monocyte transduction and Vpx incorporation of the novel PBj- and HIV-2-derived 
lentiviral vectors. Efficiency of transduction for (A) HIV-2- and (B) PBj-derived lentiviral vectors at an 
moi of one or ten. The vector particles were generated with the indicated transfer vector. (C) Western 
blot  analysis  for  Vpx-incorporation  of  the  generated  vector  particles  used  for  the  transduction 
experiments. 
     Results 
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The  transduction  experiments  confirm  that  the  fast  and  efficient  generation  of  functional 
lentiviral  transfer  vectors  by  Fusion-PCR  is  successful.  The  ability  to  transduce  primary 
human monocytes was maintained.  
Suitability of HIV-2 SEW- and PBj-SEW-derived vector particles for B-cell and 
neuron transduction 
 
The novel HIV-2- and PBj-derived lentiviral vectors were used to investigate their potential for 
the transduction of other primary cell types than monocytes. They were used to transduce 
human unstimulated primary B-cells and murine neuronal brain cells.  
 
Both the HIV-2-SEW- and PBj-SEW-derived lentiviral vectors pseudotyped with VSV-G failed 
to transduce unstimulated B-cells (data not shown). The inability to transduce unstimulated 
B-cells was not unexpected as it is described for VSV-G pseudotyped HIV-1-lentivectors in 
the literature (Funke et al., 2009). The block in unstimulated B cells could not be overcome 
by  either  of  the  PBj-  or  HIV-2-derived  vectors,  regardless  of  homologous  Vpx-
complementation. The B-cell transduction experiments were performed in cooperation with 
Sabrina Funke. 
 
For the transduction of murine neuronal cells the primary cells were provided by  Brigitte 
Anliker  and  Julia  Brynza.  Briefly,  the  Cerebella  of  5/6-days  old  mice  were  isolated  as 
described elsewhere (Rogister and Moonen, 2001), minced and taken into cell culture. After 
five days in cell culture, the cells were transduced with HIV-1-SEW-derived lentivectors as 
well as HIV-2-SEW- and PBj-SEW-derived vector particles generated in the presence and 
absence of VpxHIV-2syn and VpxPBjsyn, respectively, at the moi of ten. The transduction 
efficiency was analyzed five days post transduction. For this, the cells were stained  with 
NeuN-Cy5,  a  neuronal  cell  marker,  and  4',6-diamidino-2-phenylindole  (DAPI),  a  nucleus 
marker, and fixed. The fixed cells were analyzed by Fluorescent Laser Scanning Microscopy 
(Figure 21). The primary murine neuronal cells could efficiently be transduced with VSV-G 
pseudotyped  PBj-SEW-  and  HIV-2-SEW-derived  lentiviral  vectors.  Although  the  cell 
transduction was not specific for the brain neurons, as also transduced stromal cells were 
found, the eGFP-expression was particularly strong in those cells. The transduction of the 
neuronal cells was Vpx independent as also HIV-1-SEW- and HIV-2-SEW-derived vectors in 
absence of Vpx showed equal transduction efficiency (data not shown).      Results 
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Figure 21: Transduction of murine neuronal cells with an HIV-2- and PBj-derived vector. The 
cells were analyzed by Fluorescent Laser Scanning Microscopy for eGFP-expression, DAPI-staining 
and NeuNCy5-staining. 
 
The promising ability of the novel PBj- and HIV-2-derived lentivectors to transduce murine 
brain neurons will be further investigated in vivo in a cooperation with the Institute of Virology 
at the University of Vienna.   
4.3 Analyzing  human  monocytes  as  potential  target  for 
gp91
phox gene correction 
Patients  suffering  from  X-linked  chronic  granulomatous  disease  (xCGD)  are  highly 
susceptible to bacterial and fungal infections. The reason is a non-functional NADPH oxidase 
activity. This leads to the inability of xCGD patients to generate superoxides for monocyte- 
and granulocyte-mediated killing of intracellular  pathogens. It was therefore hypothesized 
that correcting the underlying gp91
phox gene defect in patients´ monocytes may provide a 
possible treatment option. The assumption is that monocytes can be isolated from patients‟ 
blood samples, corrected ex vivo by lentiviral gene-transfer and given back to the patient. If 
the corrected monocytes were able to decrease the bacterial and fungal load, the treatment 
could benefit the patients in various ways. In order to corroborate the assumption, the first 
step was to investigate human monocytes in their potential to phagocytose, burst and kill 
Staphycoccus aureus, a bacterium most xCGD-patients suffer from severely (Winkelstein et 
al., 2000). 
eGFP NeuNCy5
merge DAPI
eGFP NeuNCy5
merge DAPI
PBj-SEW (VpxPBjsyn) HIV-2-SEW (VpxHIV-2syn)    Results 
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4.3.1 Flavocytochrome b558  is  ubiquitously  expressed  by  human 
monocytes 
In a first experiment the ability to isolate a pure monocyte population was evaluated. For this, 
primary  human  monocytes  were  isolated  by  negative  depletion  from  peripheral  blood 
mononuclear  cells  (PBMCs)  from  two  different  donors  (3.3.4).  The  purity  of  the  isolated 
monocytes was analyzed by determination of the CD14
+-cell population by FACS-analysis 
using APC-coupled CD14 mAb (Figure 22). For the different donors about 90% and 94% of 
the isolated cells were monocytes.  
In  the  same  step,  the  isolated  monocytes  were  characterized  for  their  expression  of 
flavocytochrome b558, a membrane bound heterodimer that consists of a smaller α-subunit 
(p22
phox) and a larger ß-subunit (gp91
phox). As the flavocytochrome b558 is part of the NADPH-
oxidase,  its  detection  was  an  indirect  measurement  for  NADPH-oxidase  expression.  To 
determine  the  expression  level  of  on  the  surface  of  human  monocytes,  the  isolated 
monocytes were stained for flavocytochrome b558 and CD14. For the FACS-analysis FITC-
coupled α-flavocytochrome b558 mAb and APC-coupled α-CD14 mAb were used (3.3.10). For 
both donors, about 99% of the CD14
+-monocytes expressed flavocytochrome b558 on their 
cell surface (Figure 22). 
 
Figure 22: Flavocytochrome b558 expression of primary human blood-monocytes. (A) FSC-SSC 
FACS  profile.  (B)  Monocyte  purity  determined  by  CD14
+-expression  in  comparison  to  the  isotype 
control. (C) A α-flavocytochrome b558/α-CD14 double-positive cell staining showed that approx. 99% of 
the blood-monocytes express flavocytochrome b558 on their surface. (Representative FACS-data for 
one donor is shown.) 
4.3.2 Phagocytosis and phagoburst ability of human monocytes 
Monocytes are described to have a high ability to engulf bacteria and fungi. To assure that 
the isolated monocytes retained the ability of phagocytosis in cell culture, the endocytosis 
capacity  of  the  monocytes  was  analyzed  by  the  DQ-BSA  assay  (3.3.14).  Briefly,  the 
monocytes were isolated and incubated at either 4°C or 37°C for 30 min. Then, DQ-BSA was 
added for another 2-h incubation period after which the cells were measured for uptake of     Results 
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the DQ-BSA by FACS. More than 90% of the monocytes phagocytosed the DQ-BSA at 37°C 
compared to the inactive monocytes at 4°C (Figure 23, left). 
A high uptake of bacteria and fungi alone does not account for the ability of monocytes to 
destroy the pathogens. In order to functionally kill them, the phagocytes have the ability to 
produce reactive oxygen species (ROS) such as superoxide anions, hydrogen peroxides and 
hypochlorous  acids.  The  induction  of  ROS  by  activated  monocytes  (oxidative  burst)  was 
measured by the phagoburst assay (3.3.15). For this, the isolated blood-monocytes were 
stimulated with either PMA or washing-solution for ten minutes and their subsequent ROS 
induction was visualized using the substrate dihydrorhodamine (DHR) 123 by FACS. For 
donor  A  and  B,  94.3%  and  96.4%  of  the  monocytes  produced  a  strong  phagoburst, 
respectively (Figure 23, right). 
 
Figure  23:  Phagocytosis  and  Phagoburst  of  human  monocytes.  (Left)  Phagocytosis  capacity 
analyzed by DQ-BSA uptake of monocytes at 4°C (solid black) or 37°C (white). (Right) Phagoburst 
capacity  analyzed  by  ROS  production  of  unstimulated  (solid  black)  or  PMA  stimulated  (white) 
monocytes.  
4.3.3 Staphylococcus aureus killing by human monocytes 
The ability of monocytes to kill bacteria has been known for a long time. As S. aureus is one 
of  the  major  concerns  of  patients  suffering  from  xCGD  (Winkelstein  et  al.,  2000),  this 
bacterium was chosen to demonstrate the killing ability of human monocytes isolated from 
healthy donors. As no exact standard protocol for such an assay was available, different 
settings  were  tested  and  an  own  protocol  established  to  measure  the  killing  activity  of 
monocytes (3.2.11).      Results 
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Briefly, monocytes were isolated from heparinized whole blood (3.3.4) in order to ensure their 
ability to burst. Following isolation, 0, 1x10
4, 1x10
5, or 1x10
6 monocytes were mixed with two 
different amounts of S. aureus (~3x10
5 or ~1x10
6 bacteria), seeded in a 96well plate and 
activated with PMA. Thus, in both S. aureus killing assays the monocyte-to-bacteria ratios 
were 0.03, 0.33, 3.35 or 0.01, 0.1, 1, respectively. One single well was set up for each time 
point and monocyte-to-bacteria ratio. The samples  were incubated at 37°C. The bacteria 
concentration was determined at different time points. For this, 25 µl of a 1:1000-dilution was 
spread on Agar-plates, incubated at 37°C and the number of colonies was counted 15-24 h 
later (Figure 24).  
 
Figure 24: Capacity of human monocytes to kill S. aureus bacteria. Growth curves of 3x10
5 (left) 
and 1x10
6 (right) bacteria inoculated onto the indicated amount of PMA-activated monocytes. At the 
indicated time points the bacteria load was analyzed.  
 
Bacterial  growth  was  impaired  noticeably  with  increasing  amounts  of  monocytes.  While 
bacteria in absence of monocytes showed a normal growth curve, the S. aureus growth was 
impaired inversely proportional to the monocyte presence. Even at the lowest monocyte-to-
bacteria ratio of 0.01 the bacteria growth was reduced by 45% in comparison to the control 
after 3 h incubation. Hence, a method to investigate the ability of monocytes to kill bacteria 
was established. Using this assay, the potency of human monocytes to kill bacteria was 
confirmed.    
4.3.4 HIV-2 based lentiviral transfer vector for gp91
phox gene-transfer  
After  the  successful  demonstration  of  efficient  phagocytosis,  oxidative  burst,  and  killing 
activity of freshly isolated primary human monocytes, a vector for the correction of gp91
phox-
deficient  monocytes  from  xCGD  patients  was  constructed.  The  newly  developed,  HIV-2-
derived vectors were superior to the PBj-derived vectors (Figure 20). Hence, it was decided 
to construct a vector for the gp91
phox gene transfer on the basis of HIV-2.      Results 
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For this, an expression cassette including the gp91
phox gene under the control of the SFFV-
promoter  upstream  of  a  WPRE,  depicted  SFFV-SgW-WPRE-expression  cassette,  was 
inserted  into  the  HIV-2-MCS  vector.  In  contrast  to  the  WPRE  used  for  constructing  the 
eGFP-expressing vectors, this WPRE already contained a mutation which was introduced 
due  to  safety  concerns  (Schambach  et  al.,  2006a).  The  SFFV-SgW-WPRE-expression 
cassette was amplified from the HIV-1-based pHIV-1-SgpSw-transfer vector by PCR using 
the primer-pair BPK 51 / BPK 52 and subsequently cloned into HIV-2-MCS via the restriction 
sites  MfeI  and  AgeI.  The  resulting  transfer  vector,  designated  HIV-2-SgW,  was  used  for 
transient transfection of 293T cells together with the packaging plasmid pHIV-2d4, a Vpx-
expression plasmid and the VSV-G expression plasmid pMG.G2. The vector particles were 
harvested, concentrated and titrated on ∆gp91
phox-PLB-985 cells (Figure 25). This was done 
by  transducing  a  defined  number  of  ∆gp91
phox-PLB-985  cells  with  serial  dilutions  of  the 
vector. The cells were analyzed for gp91
phox expression five days post transduction by a α-
flavocytochrome b558-stain. They were also stained with 7-AAD, which stains dead cells (data 
not shown). Only living, 7-AAD negative cell populations were analyzed for flavocytochrome 
b558 expression (Figure 25). The gp91
phox expressing wild-type PLB-985 cells were used as 
positive  control.  A  1:5000-dilution  of  the  HIV-2-SgW  transfer  vector  generated  vector 
particles resulted in 18.1% flavocytochrome b558-positive cells. Hence, the HIV-2-SgW vector 
titer was calculated to be 3.5 x 10
8 TU/ml. 
 
Figure  25:  Titration  of  vector  particles  generated  with  the  HIV-2-SgW  transfer  vector  on 
∆gp91
phox-PLB-985 cells. Percentage of 7-AAD negative gp91
phox-expressing cells measured through 
a α-flavocytochrome b558-stain by FACS.      Results 
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4.4 Gp91
phox gene correction of murine monocytes 
The  X-linked  chronic  granulomatous  disease  is  a  rare  disease.  It  is  difficult  to  come  by 
patient  blood-samples.  However,  a  good  mouse  model,  the  xCGD-knockout  mouse,  is 
available (Pollock et al., 1995). This model was used to study the correction of the gp91
phox 
gene defect in murine monocytes with the help of lentiviral vectors.  
4.4.1 Cell-composition of murine bone marrow 
As described, the aim was to study the ability of phagocytosis, oxidative burst, and S. aureus 
killing  of  murine  monocytes  as  well  as  to  correct  the  gp91
phox  gene-defect  in  gp91
phox-
defecient murine monocytes with lentiviral vectors. In order to accomplish all of this, large 
amounts of the cells are necessary. Therefore, it was decided to isolate the cells from bone 
marrow to isolate high amounts of monocytes. This isolation of murine monocytes from the 
bone marrow was not yet established in the laboratory. To ensure that enough monocytes 
are  present  in  the  murine  bone  marrow,  the  cell-composition  of  the  bone  marrow  was 
analyzed in collaboration with Sibylle Wehner (University of Frankfurt). C57BL/6 mice were 
sacrificed and the femur was isolated. The bone was cut and the bone marrow used for 
bone-marrow smears on cover-slips. The cover-slips were Pappenheim stained. This method 
can be used to differentiate between different plasma cells. The Pappenheim stained cells 
were analyzed with a light microscope (Figure 26).  
 
Figure 26: Cellular composition of the murine bone marrow. Pappenheim stained murine bone-
marrow smears. Different cell types of the murine bone marrow are indicated (40 x magnification).      Results 
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Cells  of  erythropoiesis  (proerythroblasts,  basophilic-  /  polychromatic-  /  eosinophilic 
erythroblasts),  megakariopoiesis  (megakarioblasts,  megakariocytes)  the  myelocytopoiesis 
(myeloblasts,  promyelocytes,  myelocytes,  juvenile  myelocytes,  band  granulocytes, 
segmented granulocytes), and lymphocytopoiesis (prolymphocytes, lymphocytes) as well as 
monocytopoiesis (monoblasts, monocytes) can be distinguished. 
Although the exact cell composition could not be quantified with the generated bone-marrow 
smears, the stains revealed a normal hematopoiesis, including the presence of monocytes. 
4.4.2 Isolation  and  purification  of  functional  murine  monocytes 
from bone marrow 
Murine monocytes are not as well discernible from other cell types as their human monocyte 
counterpart, which can be easily identified by CD14-expression. Murine monocytes share 
common markers (e.g. CD11b and Gr1) with neutrophils. As the work with murine monocytes 
had not been established in our laboratory, a purification protocol was established and the 
correct monocyte isolation verified by standard murine monocyte markers. In accordance 
with the isolation of human monocytes, the murine monocytes were also purified by negative 
depletion to ensure untouched monocytes (3.3.5). Briefly, murine bone marrow was isolated, 
resuspended in PBS, layered over Ficoll-Paque
® (1.083 density) and subjected to density-
gradient  centrifugation  to  enrich  the  mononuclear  cells  and  to  remove  granulocytes  and 
erythrocytes,  among  others.  The  PBMC-containing  interface  was  collected,  washed  and 
stained with FITC-coupled antibodies against B-cells (α-CD45R (B220)), T-cells (α-CD90), 
NK-cells  (α-CD49b  (DX5),  and  erythrocytes  (α-Anti-Ter119).  A  second  α-FITC  antibody 
conjugated with magnetic beads enabled a negative depletion by magnetic associated cell 
sorting (MACS) leaving the isolated monocytes (Figure 27A).  
To verify the purification protocol the isolated monocytes were analyzed by FACS-staining.  
Different PE-coupled antibodies were used to identify contaminations of B-cells (α-CD45R 
(B220)), T-cells (α-CD90), and NK-cells (α-CD49b (DX5) and NK1.1), respectively. None of 
these cells could be found in the monocyte population but were detected in the depleted cell 
fraction (data not shown). The purity of murine monocytes was determined by the CD11b-
staining  to  be  approx.  94%.  The  CD11b  antigen  is  expressed  on  myeloid  cells  such  as 
monocytes/macrophages and to a lower extent on granulocytes, NK cells and subsets of 
dendritic cells. More than half of the CD11
+-cells were positive for Ly6G (Figure 27B). The 
marker  for  Ly6G  is  described  to  be  negative  for  murine  blood-monocytes  but  transiently 
expressed on monocytes in the bone marrow. 
The CD11b
+/Ly6G
+ stain to analyze murine monocytes was replaced with a CD11b
+/Gr1
+-
double  positive  stain  to  characterize  murine  Gr1
+-monocytes  (also  called  inflammatory     Results 
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monocytes). Of  the  isolated  cells from  the  bone  marrow,  92%  were  CD11b
+/Gr1
+-double 
positive (Figure 27C). Although neutrophils also carry the CD11b and Gr1-surface receptor 
molecules, the granulocytes were excluded from the monocyte population by Ficoll-Paque
® 
density-gradient centrifugation. 
 
Figure 27: Isolation and characterization of murine monocytes. (A) Schematic representation of 
monocyte isolation and purification. (B) Validation of the monocyte isolation protocol with the indicated 
antibodies.  (C)  Characterization  of  purified  inflammatory  Gr1
+-monocytes  by  their  CD11b
+/Gr1
+-
expression profile (CD90: T-cells, CD45R: B-cells, CD49b: NK-cells, Anti-Ter119: Erythrocytes)     Results 
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After successfully establishing the purification of CD11b/Gr1-positive murine bone marrow 
monocytes, the cells were used for functional analysis. Like human monocytes, the murine 
monocytes  of  C57BL/6  wild-type  mice  and  gp91
phox-knockout  mice  were  tested  for  their 
phagocytosis, phagoburst, and S. aureus killing ability. 
4.4.3 Phagocytosis ability of murine monocytes 
Murine monocytes derived from xCGD-mice and their parental C57BL/6 strain were analyzed 
for their phagocytosis ability. Therefore, bone-marrow derived monocytes were isolated by 
negative MACS-depletion (3.3.5). The ability of phagocytosis was determined with the DQ-
BSA-assay (3.3.14). Briefly, the cells were incubated for 30 min at 4°C (control) or at 37°C. 
The DQ-BSA was added for continuous 2-h incubation at the same temperature. Then the 
uptake  of  the  DQ-BSA,  indicative  for  phagocytosis,  was  measured  by  FACS.  The 
phagocytosis capacity of murine wt-monocytes of 93.7% was higher than that of gp91
phox-
knockout mice with 81.8% (Figure 28). 
                                  
Figure 28: Phagocytosis capacity of murine wt- and Δgp91
phox-monocytes. Cells analyzed by the 
phagocytosis assay incubated at 4°C (solid black) or 37°C (white). 
 
As expected, murine monocytes showed a high phagocytosis ability. Importantly, this ability 
was not impaired by the lack of gp91
phox expression.  This can be deducted from the level of 
the phagocytosis ability in gp91
phox-deficient monocytes in comparison to that of monocytes 
from the wild-type C57BL/6 strain.       Results 
     
72 
 
4.4.4 Phagoburst ability of murine monocytes 
Next, freshly isolated wild-type monocytes were compared to gp91
phox-deficient monocytes 
for their ability to induce an oxidative burst. For this, the cells were stimulated with PMA or 
washing solution (control) for ten minutes. To visualize the production of ROS by FACS, the 
substrate DHR was added to the cells after the stimulation (3.3.15). This way in 93% of the 
PMA stimulated wild type cells a strong burst was induced. In contrast, it was not possible to 
detect an oxidative burst for gp91
phox-deficient cells (Figure 29). 
                                    
Figure  29:  Phagoburst  capacity  of  murine  wt-  and  Δgp91
phox-monocytes.  Unstimulated  (solid 
black) or PMA stimulated (white) monocytes analyzed by the phagoburst assay.  
 
The phagoburst assay reproduces the published result, and shows a 100% inability of the 
gp91
phox-deficient monocytes to produce ROS. The sensitive assay can therefore be further 
used for the analysis of gp91
phox-corrected monocytes. 
4.4.5 Staphylococcus aureus killing by murine monocytes 
In order to analyze the capacity of murine monocytes to kill Staphylococcus aureus bacteria, 
the  same  settings  as  established  for  human  monocytes  were  applied  (3.2.11).  Hence, 
different amounts of the isolated murine bone-marrow monocytes were plated in a volume of 
75 µl in 96well plate-wells. They were mixed with either 6.1x10
4 or 2.0x10
5 S. aureus bacteria 
and stimulated with 5 µl PMA. For each ratio multiple wells were set up  – one for each 
reading point. The monocytes were incubated at 37°C and samples taken at different time 
points to determine the bacteria concentration. For this, a 1:1000 dilution was spread on     Results 
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Agar-plates, incubated at 37°C and the colonies counted 15-24 h later (Figure 30). In both 
experiments the 1x10
6 monocytes resulted in a 16-times and 5-times access of monocytes 
over bacteria numbers and therefore resulted in a very high bacteria killing rate. The bacteria 
growth was reduced 90% and 85%, respectively, after 180 min in comparison to the control. 
At monocyte-to-bacteria ratios of 1.6, 0.5, and 0.05, the resulting bacteria growth rates were 
reduced 36%, 40%, and 54%, respectively. In one of the experiments, at a monocyte-to-
bacteria ratio of 0.16 a killing of S. aureus by the monocytes failed and resulted in the same 
bacteria level as the control after 180 min incubation (Figure 30). 
 
 
Figure 30: Capacity of murine monocytes to kill S. aureus bacteria. Growth curves of 6.1x10
4 
(left) and 2x10
5 (right) bacteria inoculated onto the indicated amount of PMA-activated monocytes. At 
the indicated time points the bacteria load was analyzed. 
4.4.6 Biodistribution of murine monocytes  
In  order  to  get  an  idea  where  injected  monocytes  travel  within  the  body,  biodistribution 
studies were performed. To enable the recovery of the injected cells, the monocytes were 
isolated from the bone marrow of genetically modified mice with endogenous expression of 
eGFP. An analysis of the isolated monocytes revealed that only 52% were eGFP-positive at 
the time of injection (data not shown). 2x10
7 eGFP-monocytes were injected intravenously 
into the tail vein of two Rag-2/γc
-/- mice. This mouse strain is not capable of generating an 
immune response against transplanted cells due to a lack of B cells, T cells, and NK cells. 
For control, two other Rag-2/γc
-/- mice received 200 µl PBS. Five hours prior to the injection 
the  mice  were  irradiated  (5 gray).  In  one  of the  recipient  mice  the  transplantation  of  the 
murine eGFP-monocytes worked better. Twenty-four hours after the injection this Rag-2/γc
-/- 
mouse and one of the control mice were sacrificed.  From both mice,  tissue of  the  liver, 
spleen, bone marrow, kidney, blood-samples, and lymph nodes was taken, and fluid from the 
abdominal  cavity  was  collected.  The  cells  of  the  different  organs  were  singularized,  the     Results 
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erythrocytes lysed, and the tissues analyzed for eGFP-positive cells by FACS spectrometry. 
As  different  tissue  cell  types  have  a  different  autofluorescence  a  positive  control  was 
prepared  for  each  tissue  sample  by  mixing  1x10
6  eGFP-monocytes  with  a  part  of  the 
respective negative tissue cells. Four days post transplantation, the mouse which received 
less  eGFP-monocytes  and  the  second  control  mouse  were  sacrificed  and  their  tissues 
analyzed for GFP-positive cells.  
Cells expressing the green fluorescent protein could be detected in the transplanted mice. 
The highest amount of eGFP-positive cells were found within the blood, the bone marrow, 
and the spleen in the mouse sacrificed one day after injection. Four days after the injection, 
eGFP-positive cells were still detectable in the blood and in the bone marrow (Figure 31).  
 
 
Figure  31:  Biodistribution  of  murine  monocytes.  EGFP  expressing  cells  detected  by  FACS  in 
various tissues of Rag-2/γc
-/- one and four days after i.v. injection. Non-transplanted Rag-2/γc
-/- mouse 
tissues were used alone as negative control (neg) or mixed with eGFP-monocytes as positive control 
(pos). (BM, bone marrow; AC, abdominal cavity) 
4.4.7 Determination of the half-life of murine monocytes in vivo 
The idea to use monocytes instead of granulocytes for xCGD gene therapy is based on the 
described longer half-life of the cells. Granulocytes have a very short half-life of approx. 6 h 
which makes them all but impossible to use for gene correction. In contrast, the half-life of     Results 
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murine blood-monocytes is described to be 43.5 +/- 7.9 h (Swirski et al., 2006). These data 
rely on an indirect radioactivity measurement of [
111In]oxine-labeled blood-monocytes. In this 
thesis the murine monocytes are derived from the bone marrow. The half-life between bone-
marrow derived monocytes and blood-monocytes might differ and was therefore analyzed.  
 
To determine the half-life of murine bone-marrow monocytes, C57BL/6 mice were sacrificed 
and monocytes isolated from the bone marrow. Monocytes isolated from C57BL/6 mice carry 
the CD45.2 antigen. The amount of 9x10
7 CD45.2 monocytes were resuspended in PBS and 
injected into the tail vein of CD45.1 mice immediately after isolation. CD45.1 mice carry the 
CD45.1 antigen, an alloantigen of CD45.2. Both are expressed on all hematopoietic cells 
except mature erythrocytes and platelets. The two recipient mice and the control mouse all 
looked  healthy  and  had  weighed  26.3  g,  28.0  g  and  27.5  g,  respectively.  The  injection 
procedure into the tail vein worked flawlessly and the whole volume (200 µl) was injected. 
Blood samples were taken from the tail vein of the animals at regular intervals of 24 h until 
day five after injection. The percentage of CD45.2 monocytes within the monocyte population 
was calculated by FACS. For this the blood samples were treated with Pharm Lyse™ (BD 
Biosciences)  to  remove  erythrocytes  and  neutrophils.  The  samples  were  subsequently 
stained  with  antibodies  against  Gr-1-Vio-Blue,  CD11b-PE-Cy7,  CD45.1-PE,  and 
CD45.2-PerCP-Cy5.5. Within the double positive CD11b
+/Gr1
+-monocyte population it was 
possible  to  distinguish  between  the  CD45.1-monocytes  of  the  recipient  mouse  from  the 
CD45.2-monocytes of the donor mice.  The first blood sample was taken four hours post 
injection  where  the  amount  of  calculated  CD45.2-monocytes  (9.84%  and  7.62%)  was 
normalized to 100%. The percentage of CD45.2-monocytes decreased constantly until day 
five. The  blood of a CD45.1-mouse as well as isolated CD45.2-monocytes was  used as 
control. By a nonlinear regression (curve fit) through the time point values, the half-life of 
murine monocytes in the bloodstream was measured to be 55.2 +/- 5.1 h (Figure 32).      Results 
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Figure 32: Retention of monocytes in the blood circulation. CD45.2-monocytes were injected i.v. 
into  two  recipient  CD45.1-mice.  The  percentage  of  CD45.2-monocytes  was  measured  from  blood 
withdrawals over a period of five days. (A) FACS-measurements (3000 events) for one representative 
mouse.  (B)  Retention  of  monocytes  analyzed  by  nonlinear  regression.  The  number  of  measured 
CD45.2-monocytes immediately after injection was normalized to 100%.  
4.4.8 Gene correction of gp91
phox-deficient murine monocytes 
In a last step the gp91
phox-deficient monocytes of the knockout mice were corrected by gene 
transfer  with  a  lentiviral  vector.  For  this  purpose,  lentiviral  vectors  derived  from  PBj 
(PBj-SEW),  HIV-2  (HIV-2-SEW),  or  HIV-1  (HIV-1-SEW)  were  compared  in  their  ability  to 
transduce murine monocytes. The vectors were generated by transient transfection of 293T 
cells. Next to the transfer construct, the packaging-construct, and the envelope-construct, the 
according  VpxPBjsyn  or  VpxHIV-2syn  was  used  for  PBj  or  HIV-2  transient  transfection, 
respectively. The generated vectors were used for murine monocyte transduction at moi of 1,     Results 
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10,  30,  or  100.  PBj-  and  HIV-2-derived  vectors  failed  to  transduce  murine  monocytes 
efficiently (data not shown). In contrast, even at an moi of one, 11% and 18% of the cells 
could be transduced by HIV-1 vectors. Increasing the amount of the vectors also increased 
the transduction efficiency. A transduction at the moi of 10 or 30 in two separate experiments 
led  to  rates  of  39.0%  and  58.0%  or  52.0%  and  65.0%  positive  cells,  respectively.  A 
transduction of the cells at an moi of 100 resulted in the highest transduction rate of 70%. 
Based on these transduction results, further transduction experiments of murine monocytes 
were conducted with HIV-1-derived lentiviral vectors.  
For the lentiviral gene correction of murine gp91
phox-deficient monocytes, the HIV-1 transfer 
vector pHIV-1-SgpSw, which harbors the same expression cassette (SFFV-gp91
phox-WPRE) 
as HIV-2-SgW-vector systems, was kindly provided by Manuel Grez. For vector production, 
VSV-G pseudotyped HIV-1 particles were produced by transient transfection of 293T cells 
using  the  packaging  construct  pCMVΔR8.9,  the  envelope  construct  pMD.G2,  and  the 
pHIV-1-SgpSw transfer vector. The HIV-1 particles were titrated on ∆gp91
phox-PLB-985 cells 
(3.3.8). This way, a vector titer of 7.56x10
9 TU/ml was achieved after concentration. 
 
The  produced  high-titer  HIV-1-SgpSw  vectors  were  used  for  gp91
phox  gene  correction  of 
murine ∆gp91
phox-monocytes. For this, the murine cells were isolated from the bone marrow 
of  gp91
phox-knockout  mice  by  negative  depletion  (3.3.5)  and  plated  in  48well  plates  for 
transduction (3.3.9). The monocytes were transduced at the moi of 10, 30, and 100. The 
transduced monocytes were cultivated for six days and analyzed for their burst activity. The 
transduction  efficiency  of  HIV-1-SgpSw  vectors  was  determined  by  a  correlation  to  the 
transduction with HIV-1-SEW vectors. These two vector systems differ only in their transgene 
expression by the transfer vector. The VSV-G pseudotyped vector particles themselves are 
identical. Hence, it was assumed that within one experiment, the transduction of identical 
isolated cells from the same mouse background with the same moi will yield comparable 
transduction  efficiencies.  Based  on  this  assumption,  the  transduction  efficiencies  were 
calculated with vector particles that were generated using the eGFP-transferring HIV-1-SEW 
transfer vector. A transduction of gp91
phox-deficient murine monocytes at an moi of 10, 30, 
and 100 yielded 57.7%, 63.1%, and 64.9% eGFP-positive cells, respectively. In contrast, the 
phagoburst  ability  of  gp91
phox-corrected  monocytes  with  HIV-1-SgpSw-derived  vector 
particles  was  much  lower  (Figure  33).  Prior  to  the  FACS-analysis  of  the  HIV-1-SgpSw 
transduced  monocytes,  the  cells  were  incubated  with  α-Gr1-VioBlue  antibodies.  The 
calculated  phagoburst  for  this  Gr1
+-monocytes  was  0.9%,  2.5%,  and  10.2%  for  the 
transduction at an moi of 10, 30, and 100, respectively. The burst experiments from wild type 
monocytes show a phagoburst activity of 98.4%.The results show that the burst activity of the     Results 
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murine  monocytes  is  weak  in  comparison  to  the  corresponding  calculated  transduction 
efficiency.  
 
Figure  33:  Gene  transfer  into  murine  Δgp91
phox-monocytes  using  HIV-1  vectors.  (A)  EGFP 
expressing monocytes detected by FACS after transduction with vector particles generated with the 
HIV-1-SEW  transfer  vector.  (B)  Phagocytosis  capacity  of  gp91
phox  gene-corrected  monocytes  after 
transduction with vector particles generated with the HIV-1-SgpSw transfer vector. 
Although the experiment showed that a gp91
phox gene correction was achieved and resulted 
in  functional  ROS-producing  monocytes,  the  number  of  corrected  cells  was  low.  In  the 
following, it was analyzed whether this low correction capacity was due to an inefficient ability 
to induce an oxidative  burst in  the  corrected cells, as indicated by the high transduction 
efficiency  of  eGFP-transferring  vectors,  or  to  a  reduced  transduction  ability  of  gp91
phox-
transferring vectors. For this, the transduction efficiency of HIV-1-SgpSw vectors was not 
measured indirectly by co-transduction of eGFP-transferring vectors, but directly by detection 
of the gp91
phox-expression in the transduced monocytes. In contrast to the determination of 
gp91
phox-expressing PLB-985 cells, the expression in monocytes had to be measured by an 
intracellular stain because this cell type is known to otherwise yield false-positive signals.  
Murine bone-marrow monocytes of gp91
phox-knockout mice were isolated by MACS negative-
depletion as described before (3.3.5) and transduced with HIV-1-SgpSw at an moi of 1, 10, 
30,  100,  and  500.  Five  days  post  transduction  the  transduced  Gr1
+-monocytes  were 
analyzed for their oxidative burst activity as well as for their gp91
phox-expression. For this, the 
cells were split. In one fraction of the cells, the oxidative burst activity was analyzed by the 
phagoburst assay (3.3.15). In the other fraction, the gp91
phox-expression was determined by     Results 
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an intracellular  antibody-staining against flavocytochrome b558  (3.3.12). In both cases the 
cells were also stained against Gr1
+ with VioBlue conjugated Gr1
+-antibodies (Figure 34).  
 
 
Figure  34:  Gene  correction  of  gp91
phox-deficient  murine  monocytes.  Murine  monocytes  of 
gp91
phox-knockout  mice  were  corrected  using  HIV-1-SgpSw-derived  lentiviral  vectors.  The  gene 
transfer efficiency (flavocytochrome b558 expression) was correlated to the oxidative burst-activity. (A) 
The  FACS-analysis  of  one  exemplary  experiment.  (B)  Mean  results  for  gene  transfer  detected  by 
flavocytochrome  b558  expression  and  the  corresponding  transgene  function  determined  by  ROS 
production.      Results 
     
80 
 
The measured phagoburst activity during this experiment was in accordance with the data 
derived from the previous experiment. In contrast, the observed transduction efficiencys for 
eGFP-transferring  vectors,  analyzed  by  eGFP-expression,  were  much  higher  than  those 
observed  for  gp91
phox-transfering  vectors,  analyzed  by  an  intracellular  stain  against 
flavocytochrome b558. The transduction efficiencies calculated from the intracellular stain of 
flavocytochrome b558 were in a similar range of the percentage of monocytes able to induce 
ROS  production.  The  highest  transduction  efficiency  analyzed  from  the  intracellular  stain 
against flavocytochrome b558 was achieved at the moi of 500. Due to titer limitations, the 
transduction at this moi could only be performed once. It resulted in 62.9% gene-corrected 
cells. Within the same cell population 50.9% of the monocytes produced a phagoburst.  
 
In summary, HIV-1 vectors were used to transfer the gp91
phox gene into monocytes from 
gp91
phox-deficient  mice  and  a  successful  restoration  of  the  oxidative  burst  ability  was 
achieved in the cells.  
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5  Discussion 
Lentiviral vectors derived from SIVsmmPBj are able to overcome a still unknown block in 
primary  human monocytes  and  transduce these  quiescent  cells  with  high  efficiency. The 
transduction  is  dependent  on  the  viral  Vpx-protein.  The  ability  to  efficiently  transduce 
monocytes opens up the possibility to use these primary cells as a putative gene therapy 
target. For this purpose, the generation of enhanced transfer vectors of SIVsmmPBj and 
HIV-2 origin is described in this thesis. For future vector designs, a fast and efficient new 
cloning strategy was successfully innovated. With this tool for safe monocyte transduction, a 
new  therapeutic  application  for  chronic  granulomatous  disease  was  conceived  and  the 
foundation to test the use of gp91
phox gene-corrected monocytes as a therapeutic for xCGD 
was set.   
5.1 Vpx  of  the  HIV-2/SIVsmm/SIVmac  lentivirus  lineage 
facilitates monocyte transduction 
All viruses from the HIV-2/SIVsmm/SIVmac lineage encode for the accessory protein Vpx. 
Hence, it was suspected that not only the Vpx of SIVsmmPBj (VpxPBj), but also the protein 
homologues  of  other  family  members,  like  the  Vpx  of  HIV-2  (VpxHIV-2)  and  SIVmac 
(VpxMAC), might also facilitate monocyte transduction. This conjecture was supported by 
results  showing  that  Vpx  is  inevitable  for  virus  wild-type  replication  of  PBj,  SIVmac,  and 
HIV-2 in human and macaque macrophages (Fletcher et al., 1996; Kawamura et al., 1994; 
Sleigh et al., 1998; Yu et al., 1991). Accordingly, an HIV-2 two-plasmid-system (HIV-2-RodA) 
was investigated (Reuter et al., 2005). The structure of the vector was different to the PBj-
derived two-plasmid-system, PBj-∆EeGFP. To enable eGFP expression, the gfp gene was 
set in frame with the nef gene in the case of HIV-2-RodA and not expressed by an internal 
CMV-promoter sequence as in the case of PBj-∆EeGFP. Both vector systems encode for all 
accessory genes, including vpx. The different ways to express eGFP on the grounds of the 
different vector design should only have an effect on the strength of transgene expression 
but not on the vector‟s ability to transduce primary monocytes. This transduction ability could 
be confirmed for HIV-2-RodA and PBj-∆EeGFP, but not for an HIV-1 lentiviral vector system 
(HIV-1-NL4-3)  (Figure  9).  Interestingly,  using  the  HIV-1-NL4-3  vectors  at  an  moi  of  ten 
caused most of the monocytes to die. They stayed healthy after transduction at the same moi 
with PBj-∆EeGFP and HIV-2-RodA. As all vectors were generated and titrated the same way, 
using the envelope expression plasmid (pMD.G2), the reason for the toxicity of the HIV-1     Discussion 
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vector cannot be linked to particle production, but instead must be associated with the HIV-1 
particle or the incorporated viral proteins themselves.  
The observation that HIV-2-derived vectors are able to transduce primary human monocytes 
prompted the cloning of different Vpx-expression plasmids for functional analysis. Next to the 
existing  VpxPBj  plasmid  (Wolfrum,  2005),  expression  constructs  for  the  vpx-genes  of 
HIV-2-RodA  and  SIVmac  were  generated  using  PCR.  The  expression  in  293T  cells  was 
weak for VpxPBj and VpxHIV-2 but not detectable for VpxMAC. This is due to the αVpxHIV-2 
monoclonal antibody which has been described to be crossreactive with VpxPBj but not with 
VpxMAC.  To  enhance  the  weak  VpxPBj-  and  VpxHIV-2-expression,  codonoptimized 
plasmids  (VpxPBjsyn  and  VpxHIV-2syn)  were  obtained.  Western  blot  analysis  of  these 
revealed a well detectable expression level.  
All of the available Vpx expression plasmids, except for of the unmodified VpxHIV-2, were 
able  to  facilitate  monocyte  transduction  of  the  PBj-4xKOeGFP  vector.  It  was  not  further 
investigated whether the nonfunctional transduction with VpxHIV-2 is due to non-detectable 
protein levels in the vector particles, caused by insufficient incorporation because of the non-
homologous  PBj  background,  or  to  a  non-functional  protein.  VpxPBj  and  VpxMAC,  who 
successfully mediated monocyte transduction of PBj-4xKOeGFP, were also not detectable in 
the  vector  particles.  Whereas  the  antibody  available  did  not  detect  VpxMAC,  it  clearly 
detected VpxPBj, as the codonoptimized protein could easily be visualized. Thus, it can be 
concluded that minimal Vpx amounts are sufficient to drive monocyte transduction.  
Altogether,  the  experiments  prove  that  Vpx  proteins  other  than  VpxPBj  of  the 
HIV-2/SIVsmm/SIVmac  lentivirus  lineage  also  possess  the  ability  to  facilitate  monocyte 
transduction. Hence, the experiments disprove the assumed uniqueness of the PBj vectors. 
5.2 Generation of PBj- and HIV-2-derived lentiviral vectors 
The observation that lentiviral vectors from the HIV-2/SIVsmm/SIVmac lineage other than 
those of the SIVsmmPBj origin enabled monocyte transduction led to the generation of two 
three-plasmid vector systems. One of these is based on human origin (HIV-2) and the other 
is based on non-human origin (SIVsmmPBj). With regard to clinical applications it could be 
advantageous to have a non-human vector, since in the case of an HIV infection it is unlikely 
to recombine with the resident HIV. On the other hand, there might be higher regulatory 
restrictions  for  the  use  of  non-human  vector  systems  due  to  their  theoretical  zoonotic 
potential. Hence, it was decided to generate an HIV-2- and an SIVsmmPBj-derived three-
plasmid system. The generation of SIV-based lentiviral three-plasmid vector systems has 
been described by different authors for SIVmac (Dupuy et al., 2005; Mangeot et al., 2000;     Discussion 
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Negre  et  al.,  2000).  The  construction  of  HIV-2  derived  three  plasmid  vectors  is  also 
described in the literature (D'Costa et al., 2001; Morris et al., 2004). The latter are basic non-
SIN HIV-2 vectors and therefore not applicable for clinical purposes.  
5.2.1 Gradual enhancement of a PBj-derived transfer vector 
A basic PBj three-plasmid system was available in the lab. It consisted of the packaging 
vector  pPBj-pack,  the  envelope  plasmid  pMD.G2,  and  the  transfer  vector  pPBj-trans 
(Wolfrum, 2005). However, this system resulted in poor titers. A deletion between the splice 
donor and start-ATG within the pPBj-pack abrogates an incorporation of the RNA into the 
particles.  This  prevents  viral  replication,  as  has  been  shown  for  the  similar  HIV-2  virus 
(Poeschla et al., 1998). The packaging construct pPBj-pack itself had the ability to generate 
high amounts of vectorlike particles (data not shown), indicating that the reason for the poor 
titer lay in the transfer vector pPBj-trans. Therefore, only the pPBj-trans vector was the focus 
of a gradual enhancement. Separate enhancements of PBj-trans-SIN, such as the integration 
of an SFFV-eGFP-WPRE expression cassette (leading to pPBj-SEW-SIN) and the inclusion 
of  the  central  termination  sequence  (CTS)  downstream  of  the  central  polypurine  tract 
(leading to pPBj-trans-cSIN) increased the vector titers as expected. 
SIN-configuration 
The  first  modification  was  the  deletion  of  the  second  exons  of  Tat  and  Rev  and  of  the 
promoter and enhancer elements within the U3 region of the 3‟LTR. This step resulted in 
PBj-trans-SIN and led to a decrease in titer of about 2-fold. Such a negative influence on titer 
through  the  generation  of  SIN-vectors  was  also  found  for  SIVmac  generated  vectors 
(Mangeot et al., 2000). In order to increase the mRNA expression and titer, the size of the 
vector mRNA was decreased by the deletion of the unnecessary second exons of tat and 
rev. However, it can only be speculated whether the decrease in vector size had a positive 
impact on the vector titer as it was compensated by the generation of the SIN-configuration. 
cPPT/CTS 
The reintroduction of the correct cis-acting cPPT/CTS element and the deletion of a large 
fraction of the pol sequence resulted in an increase in unconcentrated vector titers of approx. 
2-fold, as expected. To achieve the highest possible effect, special attention was paid to 
integrate the cPPT/CTS element in sense orientation at a 5‟ vector location, as described for 
HIV-1 (De Rijck and Debyser, 2006; Van Maele et al., 2003). The cPPT/CTS sequence is 
apparently involved in the nuclear import process (Sirven et al., 2000) and inclusion of the 
element into HIV-1 vectors enhances transduction efficiency 2–10-fold (Zennou et al., 2000). 
Recent data indicate that the DNA flap formed by the interplay of cPPT and CTS during     Discussion 
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reverse transcription is not absolutely required for vector transduction (Zufferey et al., 1997) 
or even wild-type HIV-1 replication (Dvorin et al., 2002; Limon et al., 2002). It can be deleted 
or replaced in order to reduce the risk of RCL formation and to gain space for therapeutic 
sequences  (Schambach  and  Baum,  2008).  These  results  were  verified  by  showing,  that 
cPPT/CTS-deficient PBj vectors derived from PBj-trans were still able to transduce human 
monocytes  (Figure  14).  Nevertheless,  the  cPPT/CTS-element  is  described  to  be 
indispensable for the transduction of neuronal cells (Liehl et al., 2007). Although the literature 
argues  that  the  enhancement  of  titer  for  the  PBj-trans-cSIN  construct  resulted  from  the 
integration of the correct cPPT/CTS-element, it is nevertheless possible that the large pol 
sequence  deletion,  resulting  in  a  shorter  mRNA  transcript,  led  to  a  more  stable  mRNA 
expression which further enhanced the generated vector titer. 
WPRE 
The integration of the SFFV-eGFP-WPRE cassette introduced the internal SFFV-promoter, 
which is a strong ubiquitous promoter (Baum et al., 1997), and the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE). Although the internal promoter has a great 
influence on the expression level of a transgene it has no effect on the titer and transduction 
efficiency  of  the  vector  system.  In  contrast,  the  WPRE  stabilizes  the  vector  RNA  and 
enhances protein expression in the packaging cell line and in the target cell. This leads to an 
increased infectious particle formation (titer) and transgene expression (Hlavaty et al., 2005; 
Zufferey et al., 1999). In the case of the generated PBj-SEW-SIN vectors, this resulted in a 
titer increase of approximately 3-fold in comparison to PBj-trans-SIN. 
cPPT/CTS and WPRE 
The combination of both modifications - the corrected cPPT/CTS sequence and the insertion 
of a SFFV-eGFP-WPRE expression cassette - resulted in the construct pPBj-SEW-cSIN and 
a cumulative increase of the titer. Unconcentrated vector particles produced with the pPBj-
SEW-cSIN  transfer  vector  had  a  10-fold  increased  titer  compared to the  origin  PBj-trans 
vector.  
SV40/RSV-element 
Finally, the promoter elements of the U3-region within the 5´LTR were substituted with a 
chimeric  SV40-enhancer/RSV-promoter  element  to  gain  a  strong,  Tat-independent  vector 
RNA expression in the packaging cells. The Tat-independency of the so called pPBj-SR-
SEW-cSIN transfer vector within the packaging cells was not tested, as the Tat-expressing 
packaging  construct  pPBj-pack  had  been  used  for  vector  production.  Nevertheless,  the 
particle  production  was  further  increased  5-fold  resulting  in  unconcentrated  titers  of 
5x10
5 TU/ml, an overall 50-fold increase in comparison to the origin PBj-trans vectors. For     Discussion 
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concentrated  vectors,  the  increase  achieved  by  the  described  enhancement  steps  from 
PBj-trans to pPBj-SR-SEW-cSIN was 10-fold and titers up to 1,12x10
7 TU/ml were reached.     
5.2.2 Generation of lentiviral transfer vectors by Fusion-PCR 
The  conventional  construction  of  lentiviral  derived  transfer  vectors  by  gradual  enhancing 
cloning steps is a time-consuming process. A general transfer vector encompasses normally 
more  than  7000 bp  with  repetitive  sequences,  i.e.  LTR.  The  more  cloning  steps  are 
conducted, the more mutations are likely to be included and unwanted DNA sequences in 
between  necessary  vector  elements  remain  due  to  unfitting  restriction  sites.  These 
sequences enlarge the homology to the wild-type virus sequences and increase the size of 
the  transfer  vector  needlessly.  This  leads  to  a  hampered  vector  production.  In  order  to 
construct a lentiviral transfer vector quickly by simultaneously minimizing the non-functional 
DNA  sequences,  a  novel  strategy  to  design  transfer  vectors  from  a  lentiviral  origin  was 
conceived, i.e. the generation of transfer vectors directly by Fusion-PCR. 
  
The viral wild-type sequences of either SIVsmmPBj or HIV-2 were used as template for three 
different PCR reactions to yield specific segments of the transfer vector that function as the 
scaffold. These fragments were fused in different Fusion-PCR reactions and cloned into a 
vector backbone originated from the pBluescript-plasmid (Figure 7). The vectors resulting 
from these few cloning steps, pPBj-MCS or pHIV-2-MCS, respectively, are an ideal starting 
point for the integration of different vector elements, their choice depending on the transfer 
vector‟s intended purpose. In order to prove that indeed a functional transfer vector had been 
generated,  the  internal  SFFV-eGFP-WPRE  expression  cassette  was  integrated  into  the 
MCS, resulting in PBj-SEW and HIV-2-SEW. In the absence of Vpx, the generated vector 
titers were lower for PBj-SEW than they were for HIV-2-SEW. These titer differences may be 
due to the respective packaging construct used. Another explanation for titer variations are 
the virus origins themselves. It cannot be expected that vectors derived from different viruses 
produce  the  same  vector  titers.  The  promoter  strength  of  the  viral  LTRs,  the  packaging 
capacity mediated by the   sequence, or the mRNA export by the Rev protein are possible 
reasons for titer variations between differently originated vectors. Nevertheless, both novel 
generated  vectors  outperformed  the  enhanced  PBj  vector  PBj-SEW-cSIN  generated  by 
gradual  enhancement.  However,  they  did  not  reach  the  titers  of  an  HIV-1-SEW-derived 
vector system with titers above 5x10
8 TU/ml after concentration. This could be caused by 
reasons similar to those described before or by the different SD/SA profiles. In addition to the 
SD, the used HIV-1-SEW transfer vector contained an SA-site downstream of the RRE. In 
contrast,  for  PBj-SEW  and  HIV-2-SEW  the  SA  sequence  downstream  of  the  RRE  was     Discussion 
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deleted.  Only  the  SD  was  kept  in  the  5‟UTR  of  the  vectors  for  efficient  vector  RNA 
packaging. As only the SD is present in the viral construct, no splicing will occur and hence a 
Rev-mediated export of the transfer RNA is necessary. An efficient Rev-mediated export is 
dependent on a part of the splicing machinery. It should still be possible due to the present 
SD  (Chang  and  Sharp,  1989),  but  maybe  was  less  efficient  than  that  for  HIV-1-derived 
vectors.  
 
In contrast to the vector design of PBj-trans, where the gag start-ATG was mutated to an 
ACG (Wolfrum, 2005), a stop codon was introduced downstream of the gag gene start-ATG 
of  PBj-SEW  and  HIV-2-SEW  to  prevent  Gag  expression.  This  was  performed  since  the 
beginning  of  the  gag  sequence  could  be  involved  in  proper  RNA-packaging  (L.  Naldini, 
ESGCT 2007, personal communication). Here, minimal changes can reduce the ability for 
particle incorporation (Ooms et al., 2004). However, the decision to abrogate gag translation 
downstream of the start-ATG was merely a precaution as the extension of the packaging 
signal into Gag is only described for the HIV-1 virus (Yu et al., 2008). The  -site mapping is 
controversially reported for the HIV-2/SIVsmm/SIVmac lineage. Here, different sequences 
up- and downstream of the SD are described to be important with the accordance of 10 well-
conserved  nucleotides  (SIVmac,  ACACAAAAAA;  HIV-2,  ACACCAAAAA),  located 
immediately after the SD site junction most likely critical for HIV-2 and SIVmac genomic RNA 
packaging (Patel et al., 2003). As the region between the LTR and the gag sequence was 
not changed during the vector design, the „ACACCAAAAA‟ in the HIV-2 vectors remained 
unchanged.  For  PBj  the  „CAACAAAAA„  sequence  found  downstream  the  SD  was  most 
similar to the conserved HIV-2 and SIVmac sequences and therefore probably important for 
mRNA packaging. It was also not affected in the transfer vectors.  
 
In conclusion, the generation of lentiviral transfer vectors by Fusion-PCR is fast, efficient and 
opens up multiple possibilities to  easily  integrate further restriction sites between various 
elements by including them into the primer overhangs. An example is the introduction of the 
multiple-cloning site intended to integrate an expression cassette as performed here. Other 
restriction sites could be inserted e.g. upstream of the R-region within the 5‟LTR for possible 
insertions of miRNA target sequences, shRNAs, or insulator sequences.  
5.2.3 Monocyte  transduction  of  novel  generated  PBj-  and  HIV-2-
derived lentivectors 
Efficient primary human monocyte transduction by lentiviral vectors is only feasible if Vpx is 
incorporated into the vector particles. Although in early experiments, the detection of native     Discussion 
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Vpx  incorporation  into  vector  particles  was  beneath  the  detection  limit,  a  monocyte 
transduction was enabled (Figure 14B). The expression of the Vpx proteins was successfully 
improved  by  codonoptimization  and,  subsequently,  the  correlation  between  the  Vpx 
incorporation and the ability of vector particles to transduce monocytes  was shown. This 
incorporation  of  Vpx  into  vector  particles  was  achieved  through  αVpxHIV-2  monoclonal 
antibodies in a Western blot. In such a blot, VpxHIV-2syn showed two bands (Figure 20). 
The  lower  one  corresponds  to  the  VpxHIV-2syn  size  of  17  kDa.  The  upper  band  of 
approximately twice this size may point to a dimer formation, due to insufficient denaturation. 
A cross-reactivity against proteins of the vector particles can be excluded, as the band is not 
visible  for  HIV-2  vector  particles  generated  in  the  absence  of  VpxHIV-2syn.  The  dimer 
formation was also previously described for the related Vpr of HIV-1 (Fritz et al., 2008) and 
identified for Vpx (A. Berger, personal communication).  
The  highest  monocyte  transduction  was  achieved  using  HIV-2-derived  lentiviral  vectors. 
Vector  particles  generated  in  the  presence  of  VpxHIV-2syn  with  the  transfer  vector 
HIV-2-SR-g‟-SEW were able to transduce 64% or 50% of the monocytes at an moi of ten or 
one, respectively. In general, HIV-2-derived vectors were superior to PBj-derived vectors in 
their ability to transduce human monocytes. The reason for this is difficult to explain based 
on the particle design. The vectors were produced and titrated using the same protocol and 
the same amount  of infectious particles was used for  monocyte  transduction.  A possible 
explanation  is  a  different  potential  of  VpxHIV-2syn  or  VpxPBjsyn  to  facilitate  monocyte 
transduction.  Here  the transduction  experiments  indicate  that  VpxHIV-2syn  is  superior  to 
VpxPBjsyn.  This  conclusion  is  supported  by  the  experiment  in  which  both  Vpx  proteins 
facilitate  monocyte  transduction  of  the  same  4xKOeGFP  vectors.  In  that  experiment, 
VpxHIV-2syn was also superior to VpxPBjsyn (Figure 11).   
5.3 Clinical  applications  for  PBj-  and  HIV-2-derived 
lentivectors 
Now  that  PBj-  and  HIV-2-derived  three-plasmid  vector  systems  were  available  with  their 
enhanced transduction ability of primary human monocytes, the question arose whether such 
vector systems are superior to HIV-1-derived vectors for possible applications in human gene 
therapy. 
It had been confirmed for the PBj- and HIV-2-derived vectors that they do not enable an 
enhanced transduction of unstimulated B cells. The same is described for the transduction of 
unstimulated  stem-cells  with  basic  PBj-vectors  in  comparison  to  HIV-1  vectors  (Kaiser,     Discussion 
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2008). In contrast, the transduction of monocyte-derived macrophages and dendritic cells 
was  significantly  higher.  Currently,  the  vectors  are  being  tested  for  their  suitability  for 
immunotherapy applications (Kaiser, 2008).  
Furthermore,  the  vectors  are  compared  to  HIV-1-derived  vectors  on  different  murine  cell 
types in vitro and in vivo. A cooperation was started with the Max-Planck-Institute for Brain 
Research in Frankfurt (Main) to investigate the ability of the vectors to transduce murine 
retina. First experiments are promising, and tend to show a different target cell preference for 
PBj-SEW-, HIV-2-SEW-, and HIV-1-SEW-generated vectors, respectively. This transduction 
seems not to be influenced by the Vpx-protein.  
The general in vitro transduction ability of murine neurons was demonstrated for HIV-2 and 
PBj vectors in this thesis. In cooperation with the Institute of Virology at the University of 
Vienna, the HIV-2 and PBj vectors are currently being compared to HIV-1 vectors in their 
ability to transduce differentiated brain neurons in vivo in presence and absence of Vpx. 
Efficient  transduction  of  neuronal  cells  in  vivo  could  be  useful  for  clinical  applications  of 
Parkinson's disease or Alzheimer's disease. The general value of SIV-derived vectors for 
treatment of neurodegenerative diseases has been shown previously (Liehl et al., 2007). 
 
The high monocyte transduction ability of the HIV-2- and PBj-derived vectors could also be 
beneficial for clinical applications regarding gene defects in the monocytes themselves. An 
example for a  disease based on a gene defect in monocytes/macrophages is Gaucher's 
disease. In this thesis the suitability of the vector systems for treatment of another inherited 
disease, xCGD, was tested. 
5.3.1 A novel concept of xCGD treatment 
The X-linked form of the chronic granulomatous disease is based on a gene defect in the 
CYBB gene located on the x-chromosome, leading to a non-functional gp91
phox subunit of the 
NADPH oxidase. The defect is prominent on phagocytes such as neutrophils and monocytes 
and  results  in  an  insufficient  killing  of  bacteria  and  fungi.  Therefore  patients  suffer  from 
recurring and severe infections.  
If a potential donor is present the curative treatment option of choice is the hematopoietic 
stem cell transplantation. Although stem cell transplantation works very well, it is problematic 
when  ongoing  infections  are  present  at  the  time  of  transplantation  (Seger,  2008).  One 
possibility to decrease severe infections is the allogenic granulocyte transfusion, but the risk 
of  alloimmunization  to  HLA  antigens  may  complicate  a  later  allogenic  stem  cell 
transplantation  (Stroncek  et  al.,  1996).  If  no  donor  is  available  for  a  HSCT,  the  gene 
correction of CD34
+-stem cells is a possible way to cure the disease in the future. Two trials     Discussion 
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in Frankfurt and Zurich showed first promising results (Ott et al., 2006). Although a gene 
correction was possible in both patients in Frankfurt, the patients showed adverse events 
due to insertional mutagenesis (Grez, 2008).   
In  this  thesis  a  new  treatment  model  was  conceived.  It  is  proposed  that  an  autologous 
monocyte  cell  transfusion  after  ex  vivo  gp91
phox  gene  correction  will  help  to  transiently 
overcome severe infections. Depending on the potency of monocytes to kill pathogens, the 
monocytes would be able to eliminate persistent infections or even granulomas. The method 
could therefore prepare patients for possible stem cell transplantation.  
Although the killing of monocytes is described to be less efficient than that of neutrophils 
(Emmendorffer  et  al.,  1994),  monocytes  and  their  progeny  cells  -  like  inflammatory 
macrophages  and  TipDCs  -  are  described  to  kill  microbes  (Auffray  et  al.,  2009).  The 
possibility of a synergistic activation, as described for the killing of Aspergillus hyphae by 
neutrophils, could increase the killing potency (Rex et al., 1990). The application of the gene-
corrected  monocytes  is  believed  to  be  safe.  As  the  cells  used  for  injection  would  be 
autologous, no immune reactions like graft vs. host are anticipated. The risks resulting from 
insertional mutagenesis are minimal, as monocytes differentiate to macrophages and DCs, 
but usually no cell division occurs. 
To investigate the potential of monocytes for the proposed treatment model,  human and 
murine monocytes were investigated for their oxidative burst, phagocytosis, and S. aureus 
killing  potential.  Murine  gp91
phox-deficient  monocytes  were  corrected  and  functionally 
analyzed for their ability to burst. 
5.3.2 Setting up the system 
Isolation of monocytes 
Two  different  monocyte  subsets  can  be  distinguished,  the  inflammatory  and  resident 
monocytes. To investigate the potential of monocytes for a possible clinical application of 
bacterial clearance after gp91
phox gene correction, it was decided to use the inflammatory 
monocytes (CD14
+ (human), Gr1
+ (mouse)). In contrast to the resident monocytes (CD16
+ 
(human), CX3CR1
+ (mouse)), they are described to be involved in bacterial killing (Auffray et 
al., 2009). Human monocytes were isolated from donor blood by negative depletion (3.3.4). 
During  this,  the  cell  suspension  was  also  depleted  of  CD16
+-monocytes.  Therefore,  the 
isolated  monocytes  were  exclusively  inflammatory  monocytes.  In  order  to  isolate 
inflammatory murine monocytes, it was decided to use the bone marrow rather than blood. In 
the blood both monocyte subsets are present to equal quantities. The resident monocytes 
develop from the inflammatory monocytes upon release from the bone marrow into the blood     Discussion 
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(Sunderkötter et al., 2004). Therefore, it was assumed that the isolation of murine bone-
marrow monocytes results predominantly in Gr1
+-monocytes.  
As the isolation of murine bone-marrow cells had not been established in the lab, it was 
decided to adapt the negative isolation protocol of F. Swirski and coworkers (Swirski et al., 
2006) although this protocol was established for the isolation of blood monocytes. In contrast 
to the original procedure, the cells were not stained with antibodies directly conjugated to 
MicroBeads. Instead, the cells were first stained with FITC conjugated antibodies against T 
cells,  B  cells,  NK  cells,  and  erythrocytes  and  subsequently  with  MicroBeads  conjugated 
αFITC antibodies. Isolated monocytes were analyzed using a combination of PE- or APC-
labeled antibodies directed against specific cell markers of T cells (PE-CD90.2), B cells (PE-
CD45R (B220)), NK cells (PE-CD49b (DX5), PE-NK1.1), and the leukocyte markers PE-Ly-
6G  and  APC-CD11b.  The  Ly6G  marker  is  negative  for  blood  monocytes  but  transiently 
expressed on monocytes in the bone marrow. This was confirmed by FACS measurements. 
After the isolation protocol was established, the Gr1
+-monocytes were solely characterized 
by Gr1
+/CD11b
+-expression (Figure 27).  
5.3.3 Functional  analysis  of  murine  monocytes  for  gp91
phox  gene 
therapy 
Phagocytosis, Phagoburst and S. aureus killing 
While high phagocytosis and burst capacities were demonstrated for human and murine wt 
monocytes, the killing capacity was only moderate. One reason could be the lack of further 
stimuli necessary for monocytes activation like complement components in the in vitro assay 
(Leijh et al., 1982). The set-up for the killing of S. aureus bacteria by monocytes was shown 
to be generally effective but could be improved in the future. As the monocytes showed only 
a weak oxidative burst by S. aureus bacteria activation (data not shown), the cells were 
activated using PMA. PMA was added at the time of mixing the bacteria with the monocytes. 
A higher killing efficiency might be possible if the monocytes were PMA-stimulated at a later 
time, after the phagocytosis of the bacteria by the monocytes was advanced. 
Another reason for the moderate killing activity could be the production of leukocidin by the 
bacteria. S. aureus is one of the major leukocidin producers. Leukocidin is a pore forming 
cytotoxin that kills leukocytes. M. Dinauer and colleagues described that substantially higher 
numbers of neutrophils are needed to fully restore host defense in experimental infection with 
Staphylococcus  aureus  or  Burkholderia  cepacia  compared  with  Aspergillus  fumigatus 
(Dinauer et al., 2001). Therefore, the sensitivity of the assay to test the killing potential of 
gp91
phox  gene-corrected  monocytes  may  be  enhanced  using  the  less  resistant  fungus 
Aspergillus fumigates as challenge pathogen.     Discussion 
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Biodistribution 
The biodistribution data generated for murine eGFP-monocytes in Rag-2/γc
-/- mice indicate 
that  the  transplanted  cells  are  found  in  the  spleen,  the  bone  marrow,  and  in  the  blood. 
Whereas  the  cell  number  in  the  spleen  and  the  blood  decreased  four  days  after 
transplantation, the number of cells in the bone marrow seemed stable over this time. In 
some tissue samples, e.g. lung and liver, only a few eGFP-positive cells were found. They 
presumably originate from blood contaminations. 
Monocytes are described to circulate in the blood stream. Therefore, the detection of eGFP 
positive cells in the blood was expected. As one of the functions of the spleen is to filter the 
blood, it was not surprising to detect high amounts of eGFP-positive cells in the spleen one 
day after transplantation, which are absent four days after transduction. 
The constant amount of eGFP-positive cells in the bone marrow, however, was unexpected. 
Although Gr1
+-monocytes  are  described  to  home  to  the  bone  marrow  in  the  absence  of 
inflammation (Geissmann et al., 2003; Varol et al., 2007), the amount of cells suggests that, 
in addition to Gr1
+-monocytes also monocyte precursors were isolated. As bone-marrow cells 
they are presumably retargeting the bone marrow.  
Monocyte half-life 
Diverse  specifications  about  the  in  vivo  half-life  of  murine  monocytes  are  found  in  the 
literature. They  range from 43.5 +/- 7.9 h (Swirski et al., 2006) to 3 days (Mazzarella et al., 
1998). In all cases the half-life has been derived for blood-monocytes. To investigate the 
half-life  of  murine  bone-marrow  derived  Gr1
+-monocytes  in  the  bloodstream,  CD45.2 
monocytes were isolated and transplanted into CD45.1 mice. The retention of the CD45.2 
monocytes in the CD45.1 mice was traced by FACS-staining over a period of five days. The 
calculated half-life was 55.2 +/- 5.1 h.  
The discrepancy between the described half-lives for monocytes could be due to any of three 
reasons:  First,  the  difference  of  the  monocytes‟  origin  (bone-marrow  compared  to  blood 
monocytes)  could  account  for  differences  in  half-life  measurements.  Blood-derived 
monocytes might have already been in the bloodstream several days before harvest. They 
would  therefore  tend  to  leave  the  bloodstream  soon  after  transplantation.  Second,  the 
different  monocyte  subtypes  differ  in  their  half-life  due  to  their  function.  Third,  the 
experimental set-up used to analyze the half-life could in itself account for variations. An 
indirect  measurement,  i.e.  radioactive  labeling,  seems  more  error  prone  than  a  direct 
measurement of CD-markers as performed in this thesis.  
The  half-life  measured  by  F.  Swirsky  and  co-workers  relies  on  an  indirect  radioactivity 
measurement  of  [
111In]oxine-labeled  CXCR2
+-blood-monocytes  (Swirski  et  al.,  2006)  and 
therefore  differs  from  the  calculation  of  bone-marrow  derived  Gr1
+-monocytes  by  FACS-    Discussion 
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analysis. The half-life of 55.2 +/- 5.1 h will most likely be long enough for the intended gene 
therapy application. As patients receiving gp91
phox-corrected monocytes would probably have 
systemic infections at the time of infusion, the monocytes would not circulate the blood, but 
rather respond according to the type of infection by migrating to the specific tissues (Egan et 
al., 2008).  
Gp91
phox gene correction of murine xCGD-monocytes 
The ability of monocytes to kill bacteria and fungi is mediated through ROS produced by the 
NADPH  oxidase.  The  oxidative  burst  is  therefore  a  requirement  for  the  monocyte  killing 
ability.  Where  gp91
phox-deficient  monocytes  are  not  able  to  produce  ROS,  wild-type 
monocytes give a strong oxidative burst in vitro after PMA stimulation (Figure 23). For the 
lentiviral gp91
phox gene transfer into murine monocytes, HIV-1-derived vectors were used. 
The transduction efficiency for the gp91
phox gene transfer using HIV-1-SgW-derived vectors 
was  not  as  high  as  expected  on  grounds  of  eGFP-transferring  HIV-1-SEW  vector 
transduction.  Using  identical  moi  the  murine  monocyte  transduction  of  eGFP-transferring 
HIV-1-SEW vectors was much higher than that of gp91
phox-transferring HIV-1-SgW vectors.  
 
By using the gp91
phox-transferring HIV-1 vectors a phagoburst activity could be restored in 
gp91
phox-deficient monocytes. This result showed a positive correlation between the presence 
of gene-corrected monocytes and the ability to produce ROS. A correction of more than 54% 
of the gp91
phox-deficient monocytes was achieved. Of these, 85% showed an oxidative burst 
activity  (Figure  34).  In  general,  the  number  of  gp91
phox-expressing  cells  within  one 
transduction experiment was only slightly higher than the number of oxidative burst positive 
monocytes. It can be concluded from the experiments resulting in a low  gene correction 
(<20%)  that  a  single  integration  of  the  transgene  seems  to  be  sufficient  to  restore  the 
phagoburst ability in monocytes. The number of copies integrated into the host genomes was 
not  analyzed.  The  risk  of  insertional  mutagenesis  for  the  non-proliferating  monocytes  is 
marginal and therefore the number of integrations is irrelevant.   
 
The results confirm that a gene correction of gp91
phox-deficient monocytes is possible and 
that the ROS production, the prerequisite for an efficient pathogen killing, was successfully 
restored.      Discussion 
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5.4 Outlook 
The novel PBj- and HIV-2 vectors generated in this thesis meet the current requirements for 
use in clinical applications. Therefore, they could be used for the gp91
phox gene correction of 
monocytes from xCGD patients. To test the gene correction in a human setting was not 
possible  in  this  thesis  as  no  human  material  was  available.  This  test  will  have  to  be 
conducted  in  future  experiments.  A  gp91
phox  gene  correction  was  achieved  in  murine 
monocytes. This and the confirmed ability of phagocytosis, oxidative burst, and S. aureus 
killing indicates that monocytes will be suitable to eliminate infections in vivo. The potency of 
monocytes  to  kill  microbes  and  thereby  eliminate  persistent  infections  in  vivo  can  be 
addressed in a future murine challenge experiment. With regard to the moderate S. aureus 
killing by monocytes in vitro, it is advised to evaluate different pathogens in an in vitro killing 
assay prior to the challenge experiments. 
     Summary (german) 
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6  Summary (german) 
Retrovirale Vektoren werden für den Gentransfer verwendet, weil sie ihr Genom stabil in das 
der  Wirtszelle  integrieren  und  so  eine  langanhaltende  Expression  des  Transgens 
ermöglichen können. Während von γ-Retroviren (wie z.B. dem häufig verwendeten murinen 
Leukämievirus) abgeleitete Vektoren nur sich teilende Zellen transduzieren können, sind von 
Lentiviren abgeleitete Vektoren auch zum Gentransfer in nicht-mitotische Zellen in der Lage. 
Allerdings können auch mit ihnen nicht alle Typen von ruhenden Zellen transduziert werden; 
insbesondere sind nicht-stimulierte primäre Zellen des hämatopoetischen Systems gegen die 
Transduktion relativ resistent. 
 
Um  lentivirale  Vektorsysteme  für  klinische  Applikationen  einsetzen  zu  können,  muss  ein 
sicherer  Gentransfer  gewährleistet  werden.  Deshalb  verwendet  man  keine  replizierenden 
Viren, sondern Vektoren, die zwar das Transgen in die Zielzelle übertragen können, aber 
nicht mehr replikationskompetent sind. Dies wird dadurch erreicht, dass die verschiedenen 
viralen Funktionen auf unterschiedliche Plasmide verteilt sind. Diese  Plasmide werden  in 
eine sogenannte Verpackungszelle eingebracht, in der alle viralen Proteine exprimiert und zu 
Vektorpartikeln  assembliert  werden.  Diese  verpacken  aber  nur  das  für  das  Transgen 
kodierende Genomsegment, so dass die für die Virusproteine kodierenden Gene nicht in die 
Zielzelle  eingebracht  werden.  Um  zu  vermeiden,  dass  in  der  Verpackungszelle  durch 
homologe  Rekombination  der  eingebrachten  Plasmide  wieder  komplette  Virusgenome 
entstehen,  ist  die  Minimierung  viraler  Sequenzen  notwendig.  Optimal  wäre  es  jegliche 
Sequenzüberlappung  zwischen  den  verschiedenen  Bestandteilen  des  Vektorsystems  zu 
vermeiden. 
 
Ein  klassisches  lentivirales  Vektorsystem  besteht  aus  dem  Verpackungskonstrukt,  dem 
Hüllplasmidkonstrukt und dem Transfervektor. Die Vektorpartikel selbst werden dabei durch 
die  gag/pol-Gene  auf  dem  Verpackungskonstrukt  kodiert.  Das  Hüllprotein  wird  von  dem 
Hüllplasmidkonstrukt  kodiert  und  bestimmt  den  Tropismus  der  lentiviralen  Vektoren. 
Üblicherweise  wird  nicht  das  native,  sondern  ein  heterologes  Hüllprotein  verwendet 
(Pseudotypisierung).  Meistens  wird  für  die  Pseudotypisierung  das  Glykoprotein  des 
Vesikulären Stromatitisvirus (VSV-G) verwendet, da es eine ubiquitäre Transduktion erlaubt. 
Das  VSV-G  ist  zudem  sehr  stabil  und  ermöglicht  eine  Anreicherung  der  Vektoren  durch 
Ultrazentrifugation.  Der  Transfervektor  kodiert  für  die  genomische  Information,  die  in  die 
Vektorpartikel verpackt wird und übertragen werden soll. Ein solches Transgen kann z.B. ein 
Markergen  oder  ein  therapeutisch  wirksames  Gen  sein.  Die  Verpackung  der  RNA  des 
Transfervektors wird durch das Verpackungssignal ( -Sequenz), das auf die 5‟LTR-Region     Summary (german) 
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folgt, gewährleistet. Nach der Transduktion wird die genetische Information des Transfergens 
in die genomische DNA der Zielzelle integriert. Bei der zufälligen Integration der Vektor-DNA 
kann es zur Insertionsmutagenese kommen. Sowohl die Integrationsstelle selbst als auch 
Einflüsse zwischen Promotor und Enhancer-Elementen zwischen Vektor- und genomischer-
DNA  können  zu  einer  veränderten  Genexpression  der  betroffenen  Gene  in  der  Zielzelle 
führen. Aus diesem Grund ist es der Transfervektor, der eine entscheidende Rolle für die 
Sicherheit der Vektorsysteme spielt.   
 
Im Gegensatz zu herkömmlichen, meist von HIV-1 abgeleiteten lentiviralen Vektoren können 
vom  simianen  Immundefizienzvirus  (SIV)  smmPBj  abgeleitete  Vektoren  auch  primäre 
humane Monozyten transduzieren. Diese Fähigkeit von SIVsmmPBj-abgeleiteten Vektoren 
ist  von  dem  viralen  Protein  Vpx  (VpxPBj)  abhängig,  welches  bei  einer  Produktion  der 
Vektoren von einem weiteren Expressionsplasmid in trans kodiert wird. HIV-1 kodiert nicht 
für ein Vpx-Protein. Deshalb wurde im Rahmen dieser Arbeit zunächst untersucht, ob auch 
Vektorensysteme anderer Lentiviren, die ebenfalls ein vpx-Gen tragen, zur Transduktion von 
Monozyten  in  der  Lage  sind.  Es  stellte  sich  heraus,  dass  auch  von  HIV-2  abgeleitete 
Vektoren die gleiche Transduktionsfähigkeit wie SIVsmmPBj besitzen. Um den Einfluss der 
Vpx-Proteine zu untersuchen, wurden Expressionsplasmide für VpxHIV-2 und für das vom 
Rhesusaffenvirus SIVmac exprimierte VpxMAC generiert und nachgewiesen, dass sie wie 
VpxPBj  eine  Transduktion  von  Monozyten  durch  PBj-abgeleitete  Vektoren  ermöglichen. 
Aufgrund einer schwachen Expression wurden im weiteren Verlauf die nativen vpxPBj- und 
vpxHIV-2-Gene durch funktionale, kodonoptimierte Gene ersetzt. 
 
Da  Monozyten  ein  attraktives  Ziel  für  die  Gentherapie  darstellen,  sollten  sichere  und 
effiziente,  von  SIVsmmPBj-  und  HIV-2-abgeleitete  Vektorsysteme konstruiert  werden.  Für 
das PBj-System  waren bereits ein Verpackungsvektor  sowie ein  einfacher  Transfervektor 
vorhanden.  Da  sowohl  die  Sicherheit  als  auch  die  Transduktionseffizienz  der  Vektoren 
maßgeblich  durch  die  Transfervektoren  bestimmt  werden,  wurde  der  vorhandene 
Transfervektor  optimiert.  Dies  wurde  konventionell  durch  aufeinanderfolgende 
Klonierungsschritte  erreicht.  Dabei  wurden  sowohl  Verbesserungen  vorgenommen,  die 
wichtig  für  die  Sicherheit  des  Systems  sind  (self-inactivating  (SIN)-Konfiguration, 
Minimierung der viralen Sequenzen), als auch Elemente integriert, die die Vektorproduktion 
und  damit  die  Effizienz  des  Gentransfers  verbessern  (central  polypurine  tract  /  central 
termination sequence (cPPT/CTS), woodchuck hepatitis virus posttranscriptional regulatory 
element  (WPRE)).  Mit  den  graduellen  Verbesserungen  der  PBj-abgeleiteten 
Transfervektoren  war  es  möglich  den  Titer  im  Vergleich  zum  Ausgangskonstrukt  von 
9,1x10
5 TU/ml  auf  1,1x10
7  TU/ml  nach  Konzentration  zu  steigern.  Hierbei  wurde  das     Summary (german) 
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Markergen eGFP übertragen. Die Fähigkeit der Vektoren, Monozyten in Abhängigkeit von 
Vpx effizient zu transduzieren, wurde erhalten.  
 
Generell  ist  eine  sukzessive  Verbesserung  von  Transfervektoren  aufgrund  der  vielen 
notwendigen Klonierungsschritte und oft fehlender Restriktionsschnittstellen langwierig und 
kompliziert. Durch die eingeschränkten Klonierungsmöglichkeiten können überflüssige virale 
Sequenzen oft nicht einfach entfernt werden. Diese Probleme konnten in dieser Arbeit durch 
die  Entwicklung  einer  Klonierungsstrategie,  die  die  Neuklonierung  von  lentiviralen 
Transfervektoren  stark  vereinfacht,  gelöst  werden.  Hierbei  werden  drei  verschiedene 
notwendige Segmente (5„-LTR, RRE, ΔU3-3‟-LTR) des Transfervektors, ausgehend von der 
viralen Wildtypsequenz, mittels PCR amplifiziert. Alle weiteren notwendigen Elemente, wie 
das cPPT/CTS oder PPT, werden über die Fortsätze der verwendeten PCR-Primer integriert. 
Die Primer enthalten zudem komplementäre Sequenzen, durch welche die drei Segmente 
anschließend  durch  die  Methode  der  Fusions-PCR  verknüpft  werden  können.  Das 
entstandene  PCR-Fragment  bildet,  integriert  in  ein  bakterielles  Plasmid,  nunmehr  das 
Grundgerüst  des  Transfervektors.  Die  zusätzliche  Integration  einer  je  nach  Lentivirus-
Hintergrund entworfenen multiple cloning site (MCS) in die verwendeten Primer erlaubt eine 
spätere Integration verschiedener Expressionskassetten.  
Die  Besonderheit  der  Generierung  von  Transfervektoren  mittels  dieser  Fusions-PCR- 
Methode  ist  die  Flexibilität,  mit  der  man  verschiedene  Transfervektoren  unterschiedlicher 
Lentiviren ausgehend vom Virusgenom entwickeln kann. Durch die Auswahl der Primer ist 
man in der Lage Schnittstellen zur Integration gewünschter Vektorelemente, wie z.B. von 
miRNAs, shRNAs oder Insulatoren zu integrieren. Durch eine einfache, schnelle Klonierung 
im Anschluss an die Fusions-PCR kann das entstandene Konstrukt zudem in ein Plasmid-
Rückgrat nach Wahl eingefügt werden.   
 
Mit  dieser  neuen  Methode  der  Generation  von  Transfervektoren  wurden  von  HIV-2  und 
SIVsmmPBj-abgeleitete  Transfervektoren  generiert.  Hierzu  wurde  zunächst,  wie  eben 
beschrieben, das Grundgerüst der Vektoren, die eine individuelle MCS tragen (HIV-2-MCS 
und PBj-MCS), generiert. Um die Funktionalität der Transfervektoren nachzuweisen, wurde 
eine  Expressionskassette  in  die  MCS  integriert,  die  das  Markergen  eGFP  durch  den 
Promotor  des  spleen  focus-forming  virus  (SFFV)  exprimiert.  Zusätzlich  enthält  die 
Expressionskassette  ein  WPRE.  Dieses  stabilisiert  durch  RNA-Sekundärstrukturen  die 
mRNA und erhöht somit die Expression des Transgens. Lentivirale Vektoren, die mit den neu 
generierten Transfervektoren (HIV-2-SEW und PBj-SEW) hergestellt wurden, erzielten nach 
Konzentration  auf  HT1080-Zellen  Titer  bis  zu  5,4x10
8  TU/ml für  HIV-2-SEW und  4,0x10
8 
TU/ml für PBj-SEW.      Summary (german) 
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Die neu generierten Vektoren wurden zusätzlich durch zwei weitere Modifikationen für einen 
sichereren  Einsatz  in  der  Gentherapie  verbessert.  Zum  Einen  wurde  durch  eine 
Punktmutation ein Stop-Codon mehrere Tripletts nach dem  gag-Start-ATG generiert. Das 
Start-ATG selbst wurde nicht verändert, um einen möglichen Einfluss der Sequenz innerhalb 
des  -Verpackungssignals nicht zu verhindern. Durch dieses Stop-Codon wird der Bildung 
eines potentiellen Translationsprodukts vorgebeugt. Zum Anderen wurde die U3-Sequenz 
der 5‟LTR, welche die Promotor-Elemente enthält, durch ein externes SV40-Enhancer/RSV-
Promotor-Element  ausgetauscht.  Dies  ermöglicht  eine  zukünftige  Tat-unabhängige 
Transkription des Transfervektortranskripts. 
 
Vektorpartikel,  die  mit  den  neu  generierten  HIV-2  und  PBj-abgeleiteten  Transfervektoren 
hergestellt wurden, waren nach Supplementierung mit homologem, kodonoptimiertem Vpx in 
der  Lage  Monozyten  effizient  zu  transduzieren.  Die  neu  entwickelten  HIV-2-  und  PBj-
Vektoren  stellen  somit  nicht  nur  eine  Alternative  zu  den  prominenten  HIV-1-abgeleiteten 
Vektoren dar, sondern können darüber hinaus zusätzlich für einen Gentransfer in humane 
Monozyten verwendet werden. Momentan wird die Fähigkeit der neu generierten PBj- und 
HIV-2-abgeleiteten  lentiviralen  Vektoren  im  Vergleich  zu  HIV-1-abgeleiteten  Vektoren  zur 
Transduktion verschiedener anderer Zielzellen, wie z.B. von murinen Hirn-Neuronen nach in 
vivo Injektion, untersucht. 
 
Da aufgrund der neu generierten HIV-2- und PBj-abgeleiteten lentiviralen Vektoren ein hoher 
Grad an Sicherheit und Effizienz für den Gentransfer in Monozyten gegeben ist, wurde im 
Rahmen dieser Doktorarbeit eine neue potentielle Anwendungsmöglichkeit für sie entwickelt. 
Diese beruht auf der Korrektur von Monozyten, die aufgrund eines Gendefekts nicht in der 
Lage sind gp91
phox, eine Untereinheit der NADPH-Oxidase, zu exprimieren. Die Folge ist, 
dass betroffene Phagozyten keine reaktiven Sauerstoffspezies bilden können, die sie für die 
Zerstörung  von  Pathogenen  benötigen.  Patienten,  die  einen  solchen  Gendefekt  tragen, 
leiden unter chronischen Bakterien- und Pilzinfektionen. Die Krankheit, genannt Septische 
Granulomatose (engl.: chronic granulomatous disease), ist zu 60% auf die nicht funktionale 
gp91
phox-Untereinheit  zurückzuführen.  Diese  wird  über  das  Gen  CYBB  auf  dem 
X-Chromosom kodiert, weshalb man die Krankheit, die auf diesem Gendefekt beruht, auch 
X-linked chronic granulomatous disease (xCGD) nennt. Obwohl hauptsächlich neutrophile 
Granulozyten  für  die  Zerstörung  von  Pathogenen  verantwortlich  sind,  zeigen  auch 
Monozyten die Fähigkeit Pathogene durch den Oxidativen Burst zu eliminieren. Aus diesem 
Grund  wurde  in  Kooperation  mit  Manuel  Grez  (Georg-Speyer-Haus)  die  Hypothese 
aufgestellt,  dass  eine  Reinfusion  von  autologen,  gp91
phox-korrigierten  Monozyten  einen     Summary (german) 
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antibakteriellen  und  antimykotischen  Effekt  im  Patienten  zeigen  könnte.  Eine  solche 
Behandlungsmethode  wäre  möglicherweise  in  der  Lage  akute  Infektionsphasen 
einzuschränken  oder  vorhandene  Granulome  aufzulösen.  Die  Transduktion  der 
ausdifferenzierten Monozyten würde jedoch, im Gegensatz zu der Transduktion von CD34
+-
Stammzellen, keine Heilung der Krankheit bedeuten. Für eine Heilung der Krankheit bleibt 
die bevorzugte Therapie die Hämatopoetische Stammzelltransplantation. Sie hat, sofern ein 
geeigneter  Spender  vorhanden  ist,  eine  sehr  hohe  Erfolgsrate,  vorausgesetzt,  es  liegen 
keine  Infektionen  zu  dem  Zeitpunkt  der  Therapie  vor.  Eine  Reinfusion  von  autologen, 
gp91
phox-korrigierten Monozyten vor der eigentlichen Transplantation wäre daher eine weitere 
potentielle Einsatzmöglichkeit. Sie könnte akute Infektionen abschwächen und die Patienten 
schonend, ohne zusätzliche Immunsupressiva, auf die Hämatopoetische Stammzelltherapie 
vorbereiten.  
 
Aus diesem Grund beschäftigt sich der letzte Teil der Doktorarbeit mit der Frage, ob  der 
lentivirale  Transfer  des  korrekten  gp91
phox-Gens  in  Monozyten  bei  der  Therapie  der 
Erkrankung  hilfreich  sein  könnte.  Für  Monozyten  ist  die  Fähigkeit  zur  Phagozytose,  zur 
Bildung  von  reaktiven  Sauerstoffspezies  (Oxidativem  Burst)  und  zur  Zerstörung  von 
Bakterien  wie  Staphylococcus  aureus  beschrieben.  In  einem  ersten  Schritt  wurden  diese 
Eigenschaften  bei  humanen  Monozyten  gesunder  Spender  nachgewiesen.  Während 
Standard-Assays  zur  Untersuchung  der  Phagozytose  und  des  Oxidativen  Bursts  von 
Monozyten verfügbar waren, musste ein Assay für das „Killing“ von S. aureus neu etabliert 
werden. Die Monozyten waren in der Lage, in vitro Phagozytose, Oxidativen Burst sowie 
moderates S. aureus „Killing“ zu bewirken.  
 
Da in diesem frühen Stadium der Entwicklung noch kein Material von xCGD-Patienten zur 
Verfügung  stand,  wurden  weitere  Untersuchungen  zur  Korrektur  von  gp91
phox-defizienten 
Monozyten  im  Maus-Modell  durchgeführt.  Zunächst  wurden  die  Eigenschaften  von 
Monozyten  gesunder  Mäuse  untersucht.  Es  wurden  Monozyten  aus  dem  Knochenmark 
aufgereinigt  und  Protokolle  etabliert,  um  die  erwünschten  Gr1-positiven  Monozyten  zu 
identifizieren. Schließlich wurde deren Fähigkeit zur Phagozytose, zum Oxidativen-Burst und 
zur Abtötung von S. aureus Bakterien in vitro nachgewiesen. In Transplantationsversuchen 
von Monozyten aus eGFP-Mäusen in Rag-2/γc
-/--Mäuse bzw. von Monozyten aus C57BL/6-
CD45.2-Mäusen in
 C57BL/6-CD45.1-Mäuse wurde die Biodistribution bzw. die Halbwertszeit 
von Maus-Monozyten bestimmt. Die Verteilung der Monozyten in verschiedenen Geweben 
entsprach den Erwartungen: Sie konnten nach vier Tagen nur im Blut und im Knochenmark 
wiedergefunden werden. Es ergab sich eine Halbwertszeit der Monozyten im peripheren Blut 
von  55.2  +/-  5.1  h.  Insgesamt  lässt  sich  aus  den  gewonnenen  Daten  zur  Funktion,     Summary (german) 
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Halbwertszeit und Verteilung der Maus-Monozyten schließen, dass mit Hilfe der etablierten 
Methoden ein Mausmodell zur Erprobung einer Gentherapie von xCGD sinnvoll ist. 
Daraufhin wurde das  gp91
phox-Gen in Monozyten von  gp91
phox-Knock-out-Mäusen  ex vivo 
transferiert. Hierfür mussten HIV-1-Vektoren eingesetzt werden, da sich die in dieser Arbeit 
konstruierten HIV-2- oder SIVsmmPBj-Vektoren als ineffizient zur Transduktion von Maus-
Monozyten  erwiesen  haben.  Für  eine  zukünftige  Anwendung  am  Menschen  kämen 
umgekehrt nur die neuen Vektoren in Frage. Mit den HIV-1-Vektoren konnte das korrekte 
gp91
phox-Gen  in  über  50%  der  aus  Knock-out-Mäusen  isolierten  Monozyten  eingebracht 
werden.  In  über  85%  dieser  Zellen  wurde  die  Fähigkeit  zum  „Oxidativen-Burst“ 
wiederhergestellt.  
 
Zusammenfassend kann man sagen, dass jetzt sichere und effiziente lentivirale Vektoren für 
den Gentransfer  in primäre Monozyten  zur  Verfügung stehen. Die Analyse humaner  und 
muriner Monozyten und Experimente zur Übertragung des gp91
phox-Gens lassen erwarten, 
dass  die  Korrektur  von  gp91
phox-defizienten  Monozyten  hilfreich  für  die  Therapie  der 
Septischen Granulomatose sein könnte, und dass das gp91
phox-Knock-out-Mausmodell zur 
Erprobung dieses Ansatzes geeignet ist. Als nächste Schritte zur Weiterentwicklung böten 
sich in-vivo-Belastungsexperimente von gp91
phox-Knock-out-Mäusen nach ex-vivo Transfer 
von gp91
phox sowie die Korrektur von humanen xCGD-Patienten-Monozyten in vitro an.      References 
     
100 
 
7  References 
Aiken, C. (1997). Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the 
glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway 
and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J 
Virol 71(8), 5871-7. 
 
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., 
Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., Tabucchi, A., Carlucci, F., Eibl, M., 
Aker, M., Slavin, S., Al-Mousa, H., Al Ghonaium, A., Ferster, A., Duppenthaler, A., 
Notarangelo, L., Wintergerst, U., Buckley, R. H., Bregni, M., Marktel, S., Valsecchi, M. 
G., Rossi, P., Ciceri, F., Miniero, R., Bordignon, C., and Roncarolo, M. G. (2009). 
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl 
J Med 360(5), 447-58. 
 
Alexander, B. L., Ali, R. R., Alton, E. W., Bainbridge, J. W., Braun, S., Cheng, S. H., Flotte, T. 
R., Gaspar, H. B., Grez, M., Griesenbach, U., Kaplitt, M. G., Ott, M. G., Seger, R., 
Simons, M., Thrasher, A. J., Thrasher, A. Z., and Yla-Herttuala, S. (2007). Progress 
and prospects: gene therapy clinical trials (part 1). Gene Ther 14(20), 1439-47. 
 
Antoniou, M., Harland, L., Mustoe, T., Williams, S., Holdstock, J., Yague, E., Mulcahy, T., 
Griffiths, M., Edwards, S., Ioannou, P. A., Mountain, A., and Crombie, R. (2003). 
Transgenes encompassing dual-promoter CpG islands from the human TBP and 
HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 
82(3), 269-79. 
 
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., 
Cumano, A., Lauvau, G., and Geissmann, F. (2007). Monitoring of blood vessels and 
tissues by a population of monocytes with patrolling behavior. Science 317(5838), 
666-70. 
 
Auffray, C., Sieweke, M. H., and Geissmann, F. (2009). Blood Monocytes: Development, 
Heterogeneity, and Relationship with Dendritic Cells. Annu Rev Immunol. 
 
Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. 
Nature 392(6673), 245-52. 
 
Baum, C., Itoh, K., Meyer, J., Laker, C., Ito, Y., and Ostertag, W. (1997). The potent 
enhancer activity of the polycythemic strain of spleen focus-forming virus in 
hematopoietic cells is governed by a binding site for Sp1 in the upstream control 
region and by a unique enhancer core motif, creating an exclusive target for 
PEBP/CBF. J Virol 71(9), 6323-31. 
 
Belshan, M., and Ratner, L. (2003). Identification of the nuclear localization signal of human 
immunodeficiency virus type 2 Vpx. Virology 311(1), 7-15. 
 
Bjorgvinsdottir, H., Ding, C., Pech, N., Gifford, M. A., Li, L. L., and Dinauer, M. C. (1997). 
Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect 
in host defense against Aspergillus fumigatus in murine X-linked chronic 
granulomatous disease. Blood 89(1), 41-8. 
 
Bylund, J., Goldblatt, D., and Speert, D. P. (2005). Chronic granulomatous disease: from 
genetic defect to clinical presentation. Adv Exp Med Biol 568, 67-87. 
     References 
     
101 
 
Cartier, N., Hacein-Bey, S., Veres, G., Vidaud, M., Dal-Cortivo, L., Caccavelli, L., Malhaoui, 
N., Kiermer, V., Mittelstaedt, D., Simmons, A., Bellesme, C., Audat, F., Blanche, S., 
Chanaud, P., Audit, M., B., L. h., Zhao-Emmonet, J.-C., Fichelson, S., Pflumino, F., 
Dubart-Kupperschmitt, A., Salzman, R., Salzman, A., Bougneres, P., Fischer, A., 
Cavazzana-Calvo, M., and Aubourg, P. (2007). Preliminary Data from the First 
Hematopoietic Stem Cell Gene Therapy Trial with Lentiviral Vector Demonstrate 
Expression of the Therapeutic Protein in High Percentage of Lymphocytes and 
Monocytes in Two Patients with X-Linked Adrenoleukodystophy. ESGT 2007, Oral 
Presentation. 
 
Cattoglio, C., Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., von 
Kalle, C., Howe, S., Thrasher, A. J., Aiuti, A., Ferrari, G., Recchia, A., and Mavilio, F. 
(2007). Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 
110(6), 1770-8. 
 
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, 
P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L., and 
Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency 
(SCID)-X1 disease. Science 288(5466), 669-72. 
 
Chang, D. D., and Sharp, P. A. (1989). Regulation by HIV Rev depends upon recognition of 
splice sites. Cell 59(5), 789-95. 
 
Check, E. (2005). Gene therapy put on hold as third child develops cancer. Nature 
433(7026), 561. 
 
D'Costa, J., Brown, H., Kundra, P., Davis-Warren, A., and Arya, S. (2001). Human 
immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in 
expression and encapsidation. J Gen Virol 82(Pt 2), 425-34. 
 
De Rijck, J., and Debyser, Z. (2006). The central DNA flap of the human immunodeficiency 
virus type 1 is important for viral replication. Biochem Biophys Res Commun 349(3), 
1100-10. 
 
Dinauer, M. C., Gifford, M. A., Pech, N., Li, L. L., and Emshwiller, P. (2001). Variable 
correction of host defense following gene transfer and bone marrow transplantation in 
murine X-linked chronic granulomatous disease. Blood 97(12), 3738-45. 
 
Dropulic, B., and June, C. H. (2006). Gene-based immunotherapy for human 
immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum 
Gene Ther 17(6), 577-88. 
 
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L. (1998). 
A third-generation lentivirus vector with a conditional packaging system. J Virol 
72(11), 8463-71. 
 
Dupuy, F. P., Mouly, E., Mesel-Lemoine, M., Morel, C., Abriol, J., Cherai, M., Baillou, C., 
Negre, D., Cosset, F. L., Klatzmann, D., and Lemoine, F. M. (2005). Lentiviral 
transduction of human hematopoietic cells by HIV-1- and SIV-based vectors 
containing a bicistronic cassette driven by various internal promoters. J Gene Med 
7(9), 1158-71. 
 
Dvorin, J. D., Bell, P., Maul, G. G., Yamashita, M., Emerman, M., and Malim, M. H. (2002). 
Reassessment of the roles of integrase and the central DNA flap in human 
immunodeficiency virus type 1 nuclear import. J Virol 76(23), 12087-96.     References 
     
102 
 
 
Egan, C. E., Sukhumavasi, W., Bierly, A. L., and Denkers, E. Y. (2008). Understanding the 
multiple functions of Gr-1(+) cell subpopulations during microbial infection. Immunol 
Res 40(1), 35-48. 
 
Emerman, M., Guyader, M., Montagnier, L., Baltimore, D., and Muesing, M. A. (1987). The 
specificity of the human immunodeficiency virus type 2 transactivator is different from 
that of human immunodeficiency virus type 1. Embo J 6(12), 3755-60. 
 
Emmendorffer, A., Nakamura, M., Rothe, G., Spiekermann, K., Lohmann-Matthes, M. L., and 
Roesler, J. (1994). Evaluation of flow cytometric methods for diagnosis of chronic 
granulomatous disease variants under routine laboratory conditions. Cytometry 18(3), 
147-55. 
 
Felber, B. K., Hadzopoulou-Cladaras, M., Cladaras, C., Copeland, T., and Pavlakis, G. N. 
(1989). rev protein of human immunodeficiency virus type 1 affects the stability and 
transport of the viral mRNA. Proc Natl Acad Sci U S A 86(5), 1495-9. 
 
Fleming, T. J., Fleming, M. L., and Malek, T. R. (1993). Selective expression of Ly-6G on 
myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-
differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 151(5), 
2399-408. 
 
Fletcher, T. M., 3rd, Brichacek, B., Sharova, N., Newman, M. A., Stivahtis, G., Sharp, P. M., 
Emerman, M., Hahn, B. H., and Stevenson, M. (1996). Nuclear import and cell cycle 
arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-
2/SIV(SM). Embo J 15(22), 6155-65. 
 
Fogg, D. K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D. R., Cumano, A., and 
Geissmann, F. (2006). A clonogenic bone marrow progenitor specific for 
macrophages and dendritic cells. Science 311(5757), 83-7. 
 
Freed, E. O., and Martin, M. A. (2007). HIVs and Their Replication. In Fields´ Virology, 
D.M.Knipe and P.M.Howley, eds. (Philadelphia: Lippincott Williams & Wilkins), 2107-
2186. 
 
Fritz, J. V., Didier, P., Clamme, J. P., Schaub, E., Muriaux, D., Cabanne, C., Morellet, N., 
Bouaziz, S., Darlix, J. L., Mely, Y., and de Rocquigny, H. (2008). Direct Vpr-Vpr 
interaction in cells monitored by two photon fluorescence correlation spectroscopy 
and fluorescence lifetime imaging. Retrovirology 5, 87. 
 
Fuchs, T. A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Weinrauch, Y., 
Brinkmann, V., and Zychlinsky, A. (2007). Novel cell death program leads to 
neutrophil extracellular traps. J Cell Biol 176(2), 231-41. 
 
Fultz, P. N. (1991). Replication of an acutely lethal simian immunodeficiency virus activates 
and induces proliferation of lymphocytes. J Virol 65(9), 4902-9. 
 
Fultz, P. N., McClure, H. M., Anderson, D. C., and Switzer, W. M. (1989). Identification and 
biologic characterization of an acutely lethal variant of simian immunodeficiency virus 
from sooty mangabeys (SIV/SMM). AIDS Res Hum Retroviruses 5(4), 397-409. 
 
Funke, S., Schneider, I. C., Glaser, S., Muhlebach, M. D., Moritz, T., Cattaneo, R., Cichutek, 
K., and Buchholz, C. J. (2009). Pseudotyping lentiviral vectors with the wild-type 
measles virus glycoproteins improves titer and selectivity. Gene Ther.     References 
     
103 
 
 
Garriga, J., and Grana, X. (2004). Cellular control of gene expression by T-type cyclin/CDK9 
complexes. Gene 337, 15-23. 
 
Geissmann, F., Jung, S., and Littman, D. R. (2003). Blood monocytes consist of two principal 
subsets with distinct migratory properties. Immunity 19(1), 71-82. 
 
Grez, M. (2008). Gene Theraypy of Chronic Granulomatous Disease: Ups and Downs after 4 
Years Follow-Up. ASGT 11th Annual Meeting, Oral Presentation. 
 
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J. P., 
Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., Fischer, A., Davies, E. 
G., Kuis, W., Leiva, L., and Cavazzana-Calvo, M. (2002). Sustained correction of X-
linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 
346(16), 1185-93. 
 
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., 
Radford, I., Villeval, J. L., Fraser, C. C., Cavazzana-Calvo, M., and Fischer, A. (2003). 
A serious adverse event after successful gene therapy for X-linked severe combined 
immunodeficiency. N Engl J Med 348(3), 255-6. 
 
Henderson, L. E., Sowder, R. C., Copeland, T. D., Benveniste, R. E., and Oroszlan, S. 
(1988). Isolation and characterization of a novel protein (X-ORF product) from SIV 
and HIV-2. Science 241(4862), 199-201. 
 
Hirsch, V. M., Sharkey, M. E., Brown, C. R., Brichacek, B., Goldstein, S., Wakefield, J., 
Byrum, R., Elkins, W. R., Hahn, B. H., Lifson, J. D., and Stevenson, M. (1998). Vpx is 
required for dissemination and pathogenesis of SIV(SM) PBj: evidence of 
macrophage-dependent viral amplification. Nat Med 4(12), 1401-8. 
 
Hlavaty, J., Schittmayer, M., Stracke, A., Jandl, G., Knapp, E., Felber, B. K., Salmons, B., 
Gunzburg, W. H., and Renner, M. (2005). Effect of posttranscriptional regulatory 
elements on transgene expression and virus production in the context of retrovirus 
vectors. Virology 341(1), 1-11. 
 
Högner, K. (2007). Herstellung und Erprobung von lentiviralen Vektoren zur Übertragung des 
gp91phox-Gens in primäre humane Monozyten. Diplomarbeit am Paul-Ehrlich-Institut, 
Abteilung: Medizinische Biotechnologie. 
 
Jarraya, B., Ralph, S., Boulet, S., Shin, M., Bonvento, G., Jan, C., Delzescaux, T., Drouot, 
X., Herard, A.-S., Brouillet, E., Conde, F., Day, D., Stratful, E., Miskin, J., McDonald, 
M., Kingsman, S. M., Hantraye, P., Mitrophanous, K., and Palfi, S. (2008). Preclinical 
and Clinical Development of ProSavin, an EIAV-Based Gene Therapy for Parkinson's 
Disease. ASGT 11th Annual Meeting, Oral Presentation. 
 
Johnston, R. B., Jr. (2001). Clinical aspects of chronic granulomatous disease. Curr Opin 
Hematol 8(1), 17-22. 
 
Kaiser, J. K. (2008). Eignung von SIVsmmPBj-abgeleiteten lentiviralen Vektoren für die 
Transduktion primärer Zellen und für immuntherapeutische Anwendungen. 
Dissertation am Paul-Ehrlich-Institut, Abteilung: Medizinische Biotechnologie. 
 
Kappes, J. C., Wu, X., and Wakefield, J. K. (2003). Production of trans-lentiviral vector with 
predictable safety. Methods Mol Med 76, 449-65. 
     References 
     
104 
 
Karlsson Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J., and 
Wyatt, R. T. (2008). The challenges of eliciting neutralizing antibodies to HIV-1 and to 
influenza virus. Nat Rev Microbiol 6(2), 143-55. 
 
Kawamura, M., Sakai, H., and Adachi, A. (1994). Human immunodeficiency virus Vpx is 
required for the early phase of replication in peripheral blood mononuclear cells. 
Microbiol Immunol 38(11), 871-8. 
 
Kikuta, A., Ito, M., Mochizuki, K., Akaihata, M., Nemoto, K., Sano, H., and Ohto, H. (2006). 
Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with 
severe organ dysfunction. Bone Marrow Transplant 38(10), 665-9. 
 
Kimura, H., Sawada, T., Oshima, S., Kozawa, K., Ishioka, T., and Kato, M. (2005). Toxicity 
and roles of reactive oxygen species. Curr Drug Targets Inflamm Allergy 4(4), 489-95. 
 
Kingsman, S. M., Mitrophanous, K., and Olsen, J. C. (2005). Potential oncogene activity of 
the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 
12(1), 3-4. 
 
Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., and Mitrophanous, K. A. 
(2000). A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based 
vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74(10), 4839-52. 
 
Leijh, P. C., van den Barselaar, M. T., Daha, M. R., and van Furth, R. (1982). Stimulation of 
the intracellular killing of Staphylococcus aureus by monocytes: regulation by 
immunoglobulin G and complement components C3/C3b and B/Bb. J Immunol 
129(1), 332-7. 
 
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R. R., Rebello, T., Lu, X., Binder, G. K., 
Slepushkin, V., Lemiale, F., Mascola, J. R., Bushman, F. D., Dropulic, B., and June, 
C. H. (2006). Gene transfer in humans using a conditionally replicating lentiviral 
vector. Proc Natl Acad Sci U S A 103(46), 17372-7. 
 
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, 
F., Shinn, P., Leipzig, J., Hannenhalli, S., Berry, C. C., Ecker, J. R., and Bushman, F. 
D. (2006). Retroviral DNA integration: viral and cellular determinants of target-site 
selection. PLoS Pathog 2(6), e60. 
 
Liehl, B., Hlavaty, J., Moldzio, R., Tonar, Z., Unger, H., Salmons, B., Gunzburg, W. H., and 
Renner, M. (2007). Simian immunodeficiency virus vector pseudotypes differ in 
transduction efficiency and target cell specificity in brain. Gene Ther 14(18), 1330-43. 
 
Limon, A., Nakajima, N., Lu, R., Ghory, H. Z., and Engelman, A. (2002). Wild-type levels of 
nuclear localization and human immunodeficiency virus type 1 replication in the 
absence of the central DNA flap. J Virol 76(23), 12078-86. 
 
Mangeot, P. E., Negre, D., Dubois, B., Winter, A. J., Leissner, P., Mehtali, M., Kaiserlian, D., 
Cosset, F. L., and Darlix, J. L. (2000). Development of minimal lentivirus vectors 
derived from simian immunodeficiency virus (SIVmac251) and their use for gene 
transfer into human dendritic cells. J Virol 74(18), 8307-15. 
 
Mazzarella, G., Petillo, O., Margarucci, S., Calabrese, C., and Peluso, G. (1998). Role of 
monocyte/macrophage population in immune response. Monaldi Arch Chest Dis 
53(1), 92-6. 
     References 
     
105 
 
Mills, E. L., Rholl, K. S., and Quie, P. G. (1980). X-linked inheritance in females with chronic 
granulomatous disease. J Clin Invest 66(2), 332-40. 
 
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). Development 
of a self-inactivating lentivirus vector. J Virol 72(10), 8150-7. 
 
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, 
L., Benedicenti, F., Ambrosi, A., Di Serio, C., Doglioni, C., von Kalle, C., and Naldini, 
L. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model 
uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24(6), 687-
96. 
 
Morris, K. V., Gilbert, J., Wong-Staal, F., Gasmi, M., and Looney, D. J. (2004). Transduction 
of cell lines and primary cells by FIV-packaged HIV vectors. Mol Ther 10(1), 181-90. 
 
Mouy, R., Fischer, A., Vilmer, E., Seger, R., and Griscelli, C. (1989). Incidence, severity, and 
prevention of infections in chronic granulomatous disease. J Pediatr 114(4 Pt 1), 555-
60. 
 
Mühlebach, M. D., Wolfrum, N., Schule, S., Tschulena, U., Sanzenbacher, R., Flory, E., 
Cichutek, K., and Schweizer, M. (2005). Stable Transduction of Primary Human 
Monocytes by Simian Lentiviral Vector PBj. Mol Ther. 
 
Naik, S. H., Metcalf, D., van Nieuwenhuijze, A., Wicks, I., Wu, L., O'Keeffe, M., and 
Shortman, K. (2006). Intrasplenic steady-state dendritic cell precursors that are 
distinct from monocytes. Nat Immunol 7(6), 663-71. 
 
Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996a). Efficient transfer, 
integration, and sustained long-term expression of the transgene in adult rat brains 
injected with a lentiviral vector. Proc Natl Acad Sci U S A 93(21), 11382-8. 
 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and 
Trono, D. (1996b). In vivo gene delivery and stable transduction of nondividing cells 
by a lentiviral vector. Science 272(5259), 263-7. 
 
Negre, D., Mangeot, P. E., Duisit, G., Blanchard, S., Vidalain, P. O., Leissner, P., Winter, A. 
J., Rabourdin-Combe, C., Mehtali, M., Moullier, P., Darlix, J. L., and Cosset, F. L. 
(2000). Characterization of novel safe lentiviral vectors derived from simian 
immunodeficiency virus (SIVmac251) that efficiently transduce mature human 
dendritic cells. Gene Ther 7(19), 1613-23. 
 
Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T., and Nishimune, Y. (1997). 'Green mice' 
as a source of ubiquitous green cells. FEBS Lett 407(3), 313-9. 
 
Ooms, M., Huthoff, H., Russell, R., Liang, C., and Berkhout, B. (2004). A riboswitch regulates 
RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J 
Virol 78(19), 10814-9. 
 
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., 
Kuhlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., 
Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N. A., Copeland, N. G., 
Luthi, U., Hassan, M., Thrasher, A. J., Hoelzer, D., von Kalle, C., Seger, R., and Grez, 
M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, 
augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 
12(4), 401-9.     References 
     
106 
 
 
Pancio, H. A., and Ratner, L. (1998). Human immunodeficiency virus type 2 Vpx-Gag 
interaction. J Virol 72(6), 5271-5. 
 
Patel, J., Wang, S. W., Izmailova, E., and Aldovini, A. (2003). The simian immunodeficiency 
virus 5' untranslated leader sequence plays a role in intracellular viral protein 
accumulation and in RNA packaging. J Virol 77(11), 6284-92. 
 
Poeschla, E., Gilbert, J., Li, X., Huang, S., Ho, A., and Wong-Staal, F. (1998). Identification 
of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and 
transduction of nondividing human cells by HIV-2-based lentivirus vectors. J Virol 
72(8), 6527-36. 
 
Pollock, J. D., Williams, D. A., Gifford, M. A., Li, L. L., Du, X., Fisherman, J., Orkin, S. H., 
Doerschuk, C. M., and Dinauer, M. C. (1995). Mouse model of X-linked chronic 
granulomatous disease, an inherited defect in phagocyte superoxide production. Nat 
Genet 9(2), 202-9. 
 
Rada, B. K., Geiszt, M., Kaldi, K., Timar, C., and Ligeti, E. (2004). Dual role of phagocytic 
NADPH oxidase in bacterial killing. Blood 104(9), 2947-53. 
 
Ramezani, A., Hawley, T. S., and Hawley, R. G. (2003). Performance- and safety-enhanced 
lentiviral vectors containing the human interferon-beta scaffold attachment region and 
the chicken beta-globin insulator. Blood 101(12), 4717-24. 
 
Recillas-Targa, F., Valadez-Graham, V., and Farrell, C. M. (2004). Prospects and 
implications of using chromatin insulators in gene therapy and transgenesis. 
Bioessays 26(7), 796-807. 
 
Reeves, E. P., Lu, H., Jacobs, H. L., Messina, C. G., Bolsover, S., Gabella, G., Potma, E. O., 
Warley, A., Roes, J., and Segal, A. W. (2002). Killing activity of neutrophils is 
mediated through activation of proteases by K+ flux. Nature 416(6878), 291-7. 
 
Reuter, S., Kaumanns, P., Buschhorn, S. B., and Dittmar, M. T. (2005). Role of HIV-2 
envelope in Lv2-mediated restriction. Virology 332(1), 347-58. 
 
Rex, J. H., Bennett, J. E., Gallin, J. I., Malech, H. L., and Melnick, D. A. (1990). Normal and 
deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect 
Dis 162(2), 523-8. 
 
Rogister, B., and Moonen, G. (2001). Microexplant Cultures of the Cerebellum. Protocols for 
Cell Culture, 3rd Ed., Ed.: S. Fedoroff and A. Richardson, Human Pess, Inc., Totowa, 
NJ. 
 
Rohloff, L.-H., Wiesner, A., and Götz, P. (1994). A fluorescence assay demonstrating 
stimulation of phagocytosis by haemolymph molecules of Galleria mellonella. Journal 
of Insect Physiology 40(12), 1045-1049. 
 
Schambach, A., and Baum, C. (2008). Clinical application of lentiviral vectors - concepts and 
practice. Curr Gene Ther 8(6), 474-82. 
 
Schambach, A., Bohne, J., Baum, C., Hermann, F. G., Egerer, L., von Laer, D., and 
Giroglou, T. (2006a). Woodchuck hepatitis virus post-transcriptional regulatory 
element deleted from X protein and promoter sequences enhances retroviral vector 
titer and expression. Gene Ther 13(7), 641-5.     References 
     
107 
 
 
Schambach, A., Mueller, D., Galla, M., Verstegen, M. M., Wagemaker, G., Loew, R., Baum, 
C., and Bohne, J. (2006b). Overcoming promoter competition in packaging cells 
improves production of self-inactivating retroviral vectors. Gene Ther 13(21), 1524-33. 
 
Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., and Bushman, F. (2002). HIV-1 
integration in the human genome favors active genes and local hotspots. Cell 110(4), 
521-9. 
 
Seger, R. A. (2008). Modern management of chronic granulomatous disease. Br J Haematol 
140(3), 255-66. 
 
Seger, R. A., Gungor, T., Belohradsky, B. H., Blanche, S., Bordigoni, P., Di Bartolomeo, P., 
Flood, T., Landais, P., Muller, S., Ozsahin, H., Passwell, J. H., Porta, F., Slavin, S., 
Wulffraat, N., Zintl, F., Nagler, A., Cant, A., and Fischer, A. (2002). Treatment of 
chronic granulomatous disease with myeloablative conditioning and an unmodified 
hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 
100(13), 4344-50. 
 
Sirven, A., Pflumio, F., Zennou, V., Titeux, M., Vainchenker, W., Coulombel, L., Dubart-
Kupperschmitt, A., and Charneau, P. (2000). The human immunodeficiency virus 
type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and 
gene transduction of human hematopoietic stem cells. Blood 96(13), 4103-10. 
 
Sleigh, R., Sharkey, M., Newman, M. A., Hahn, B., and Stevenson, M. (1998). Differential 
association of uracil DNA glycosylase with SIVSM Vpr and Vpx proteins. Virology 
245(2), 338-43. 
 
Srivastava, S., Swanson, S. K., Manel, N., Florens, L., Washburn, M. P., and Skowronski, J. 
(2008). Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for 
cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4(5), 
e1000059. 
 
Stein, S., Siler, U., Ott, M. G., Seger, R., and Grez, M. (2006). Gene therapy for chronic 
granulomatous disease. Curr Opin Mol Ther 8(5), 415-22. 
 
Stroncek, D. F., Leonard, K., Eiber, G., Malech, H. L., Gallin, J. I., and Leitman, S. F. (1996). 
Alloimmunization after granulocyte transfusions. Transfusion 36(11-12), 1009-15. 
 
Suggs, S. V., Wallace, R. B., Hirose, T., Kawashima, E. H., and Itakura, K. (1981). Use of 
synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA 
sequences for human beta 2-microglobulin. Proc Natl Acad Sci U S A 78(11), 6613-7. 
 
Sunderkötter, C., Nikolic, T., Dillon, M. J., Van Rooijen, N., Stehling, M., Drevets, D. A., and 
Leenen, P. J. (2004). Subpopulations of mouse blood monocytes differ in maturation 
stage and inflammatory response. J Immunol 172(7), 4410-7. 
 
Suzuki, Y., and Craigie, R. (2007). The road to chromatin - nuclear entry of retroviruses. Nat 
Rev Microbiol 5(3), 187-96. 
 
Swirski, F. K., Pittet, M. J., Kircher, M. F., Aikawa, E., Jaffer, F. A., Libby, P., and Weissleder, 
R. (2006). Monocyte accumulation in mouse atherogenesis is progressive and 
proportional to extent of disease. Proc Natl Acad Sci U S A 103(27), 10340-5. 
     References 
     
108 
 
Towbin, H., Staehelin, T., and Gordon, J. (1979). Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc 
Natl Acad Sci U S A 76(9), 4350-4. 
 
Van Maele, B., De Rijck, J., De Clercq, E., and Debyser, Z. (2003). Impact of the central 
polypurine tract on the kinetics of human immunodeficiency virus type 1 vector 
transduction. J Virol 77(8), 4685-94. 
 
Varol, C., Landsman, L., Fogg, D. K., Greenshtein, L., Gildor, B., Margalit, R., Kalchenko, V., 
Geissmann, F., and Jung, S. (2007). Monocytes give rise to mucosal, but not splenic, 
conventional dendritic cells. J Exp Med 204(1), 171-80. 
 
von Planta, M., Ozsahin, H., Schroten, H., Stauffer, U. G., and Seger, R. A. (1997). Greater 
omentum flaps and granulocyte transfusions as combined therapy of liver abscess in 
chronic granulomatous disease. Eur J Pediatr Surg 7(4), 234-6. 
 
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Jr., Boyle, J., Curnutte, J., Gallin, J. I., 
Malech, H. L., Holland, S. M., Ochs, H., Quie, P., Buckley, R. H., Foster, C. B., 
Chanock, S. J., and Dickler, H. (2000). Chronic granulomatous disease. Report on a 
national registry of 368 patients. Medicine (Baltimore) 79(3), 155-69. 
 
Wolach, B., Gavrieli, R., de Boer, M., Gottesman, G., Ben-Ari, J., Rottem, M., Schlesinger, 
Y., Grisaru-Soen, G., Etzioni, A., and Roos, D. (2008). Chronic granulomatous 
disease in Israel: clinical, functional and molecular studies of 38 patients. Clin 
Immunol 129(1), 103-14. 
 
Wolfrum, N. (2005). Untersuchung der besonderen Transduktionseigenschaften eines 
SIVsmmPBj Vektors und Etablierung eines davon abgeleiteten Dreiplasmid-
Vektorsystems. Dissertation am Paul-Ehrlich-Institut, Abteilung: Medizinische 
Biotechnologie. 
 
Wolfrum, N., Muhlebach, M. D., Schule, S., Kaiser, J. K., Kloke, B. P., Cichutek, K., and 
Schweizer, M. (2007). Impact of viral accessory proteins of SIVsmmPBj on early 
steps of infection of quiescent cells. Virology. 
 
Wu, X., Conway, J. A., Kim, J., and Kappes, J. C. (1994). Localization of the Vpx packaging 
signal within the C terminus of the human immunodeficiency virus type 2 Gag 
precursor protein. J Virol 68(10), 6161-9. 
 
Wu, X., Li, Y., Crise, B., and Burgess, S. M. (2003). Transcription start regions in the human 
genome are favored targets for MLV integration. Science 300(5626), 1749-51. 
 
Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., and Kappes, J. C. 
(2000). Development of a novel trans-lentiviral vector that affords predictable safety. 
Mol Ther 2(1), 47-55. 
 
Yu, E. T., Hawkins, A., Eaton, J., and Fabris, D. (2008). MS3D structural elucidation of the 
HIV-1 packaging signal. Proc Natl Acad Sci U S A 105(34), 12248-53. 
 
Yu, X. F., Yu, Q. C., Essex, M., and Lee, T. H. (1991). The vpx gene of simian 
immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and 
macrophage. J Virol 65(9), 5088-91. 
 
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., and Charneau, P. (2000). 
HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101(2), 173-85.     References 
     
109 
 
 
Zhang, F., Thornhill, S. I., Howe, S. J., Ulaganathan, M., Schambach, A., Sinclair, J., Kinnon, 
C., Gaspar, H. B., Antoniou, M., and Thrasher, A. J. (2007). Lentiviral vectors 
containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) 
provide highly reproducible and stable transgene expression in hematopoietic cells. 
Blood 110(5), 1448-57. 
 
Zhen, L., King, A. A., Xiao, Y., Chanock, S. J., Orkin, S. H., and Dinauer, M. C. (1993). Gene 
targeting of X chromosome-linked chronic granulomatous disease locus in a human 
myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc 
Natl Acad Sci U S A 90(21), 9832-6. 
 
Zufferey, R., Donello, J. E., Trono, D., and Hope, T. J. (1999). Woodchuck hepatitis virus 
posttranscriptional regulatory element enhances expression of transgenes delivered 
by retroviral vectors. J Virol 73(4), 2886-92. 
 
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. 
(1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J 
Virol 72(12), 9873-80. 
 
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997). Multiply attenuated 
lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15(9), 871-5. 
 
 
     Abbreviations 
     
110 
 
8  Abbreviations 
A  amper 
ADA-SCID  adenosine deaminase-deficient severe combined immunodeficiency  
AIDS  Acquired Immune Deficiency Syndrome 
ALD  adrenoleukodystrophy  
Amp   ampicillin 
APC  allophycocyanin 
approx.  approximately 
ATCC  American Type Culture Collection 
BAF  barrier-to-autointegration factor 
bp  base pairs 
BSA  bovine serum albumin 
°C  degree Celsius 
CCR5  chemokine (C-C motif) receptor 5 
CD  cluster of differentiation 
cDC  splenic dendritic cell  
CGD  chronic granulomatous disease  
CMV  cyto-megalo-virus 
cPPT  central polypurine tract 
CTS  central termination sequence 
CXCR4  chemokine (C-X-C motif) receptor 4 
DAPI  4',6-diamidino-2-phenylindole 
DC  dendritic cell  
DHR  dihydrorhodamine 
DMEM   Dulbecco`s modified Eagle medium 
DNA  deoxyribonucleic acid 
E. coli   Escherichia coli 
ECL  enhanced chemiluminescence 
EDTA  ethylene-diamine-tetra-acetate 
eGFP   enhanced green fluorescent protein 
EIAV  equine infectious anemia virus 
Env   envelope protein 
et al.   and others 
FACS   fluorescence activated cell sorting 
FCS  fetal calf serum  
FITC   fluorescence isothiocyanate 
flavo. b558  flavocytochrome b558 
FSC  forward scatter 
g   gram or gravitational acceleration 
Gag  group-specific-antigen 
gp  glycoprotein 
h   hour 
HIV-1  Human immunodeficiency virus-1 
HIV-2  Human immunodeficiency virus-2 
HLA  human leukocyte antigens 
HRP   horseradish peroxidase 
HSC  hematopoietic stem cells     Abbreviations 
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HSCT  hematopoietic stem cell transplantation  
i.e.  id est, that is 
i.v.   intravenous 
IFN  interferon 
IL  interleukin 
IN  integrase 
iNOS  inducible nitric oxide synthase 
kb  kilobase pair  
kDa  kilodalton 
l  liter 
LB  Luria-Bertani 
LTR  long terminal repeat 
m  meter 
M  molar 
m-   milli 
MA  matrix 
mAb  monoclonal antibody 
MDP  macrophage and dendritic cell precursor  
MLV  murine leukaemia virus 
moi  multiplicity of infection  
MOPS   morpholinepropanesulfonate 
mRNA  messenger RNA  
n  number 
n-  nano 
NADPH  nicotinamide adenine dinucleotide phosphate 
NC  nucleocapsid 
NEAA  non essential amino acids 
NEB   New England Biolabs 
Nef  negative factor 
NK cell  natural killer cell 
NPC  nuclear pore complex 
N‐terminal  aminoterminal 
PBj  see SIVsmmPBj 
PBS  primer binding site or phosphate buffered saline 
PCR   polymerase chain reaction 
pDC  plasmacytoid dendritic cell  
PE   R-Phycoerythrin 
phox  phagocytic oxidase 
PIC  pre-integration complex 
PMA  phorbol 12-myristate 13-acetate 
Pol  polymerase 
PPT  polypurine tract 
RCL  replication competent lentivirus  
Rev  regulator of virion expression 
RNA  ribonucleic acid 
RNase  ribonuclease 
ROS  reactive oxygen species  
rpm   revolutions per minute     Abbreviations 
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RPMI   culture medium developed in the “Roswell Park Memorial Institute” 
RRE  Rev-responsive element 
RSV  Rous-Sarkom-Virus 
RT   room temperature or reverse transcriptase 
RTC  reverse transcription complex 
S. aureus  Staphylococcus aureus 
SA  splice acceptor 
SCID-X1  X-linked severe combined immunodeficiency  
SD  slice donor 
sec  second 
SFFV  spleen focus-forming virus 
SIN  self-inactivating  
SIVdrl  Simian immunodeficiency virus of drill monkeys  
SIVmac  Simian immunodeficiency virus of rhesus macaques  
SIVmnd-2  Simian immunodeficiency virus of mandrills 
SIVrcm  Simian immunodeficiency virus of red-capped mangabey 
SIVsmm  Simian immunodeficiency virus of sooty mangabey monkeys 
SSC  side scatter 
SV40  Simian virus 40 
TAE  Tris-acetate-EDTA 
TAR   trans activation response 
Tat  transactivator of transcription 
Tip-DC  TNF-α/iNOS-producing dendritic cell  
TNF-α   Tumor Necrosis Factor α  
tRNA  transfer RNA 
TU  transducing units 
UCOE  ubiquitously acting chromatin opening elements 
UTR  Untranlational region 
UV  Ultraviolet 
V  volt 
Vif  virion infectivity factor 
Vpr  viral protein r 
Vpu  viral protein u 
Vpx  viral protein x 
VSV-G  glycoprotein of vesicular stomatitis virus 
w/v   weight/volume 
WPRE  woodchuck hepatitis virus posttranscriptional regulatory element 
xCGD   X-linked chronic granulomatous disease  
α   anti- 
μ   micro- 
   psi-packaging signal of retroviral genomic RNA 
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9  Appendix 
9.1  Plasmid map of pVpxPBjsyn 
                   
 
9.2  Plasmid map of pMD.G2 
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9.3  Plasmid map of pCMVΔR8.9 
 
 
9.4  Plasmid map of pPBj-pack 
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9.5  Plasmid map of pHIV-2d4 
       
 
 
9.6  Plasmid map of pPBj-SR-SEW-cSIN 
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9.7  Plasmid map of pPBj-MCS 
            
 
9.8  Plasmid map of pPBj-SR-g’-SEW 
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9.9  Plasmid map of pHIV-2-MCS 
   
9.10 Plasmid map of pHIV-2-SR-g’-SEW 
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9.11 Plasmid map of pHIV-2-SgW 
 
 
9.12 Plasmid map of pHIV-1-SgpSw 
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9.13 Plasmid map of pHIV-1-SEW 
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